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Chromatin, a polymer formed from DNA, histones, and associated 
proteins, is the physiological form of genetic information in all eukaryotic 
cells. Posttranslational modification of histones, such as acetylation, 
methylation, and phosphorylation, regulates various DNA-dependent 
processes, ranging from transcription to replication, DNA repair, and 
apoptosis. A key mechanism by which histone modifications exert these 
effects is by recruitment of specific binding partners (effector proteins), 
that in turn direct downstream functions. Insight into the underlying 
mechanisms are of great importance for a full understanding of chromatin 
structure and function.
One of these effector proteins, Heterochromatin Protein 1 (HP1), plays 
important roles in heterochromatin formation. It is recruited to chromatin 
by interaction with methylated lysine 9 of histone H3 (H3K9me). However, 
it has remained enigmatic how HP1 reversibly dissociates  from chromatin 
during mitosis, while the histone mark that recruits the protein, H3K9me, 
persists.
In the first part of my thesis, my collaborators and I show through a 
combination of in vitro and in vivo experiments that this release depends on 
a novel mechanism, “methyl-phos switching”, in which two nearby histone 
marks collaborate to accomplish the dynamic regulation of effector protein 
binding. Phosphorylation of histone H3 at serine 10, immediately adjacent 
to HP1’s binding site at H3K9me, at the onset of mitosis interferes with 
HP1 binding to H3K9me, resulting in the release of the effector protein.
In the second part of my thesis, I investigate to what extent 
posttranslational modification of HP1 itself is involved in the regulation of 
the effector protein. I identify ten novel phosphorylation sites for the three 
human HP1 isoforms (α, β, γ), most of which map to the HP1 “hinge region” 
and are specifically phosphorylated in mitosis. For one highly conserved 
site, HP1α serine 92 phosphorylation, I identify Aurora B as the responsible 
kinase in vivo. In vitro data suggest that mitotic phosphorylation of the 
HP1α hinge may play a role in the regulation of HP1 association with 
RNA.
My thesis work indicates that HP1’s behavior and interactions in 
mitosis are regulated by posttranslational modifications on two levels: 
phosphorylation of histone H3 as well as phosphorylation of HP1 itself.
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 time-of-flight
MDa mega dalton (106 dalton)
min minute
mRNA messenger RNA
MS mass spectrometry
MSK1 Mitogen- and stress-activated kinase 1
MW molecular weight
NGS normal goat serum
Ni-NTA nickel nitrilo-triacetic acid
nt nucleotide
OD600 optical density at 600 nm
P phosphorylation
PAGE polyacrylamide gel electrophoresis
Pbs phosphoate buffered saline
PeV position effect variegation
ph phosphorylation
Phos-HP1α antibody recognizing phosphorylated serine 92
 of HP1α
pi isoelectric point
PMSF phenylmethanesulfonyl fluoride
PP1 protein phosphatase 1
rb rabbit
PV pellet volume
RC reverse complement
xxi
rec. recombinant
RnA ribonucleic acid
Rnase ribonuclease
RnAi RnA interference
RP-HPLC reversed-phase high-performance
 liquid chromatography
PCR polymerase chain reaction
PVDF polyvinylidene fluoride
RnAi RnA interference
rpm rotations per minute
RT room temperature
RT-PCR reverse transcriptase PCR
s second
s10 serine 10
s. d. standard deviation
SDS sodium dodecyl sulfate
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel
 electrophoresis
siRnA short interfering RnA
ssDNA single-stranded DNA
S to A serine to alanine mutation
su(var) suppressor of variegation
T thymine
TAE tris-acetate-EDTA
Taq thermus aquaticus
TBS tris-buffered saline
TcA trichloro acetic acid
TEA tri-ethanol amine
TPR translocated promoter region
Tris tris(hydroxymethyl)minomethane
tRnA transfer RnA
U unit
UTR untranslated region
UV ultra violet
wt wild-type, original sequence without mutation
1Chapter 1
General IntroduCtIon
Posttranslational modifications of histone proteins control chromatin 
structure and function, thereby playing a regulatory role in many 
fundamental cellular processes. An important mechanism how histone 
modifications accomplish their biological function is by recruiting specific 
binding proteins (effectors) to chromatin, that then in turn induce 
downstream functions.
Insight into the mechanisms for how these effectors are recruited 
and how their downstream functions are controlled lies at the heart of a 
deeper understanding of chromatin function. In my Ph.D. project, I studied 
how an important chromatin effector protein, Heterochromatin Protein 1 
(HP1) is regulated by posttranslational modifications, both of the histone 
and of the effector protein itself.
In this introductory chapter, I will review relevant literature to 
provide a framework for describing my research course. The first part of the 
chapter will give a general overview of what is known about chromatin, its 
molecular components and the mechanisms that guide its functions. In the 
second part, I summarize the current knowledge about Heterochromatin 
Protein 1, highlight important findings already reported, point out open 
questions, and put the research of my Ph.D. into context.
2Chromatin
1.1Figure 1.1: Chromatin and the organization of dna within the cell.
At regular intervals, the double helix of DNA is wrapped around complexes of 
histone molecules, forming nucleosomes that are arranged like beads on a string. 
By mechanisms that are currently not well understood, the nucleosome units 
are then folded into a fiber 30 nm in diameter and further into higher-order 
structures. The overall compaction of DNA by this organization is more than 
10,000-fold (adapted from Felsenfeld and Groudine, 2003).
The genetic information of eukaryotic cells is stored in the form of DNA in 
the cell nucleus (Avery et al., 1944). In order to fit 2 meters worth of DNA 
(in human cells) into a cell nucleus only a few micrometers in diameter, the 
DNA ‘fibers’ must be significantly condensed. This enormous compaction 
is achieved by association of the DNA with a set of nuclear proteins, 
resulting in the formation of chromatin (Figure 1.1), which constitutes the 
physiological form of all genetic and inheritable information (Felsenfeld 
and Groudine, 2003).
3 Early cytological studies established the existence of two different 
forms of chromatin (Heitz, 1928): euchromatin has an open, accessible 
conformation, replicates early in S-phase, and contains the majority of 
active genes; heterochromatin, in contrast, is tightly compacted, replicates 
late in the cell cycle, and contains very few active genes. Some regions of 
the genome, such as centromeres, pericentric regions and telomeres, are 
heterochromatic in all types of cells and at all times, and have therefore 
been called constitutive heterochromatin. Other heterochromatic regions of 
the genome can change their status during development or differentiation 
and are therefore referred to as facultative heterochromatin.
nucleosomes and histones
The fundamental repeating unit of chromatin is the nucleosome (Kornberg, 
1974; Olins and Olins, 1974), which is formed by wrapping a stretch of 
147 bp of DNA around a protein core of eight histone proteins – two copies 
each of the histones H2A, H2B, H3 and H4 (Figure 1.2) (Luger et al., 1997). 
An additional histone, linker histone H1 (and, in some organisms, H5), 
interacts with the nucleosomal core as well as with the adjoining linker 
DNA, forming higher levels of chromatin organization and architecture 
(Thomas, 1999).
Histones are a family of small basic proteins with remarkable 
conservation among distantly related species. Structurally, they consist of 
two parts (Arents et al., 1991): The C-terminal domain is mainly α-helical; 
by forming histone-histone and histone-DNA interactions these histone-
fold domains are critical for the formation of the nucleosome core. The 
N-terminal tails of histones, on the other hand, are far less structured. 
Because of their accessibility to proteases, histone tails are thought to 
4protrude outwards from the core nucleosome (Luger and Richmond, 1998). 
This exposed localization makes them available for contacts with adjacent 
nucleosomes and with other chromatin-associated proteins (Ausio et al., 
1989; Hansen et al., 1998; Shogren-Knaak et al., 2006; Whitlock and 
Simpson, 1977).
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Figure 1.2: Composition of the nucleosome.
(a) Cartoon depiction and (B) crystal structure of the nucleosome (solved with 
Xenopus laevis histones (Davey et al., 2002); view down the DNA superhelical 
axis shown). The nucleosome core is formed by an octamer of histone proteins, 
two copies each of the four core histones H2A, H2B, H3 and H4. Around this 
protein core of mostly α-helical structure (shown as cylinders), the DNA is wound 
in roughly two superhelical turns (147 bp). Binding of the linker histone H1 
to this assembly (not shown) confers additional stability and compaction. The 
N-terminal histone tails protrude outwards from the nucleosome core.
5regulatory role of chromatin
For a long time it was believed that the only function of chromatin was to 
serve as a protective and static scaffold for storage of the genetic information 
encoded in the DNA sequence. However, in the last decade it has become 
clear that dynamic changes in chromatin actively regulate numerous 
genomic processes. Every nuclear process that requires access to DNA has 
to function in the context of chromatin, and thus all template-dependent 
processes, such as transcription, replication, mitotic chromosome 
condensation, and recombination as well as apoptosis and DNA repair are 
impacted and controlled by structural changes in chromatin.
Chromatin function is regulated by two general and overlapping 
mechanisms: (A) through changes in chromatin structure ("cis" 
mechanisms) and (B) through the recruitment of specific effector proteins 
("trans" mechanisms).
A. Changes in chromatin structure
Structural changes of chromatin result in the adoption of more open 
or condensed conformations of chromatin. Such structural changes 
significantly affect the accessibility of DNA and thus can control various 
processes that require access to the DNA template (Hansen, 2002). On 
a molecular level, changes in chromatin structure are achieved in three 
different ways: 1) through chromatin remodelling complexes, 2) through 
the incorporation of histone variants, and 3) through the addition or 
subtraction of posttranslational modifications of histone proteins (Allis 
et al., 2007). Each will be briefly discussed below as follows:
1. Chromatin remodeling complexes are ATP-hydrolyzing machines 
that modify DNA-histone contacts, facilitate nucleosome sliding, 
relocate nucleosomes, or even actively remove core histone dimers, 
6thus modulating the exposure of DNA within chromatin (Cairns, 
2007; Johnson et al., 2005). Based on their composition and 
activities, several families (such as the Swi/Snf, ISWI or NuRD 
families) with various members have been delineated. Their 
mechanisms of action are not yet completely understood (Cairns, 
2007), but it is clear that they mediate chromatin rearrangements to 
facilitate processes such as transcription, DNA repair, replication, 
chromatin assembly, and homologous recombination (Becker and 
Horz, 2002; Georgel et al., 1997; Lee et al., 2001).
2. Chromatin structure and function can be altered through the 
incorporation of histone variants (Kamakaka and Biggins, 2005). 
These variants differ from the corresponding major histones in their 
primary sequence, in some cases by very subtle differences of a few 
amino acids, in others dramatically by the presence of specialized 
domains (Bernstein and Hake, 2006). In several cases, histone 
variants are localized to specific regions of the genome: macroH2A, 
e.g., is found at the inactive X chromosome of female mammals 
(Costanzi and Pehrson, 1998), CENP-A at centromeric chromatin 
(Black and Bassett, 2008), or H3.3 at actively transcribed genes 
(Ahmad and Henikoff, 2002). For the deposition of some of these 
histone variants specialized chromatin remodeling complexes have 
been identified (Mizuguchi et al., 2004; Tagami et al., 2004). It is 
believed that the sequence differences amongst histone variants 
gives them distinct biophysical characteristics that alter the 
properties of the nucleosome. In addition, the sequence variation 
allows them to acquire specific patterns of histone modifications 
(such as the phosphorylation of H2A.X on a serine unique to this 
7variant at DNA repair sites; Fernandez-Capetillo et al., 2004; 
Rogakou et al., 1998) and to undergo specific and distinct molecular 
interactions.
3. Changes in chromatin structure are also brought about by covalent 
posttranslational modifications of histone proteins, especially of the 
N-terminal tails of the core histones. Many histone modifications 
change the electrostatic charge of the histone tails, thereby 
strengthening or weakening histone-DNA and histone-histone 
contacts ("cis" mechanism). This, in turn, is thought to modulate 
higher-order chromatin structure (Kouzarides, 2007; Shogren-
Knaak et al., 2006; Workman and Kingston, 1998; see below 
Section "Mechanism of histone modifications").
B. Recruitment of effector proteins
Besides direct changes in chromatin structure, the function of chromatin 
can also be modulated in an indirect fashion: Distinct patterns of 
covalent modifications within histones act as "signaling platforms", 
recruiting specific nuclear factors that in turn mediate downstream 
functions (Seet et al., 2006; Strahl and Allis, 2000; Taverna et al., 2007; 
see below, Section "Mechanism of histone modifications").
These mechanisms to regulate chromatin structure and function 
are also evident in the molecular characteristics of euchromatin and 
heterochromatin. The two forms of chromatin show differences in the 
patterns of their histone modifications as well as in their non-histone 
protein constituents (Dillon and Festenstein, 2002; see Table 1.1).
Since my thesis work focuses on a specific effector protein, Heterochromatin 
Protein 1, which is recruited to chromatin by a histone modification 
8("trans" mechanism), I will in the following section provide a more detailed 
background on histone modifications, the enzymes that establish them, 
and the mechanisms underlying their functions.
Table 1.1: Molecular characteristics of euchromatin and heterochromatin 
Euchromatin Heterochromatin 
Conformation 
during interphase 
decondensed condensed 
Gene density high low 
Replication mainly early late 
Levels of H3 and H4 
acetylation 
high low 
Other specific 
modifications 
H3K4me 
H3K9me, H3K27me, 
H4K16Ac 
Effector proteins e.g. BPTF, WDR5 e.g. HP1, Pc 
Histone variants H3.3, H2A.Z  
Levels of DNA 
methylation 
low high 
 
Histone modifications – histone marks
As early as the 1960s Vincent Allfrey and collegues discovered that histones 
can be extensively post-translationally modified (Allfrey, 1966). In fact, 
some types of post-translational protein modifications (like acetylation and 
phosphorylation) were actually first discovered on histone proteins.
Over the last decades, an enormous number of distinct post-
translational modification types and sites have been identified on histones 
(so-called "marks") have been unveiled, especially since the introduction 
of mass spectrometric approaches to histone biology a few years ago. In 
particular the histone tails have been found to be subject to a great variety 
and high density of posttranslational modifications (Figure 1.3). Lysine 
9residues in histones can be modified by acetylation, (mono-, di-, or tri-) 
methylation, ubiquitylation and sumoylation; arginine residues can be 
(mono-, and symmetrically/asymmetrically di-) methylated, serine and 
threonine residues can be phosphorylated, and glutamate residues can be 
ADP-ribosylated (Kouzarides, 2007; Peterson and Laniel, 2004). All in all, 
close to a hundred individual histone marks have been identified to date, 
about half of which have been confirmed by independent experimental 
methods (i.e. detected by mass spectrometry and immunological/enzymatic 
methods).
1.3
Figure 1.3: Posttranslational modifications of histone molecules.
Histone proteins, in particular their N-terminal tails, are subject to a great 
diversity and extreme density of posttranslational modifications. Depiction of a 
half nucleosome (one copy of each of the core histones), DNA shown in turquois. 
Ac: acetylation. M: methylation. P: phosphorylation. Ub: ubiquitylation. Note that 
lysine residues can be mono-, di-, or tri-methylated and arginine residues can be 
mono- and di-methylated. In addition, other classes of modifications have been 
found, such as sumoylation or ADP-ribosylation. Figure courtesy of Dr. Wolfgang 
Fischle.
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Correlation of histone modifications with biological effects
The idea that histone modifications may play important regulatory roles 
within the cell was raised by Allfrey and colleagues more than thirty years 
ago, when they described a positive correlation between the levels of 
histone acetylation and gene expression (Allfrey, 1966; Allfrey et al., 1964; 
Pogo et al., 1968). Since then, it has been possible to directly correlate 
many histone marks with defined cellular events. For example, besides 
H3 and H4 acetylation (reviewed in Kurdistani and Grunstein, 2003), gene 
activation also correlates with methylation of H3 at K4 (Honda et al., 1975; 
Ruthenburg et al., 2007a). Gene repression correlates with hypoacetylation 
of H3 and H4 (Allfrey et al., 1964; Green, 2005; Peterson, 2002), with 
methylation of H3 at K9 (Grewal and Jia, 2007; Peters et al., 2001) and 
with methylation of H3 at K27 (Schuettengruber et al., 2007). And mitotic 
chromosome condensation correlates with the phosphorylation of H3 at 
S10 and S28 (Gurley et al., 1973; Hendzel et al., 1997; Nowak and Corces, 
2004) (for more examples see Table 1.2).
"histone Code"
Understanding how an ever-increasing number of post-translational 
histone modifications can work together to bring about specific biological 
outcomes has been a challenge for the field. As solution to this problem, 
the existence of a "histone code" has been proposed. According to this 
concept, different combinations of post-translational histone modifications 
are established and maintained in particular regions of chromatin, 
and function in a sequential or combinatorial fashion to specify unique 
downstream biological functions (Jenuwein and Allis, 2001; Strahl and 
Allis, 2000; Turner, 2000).
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Table 1.2: Examples of histone marks, functions they correlate with and 
the responsible enzymes (Homo sapiens, Mus musculus) 
Mark Function Enzyme(s) 
H2A K119ub1 
Polycomb silencing, 
UV damage response 
RING1B 
H2B S14ph 
Apoptosis, Somatic hypermutation 
and class switch recombination 
Mst1/krs2 
 K120ub Cell cycle progression, meiosis  
 R2me Gene Expression CARM1 (me2a) 
 K4me 
Transcriptional activation 
Trithorax activation 
SET7/SET9 (me1) 
MLL1/MLL2/MLL3 (me3) 
 K9ac Nuclear receptor coactivator SRC1 
 K9me 
Transcriptional repression, Im-
printing 
Pericentric heterochromatin, 
Rb-mediated silencing 
G9a (me1, me2) 
 
SUV39H1/2 (me3) 
H3 S10ph 
Transcriptional activation of im-
mediate early genes 
Mitotic chromosome condensation 
MSK1/2, RSK2 
 
Aurora B 
 K14ac Transcriptional activation 
Gcn5, P300, PCAF, 
TAFII230, TAFII250 
 K18ac Transcriptional activation P300, CBP 
 K23Ac Transcriptional activation CBP 
 K27me 
Polycomb repression 
Early B cell development 
X chromosome inactivation 
EZH2 (me3) 
 S28ph 
UVB induced phosphorylation 
Mitotic chromosome condensation 
MSK1 
Aurora B 
 K79me 
Telomeric silencing, 
pachytene checkpoint 
DOT1L (me2) 
 R3me Transcriptional activation PRMT1 
 K5ac 
Histone deposition 
Transcriptional activation 
Hat1 
p300 
H4 K8ac Transcriptional activation PCAF/p300 
 K12ac Excluded from Xi, Histone deposition Hat1 
 K16ac Sequence-specifc TF ATF2 
 K20me 
Transcriptional silencing, 
mitotic condensation 
Pr-SET7/Set8 (me1) 
 
Adapted from Allis et al., 2007. For references and a more complete list, see 
there. 
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Enzymes that establish histone marks
In 1996, it was discovered that certain transcriptional coactivators and 
corepressors had histone acetyltransferase (HAT) and deacetylase (HDAC) 
activity, respectively (Brownell et al., 1996; Taunton et al., 1996). These 
findings provided the first real functional link between histone acetylation 
and transcription, and therefore precipitated a significant wave of interest 
in the role of histone modifications in the regulation of DNA-dependent 
processes. As a consequence, over the last decade a remarkable number of 
enzymes that establish histone marks ("writers") has been identified. Among 
these are histone acetyltransferases (HATs; Sterner and Berger, 2000), 
histone kinases (Nowak and Corces, 2004), histone methyltransferases 
(HMTases; Qian and Zhou, 2006; Zhang and Reinberg, 2001), and 
enzymes that mediate histone ubiquitylation (Weake and Workman, 2008), 
sumoylation (Nathan et al., 2006), and ADP-ribosylation (Hassa et al., 
2006) (see Table 1.2 for specific examples).
Many histone marks have turned out to be reversible. Indeed, several 
classes of enzymes have been identified that can remove specific histone 
modifications ("erasers"), such as histone deacetylases (HDACs, Holbert 
and Marmorstein, 2005) and phosphatases that work on histones (Nowak 
and Corces, 2004). Histone methylation was for a long time considered to 
be more stable than the other modifications, based on early studies looking 
at the turnover of methyl groups in bulk histones (Byvoet, 1972; Duerre 
and Lee, 1974). However, recently several classes of enzymes have been 
identified that can reverse specific methyl marks on histones (Lan et al., 
2008; Shi et al., 2004; Tsukada et al., 2006; Wang et al., 2004; reviewed 
in Lan et al., 2008).
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In addition to the removal of individual histone modifications by 
specific enzymes, proteolytic clipping of histone tails (Allis et al., 1980; 
Duncan et al., 2008) and histone replacement (Ahmad and Henikoff, 2002) 
also result in the removal of histone marks.
Molecular mechanisms of histone modifications
As described above, correlations with distinct biological events have been 
found for many histone modifications. However, the exact molecular 
mechanisms how these histone marks exert their physiological functions is 
in many cases not fully understood. As outlined before, histone modifications 
use two general (albeit not mutually exclusive) mechanisms: They either 
modulate chromatin structure in cis by directly affecting internucleosomal 
contacts and histone-DNA interactions, or they act in trans by recruiting 
binding partners that then induce and direct downstream functions (Figure 
1.4; Allis et al., 2007).
Several mutational studies have led to observations that can best be 
explained by direct or cis effects of histone marks. For example, deletions 
of large regions of the histone tails of H3 and H4 in yeast have very little 
effect (Ling et al., 1996; Smith and Stirling, 1988), pointing to redundancy 
among lysine acetylation marks. Similarly, the effects of several lysine 
residues within the H3 tail that can be acetylated have been explained in 
the sense of charged patches: Only the number of charged residues/lysines 
was important for transcriptional activation in S. cerevisiae, whereas their 
exact position was irrelevant (Kristjuhan et al., 2002).
Published reports have repeatedly confirmed the importance of 
histone tails for the regulation of higher-order chromatin structure 
(reviewed in Hansen, 2002). The extensive involvement of the histone 
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tails in folding of the chromatin fiber suggests that at least some histone 
marks may have an effect on chromatin fiber dynamics, and in specific 
cases there is already experimental evidence that strongly supports such 
a conclusion (e.g. for H4K16ac; Shogren-Knaak et al., 2006). However, at 
this point biophysical and structural studies of mononucleosomes and 
nucleosomal arrays containing modified histones have not yet succeeded 
in demonstrating a significant difference to their corresponding less or un-
modified counterparts.
1.4
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CDBD
BRCT
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MAc
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Ac
Ac
Ac
Ac
Ac
Ac
binding modules
‘trans’‘cis’
histone-histone and
histone-DNA contactsFigure 1.4: Molecular mechanisms of histone modifications.
Histone modifications fulfill their function by two general mechanisms. They either 
change the net charge of the histone tail, which affects inter/intranucleosomal 
contacts and results in structural changes of the chromatin fiber ("cis" 
mechanisms, left). Or they recruit proteins with specific binding modules, such as 
bromodomains (acetyl-lysine binders), chromo domains (methyl-lysine binders), 
or BRCT domains (phospho-serine/threonine binders). Upon recruitment, theses 
effector proteins mediate downstream functions ("trans" mechanisms, right).
Ac: acetylation. M: methylation. P: phosphorylation. BD: bromodomain. CD: 
chromodomain. BRCT: Breast-cancer-susceptibility protein-1 C-terminal 
domain.
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The trans mechanism has attracted even more interest in recent 
years, and several histone modification-specific effector modules (some of 
which had been observed in other context before, Seet et al., 2006) and a 
number of specific binding proteins ("readers") have been identified over 
the last years: Bromodomains, e.g., are binding modules that recognize 
acetylated lysines (Dhalluin et al., 1999). They are found in several 
transcription factors (Gcn5, TAFII250, PCAF) and chromatin remodeling 
complexes (Swi/Snf, RSC) and recruit these proteins to sites of active 
transcription (Zeng and Zhou, 2002). In fact, successive recruitment of 
multiple bromodomain containing proteins to promoter regions during 
the course of transcriptional activation has been demonstrated in several 
model systems (Agalioti et al., 2002; Agalioti et al., 2000; Cosma et al., 
1999).
Chromo domains, in contrast, act as binding modules for methylated 
lysines. The list of chromo domain-containing proteins includes HP1 
(Heterochromatin Protein 1), which recognizes histone H3 methylated at 
lysine 9 and mediates gene silencing and heterochromatinization (Jacobs 
et al., 2001; Lachner et al., 2001), and Polycomb, a repressive protein 
complex in Drosophila with important functions in development (Fischle et 
al., 2003c). In addition, several other binding modules have been identified, 
including domains recognizing methyl-arginine and phospho-serine/
threonine residues (Seet et al., 2006; Taverna et al., 2007; see Table 1.3 
for more examples).
Frequently, effector proteins carry multiple binding modules (Seet et 
al., 2006), for example the chromatin remodeler BPTF (two PHD fingers) or the 
methyltransferase MLL1 (bromo domain, several PHD fingers). Furthermore, 
often several proteins with binding affinity for histone marks are united in a 
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multisubunit complex, for example in the chromatin remodeling complexes 
RSC (yeast RSC contains eight bromodomains in different subunits of the 
complex) or NURF (which contains, in addition to BPTF, several complex 
members with multiple WD40 repeat domains) (Ruthenburg et al., 2007b). 
The observation that binding modules are often linked is mirrored by the 
finding that different histone marks often seem to collaborate to achieve 
Table 1.3: Examples of binding modules and effector proteins for histone 
marks 
Binding 
module
Mark Examples 
Bromo domain acetylated lysine 
PCAF (H4K16ac), 
TAFII250 (H3K9ac, H3K14ac) 
Chromo domain di/tri-methylated lysine 
HP1 (H3K9me), 
Polycomb (H3K27me) 
PHD finger (methylated) lysine 
BPTF (H3K4me2/3), 
BHC80 (H3K4me0) 
MBT domain 
mono/di-methylated 
lysine 
L3MBT, pocket 2 (a. o. 
H4K20me1/2) 
Tudor domain methylated arginine 
JMJD2A (H4K20me1/2) 
53BP1 (H4K20me1/2) 
WD40 repeats di-metylated arginine WDR5 (H3K4me2) 
14-3-3 
phosphorylated 
serine/threonine 
14-3-3 (H3S28ph) 
BRCT domain 
phosphorylated 
serine/threonine 
MDC1 (H2A.XS139ph) 
 
PCAF: p300/CBP-associated factor. TAFII250: TATA-binding protein-associated 
factor II 250. Chromo: Chromatin organization modifier. HP1: Heterochromatin 
protein 1. PHD: Plant homeodomain. BPTF: bromodomain and PHD finger 
transcription factor. BHC80: BRAF-HDAC complex 80. MBT: malignant brain 
tumor. L3MBTL1: lethal-(3) malignant brain tumor repeat–like protein-1. 
JMJD2A: Jumonji domain–containing protein-2A. 53BP1: p53-binding protein 
1. WDR5: WD repeat domain 5. BRCT: Breast-cancer-susceptibility protein-1 C-
terminal. MDC1: Mediator of DNA damage checkpoint 1. See Ruthenburg et al., 
2007; Seet et al., 2006; Taverna et al., 2007 for more details. 
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specific biological effects, as illustrated by the coexistence of H3S10ph and 
H3K14ac at sites of immediate early gene activation (Cheung et al., 2000), 
H3K4me2/3 and H4K16ac at transcriptionally active homeotic genes (Dou 
et al., 2005), or H3K27me3 and H2AK119ub1 at silent homeotic genes 
(Bernstein et al., 2005; Schuettengruber et al., 2007). Linking together 
multiple binding modules may lead, through thermodynamic and kinetic 
effects, to dramatic increases in affinity and specificity, while keeping the 
effector recruitment dynamic and susceptible to competition (Ruthenburg 
et al., 2007b).
While histone modifications can this way work together to recruit 
an effector protein/complex with multiple binding modules, they can 
also influence each other directly in various ways ("cross-talk" of histone 
modifications; Fischle et al., 2003b). For example, it has been found 
that the presence of certain marks enhances or decreases others. In 
the simplest case, this is just by directly blocking the site (e.g. H3K9 
acetylation blocks H3K9 methylation). But there are also effects of enyzme 
recruitment and substrate recognition/turnover (e.g. the activity of the 
H3K79 methyltransferase Dot1 is activated by the presence of ubiquitylated 
histone H2B in the same nucleosome; McGinty et al., 2008). Such 
"cross-talk" between modifications (for recent reviews, see Fischle, 2009; 
Suganuma and Workman, 2008) represents, together with the finding that 
multivalency is important in effector recruitment, additional support for 
the existence of a histone code.
Histone modifications and disease
Mutations in various factors involved in chromatin formation and regulation 
have been linked to the development of disease, in particular cancer (Wang 
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et al., 2007). Through diverse mechanisms, these mutations lead either to 
repression of normally active genes (e.g. tumour suppressor genes) or result 
in the activation of genes that are normally silent (such as oncogenes).
Connections have been found for various modifications and at 
all levels of chromatin formation/regulation: for "writers" such as the 
H3K27 methyltransferase EZH2 (overexpressed in metastatic prostate 
cancer, Varambally et al., 2002), "readers" like the H3K9me-binder HP1 
(downregulated in invasive metastatic breast cancer, Norwood et al., 2006), 
for "erasers" such as HDAC1 (aberrant recruitment to promotors due to 
fusion with DNA-binding proteins, Lin et al., 1998), and for chromatin 
remodelers such as the NuRD complex (deletion of its ATPase subunit in 
certain neuroblastomas, Bagchi et al., 2007).
The multitude and variety of these connections foreshadows the 
enormous potential that intervention with these processes may have for the 
treatment of cancer in the clinic. In fact, first steps to exploit the insights 
of chromatin biology in the interest of the patient have already been taken: 
Small molecule inhibitors of histone deacetylases have been tested with 
promising results for the treatment of tumors, and many such compounds 
have already entered into clinical trials (Bolden et al., 2006).
It is clear at this point, however, that a much deeper understanding 
of the principle mechanisms regulating chromatin structure and function 
and the specific mechanisms of chromatin-dependent tumorigenesis is 
required, and much basic research will still be necessary, to achieve the 
full potential of chromatin-based therapeutics. The close connections 
between chromatin and cancer make such research imperative.
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 Having outlined the basic principles of chromatin biology, I will in the 
following give a more detailed view of one specific non-histone component 
of chromatin: Heterochromatin Protein 1, the chromatin effector protein 
that was at the center of my Ph.D. research.
heterochromatin protein 1
Identification of HP1 and its gene
As early as 1930, it had been observed in experiments with flies that 
genes translocated by X-rays from euchromatic regions into the vicinity 
of pericentric heterochromatin acquire a variegated pattern of expression 
(Muller and Altenburg, 1930). The effect, which is caused by the repressive 
properties of heterochromatin, was called Position Effect Variegation (PEV, 
Figure 1.5), and it was exploited starting in the 1980s to systematically 
screen for factors that positively or negatively regulate heterochromatin 
formation.
One of the genes identified in such screens was the gene of 
Heterochromatin protein 1 (HP1). HP1 had previously been described as a 
protein that localizes to heterochromatin in immunofluorescence stainings 
(James and Elgin, 1986). The HP1 mutation Su(var)2-5 turned out to be 
a strong suppressor of PEV, suggesting that HP1 plays an key role in the 
formation of heterochromatic structures (Eissenberg and Hartnett, 1993; 
Eissenberg et al., 1990; Eissenberg et al., 1992; Wustmann et al., 1989). 
Complete loss of Drosophila HP1 in homozygous Su(var)2-5 null mutants 
is lethal, underlining the importance of HP1 in normal development. Flies 
die at the late third instar larval stage, at the time when the maternal 
supply of HP1 becomes exhausted (Eissenberg and Hartnett, 1993; Lu et 
al., 2000), probably due to the failure of HP1 null cells to segregate their 
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chromosomes faithfully (Fanti et al., 1998). Deletion of the HP1 homolog 
Swi6 in S. pombe results in impaired silencing at the centromeres and a 
significant increase in chromosome loss (Ekwall et al., 1995).
1.5
Inversion
wt
Su(var) E(var)
W+ Heterochromatin
 red facet
red eye
 white facet
mostly red eye mostly white eye
partly red,
partly whiteW
+ gene close to
heterochromatin
Figure 1.5: position effect variegation in Drosophila melanogaster.
The white gene (W+) is essential for normal red pigmentation of the flye eye. In 
wild-type flies, its gene locus (depicted in red) is located within distal euchromatin 
(grey). Through X-ray-induced inversion, W+ can end up in the proximity of 
pericentric heterochromatin (blue), resulting in a variegating phenotype: In some 
cells, the white gene is still regularly expressed at this new location, leading 
to red eye facets; in others, heterochromatic proteins spread over the break 
points, condensing the relocated W+ locus and silencing the gene, leading to 
white eye facets. Based on this position effect variegation, selection for second-
site mutations allows the identification of proteins that affect heterochromatic 
structure: Suppressors of variegation (mutation leads to reduced silencing and 
thus more red eye facets) encode proteins that contribute to heterochromatic 
silencing. Enhancers of variegation (mutation results in further spreading of 
heterochromatin and thus more white eye facets) encode proteins that contribute 
to the active state. Similar PEV screens have been carried out in fission yeast.
(Fly depiction adapted from Grewal and Elgin, 2002.)
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Conservation of hp1 in different organisms
Heterochromatin protein 1 is a rather small, phylogenetically conserved 
protein of about 200 amino acids (Singh et al., 1991). Characteristic of 
all HP1 proteins in different organisms is their specific domain structure: 
a highly conserved N-terminal chromo (chromatin-organization modifier) 
domain is connected by a less conserved "hinge region" to a well conserved 
C-terminal chromoshadow domain (see Figure 1.6A for schematic).
HP1 is found in virtually all higher eukaryotes, ranging from yeast 
(S. pombe) and plants to flies, frogs, and mammals (for an overview see 
Kwon and Workman, 2008). A notable exception is the budding yeast S. 
cerevisiae, in which silent information regulatory (SIR) proteins likely fulfill 
a similar role. In many organisms there are several different HP1 isoforms 
(see Figure 1.6B for examples). While there is one HP1 protein found in 
Tetrahymena thermophila (Hhp1p) and S. pombe (Swi6; recently it has been 
suggested that another chromatin protein in fission yeast, Chp2, may also 
be part of the HP1 family; Sadaie et al., 2008), there are two HP1 isoforms 
in C. elegans (HPL-1 and HPL-2) and three in Drosophila (HP1a, HP1b, 
HP1c; HP1a was the first HP1 protein identified, and the literature refers 
to it often as "Drosophila HP1") and Xenopus laevis (HP1α, HP1β, HP1γ). 
Mammals also have three HP1 isoforms (HP1α, HPβ, HPγ), which share an 
overall sequence identity of about 50% with Drosophila HP1; my thesis will 
focus on the mammalian HP1 isoforms.
The different isoforms have similarities in their amino acid sequence 
(see Figure 1.7 for an alignment; ; see Appendix for human HP1 sequences 
with numbered residues). To what extent there is redundancy among 
isoforms  is currently not completely clear. In Drosophila, deletion of one 
isoform (dHP1a) is lethal (Eissenberg and Hartnett, 1993), causing cell 
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Figure 1.6: domain structure of hp1.
a: HP1 proteins comprise three domains, an N-terminal chromo domain, a hinge 
region, and a C-terminal chromoshadow domain. For details on the molecular 
interactions of the three domains, see section "HP1 domains and molecular 
interactions".
B: left: Schematic representation of HP1 isoforms in human, mouse, Xenopus 
laevis, Drosophila melanogaster and Schizosaccharomyces pombe. Even though 
there is some variation in the length and amino acid sequence of the domains, 
all HP1 proteins have a chromo domain, a hinge region and a chromoshadow 
domain. Especially dHP1b, dHP1c and Swi6 have extensive additional sequence 
stretches. right: Table showing the conservation (% identity) of the different 
domains, compared to the most intensely studied HP1 protein, Drosophila HP1a. 
The hinge region is less conserved than the CD and CSD. Table adapted from Li 
et al., 2002.
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1.6
Chromoshadow
domainChromo domain Hinge
A
B
hHP1
hHP1
hHP1
xHP1
xHP1
xHP1
mHP1
mHP1
mHP1
dHP1a
dHP1b
dHP1c
Swi6
18 71 109 168
191
19 72 115 174
185
28 81 119 178
183
18 71 109 168
191
19 72 115 174
185
28 81 119 178
183
34 87 127 186
189
19 74 114 173
184
18 73 110 169
174
22 75 145 204
206
2 55 97 156
240
6 60 83 142
237
75 136 199 252
328
Human:
Mouse:
Xenopus:
Drosophila:
S. pombe:
 Total C D  Hinge C S D  
dHP1a 1 0 0  1 0 0  1 0 0  1 0 0  
dHP1b 5 1  5 8  4 2  5 8  
dHP1c 4 4  5 3  3 3  3 6  
hHP1  4 9  6 0  2 7  5 4  
hHP1  5 4  6 7  2 6  5 6  
hHP1  5 2  5 9  2 4  5 2  
mHP1  4 9  6 0  2 7  5 4  
mHP1  5 4  6 7  2 6  5 6  
mHP1  5 2  5 9  2 4  5 2  
Swi6 2 5  4 8  1 3  1 7  
% Identity
H3K9me binding interactions with
proteins and RNA
various protein-protein
interactions
Figure 1.6
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Figure 1.7: alignment of hp1 proteins of different organisms.
Amino acid alignment of HP1 proteins from different organisms. The chromo 
domain and chromoshadow domain are highly conserved, while there is less 
conservation of the hinge region (for exact % identity see Table in Figure 1.6B, 
right).
hHP1: human HP1. mHP1: mouse HP1. xHP1: Xenopus laevis HP1. dHP1: 
Drosophila melanogaster HP1. Identical residues in red (identity threshhold 0.75), 
similar residues in yellow. The CD is marked with a red line, the hinge region 
with yellow and the chromoshadow domain with blue. Green astersiks indicate 
amino acids of the aromatic cage. Residue numbers for human HP1α are given 
above the sequence.
Alignment generated with ClustalW. The S. pombe homolog Swi6 was not included 
in the alignment, because its significantly larger length and lower sequence 
conservation made an inclusion in this multiple-species alignment difficult. For 
dHP1b and dHP1c, not the full sequence is shown, but the last 58 aa resp. 69 aa 
of their long C-terminal tails are omitted (compare to Figure 1.6B, left).
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death through chromosome fusions (Fanti et al., 1998). In mammals, 
knock-down of HP1α by RNA interference does not lead to directly 
observable effects, while HP1α/HP1γ double RNAi results in the formation 
of micronuclei, indicative of aberrant mitotic chromosome segregation 
(Obuse et al., 2004). This indicates differences between organisms in how 
the multiple functions of HP1 are distributed among the isoforms, as well 
as organism-specific differences in the exact functions fulfilled by HP1. 
In line with such an interpretation, various differences in the molecular 
interactions and cellular localization of the different isoforms have been 
observed (see Sections "HP1 domains and molecular interactions" and 
"Cellular localization and functions of HP1").
hp1 domains and molecular interactions
In the following, I will give a brief summary of what is known about the 
three domains of HP1 and the molecular interactions they undergo.
A. Chromo domain
The chromo domain (CD) was originally described as an evolutionarily 
highly conserved domain of about 40 amino acid with an obscure 
biological role that was present in various proteins involved in chromatin 
organization and gene regulation (Koonin et al., 1995). The CD of HP1 
was actually the first chromo domain for which finally a molecular 
function could be identified: A series of landmark papers published in 
2001 demonstrated that the HP1 chromo domain is a binding module 
for a methyl mark on the histone H3 tail, methylated lysine 9 (H3K9me, 
see Figure 1.8A; Bannister et al., 2001; Jacobs et al., 2001; Lachner 
et al., 2001). Subsequently, it was shown that chromo domains in 
general are methyl-lysine binding domains. The chromo domain of HP1 
27
in particular has since developed into a highly studied paradigm for 
methyl-lysine binding and the recruitment of effector proteins.
A
B
1.8
H3 tail:
91
CD
M
HP1
CSD
NH2-A R T K Q T A R K S T G G K A...
Y24
W45
Y48
N
C
Figure 1.8: The chromo domain of HP1 binds methylated lysine 9 of 
histone h3.
a: The HP1 CD binds methylated lysine 9, a histone mark that is part of a 
sequence motif "ARKS" within the N-terminal tail of histone H3.
B: Crystal structure of the CD of Drosophila HP1a (23-76) bound to a trimethyl-K9 
H3 tail peptide (1-15) (Jacobs and Khorasanizadeh, 2002). Two different views 
of the same structure are shown, the view on the right is rotated by 90° to the 
left around the vertical axis. The peptide (yellow, trimethyl-K9 shown) is bound 
by the CD (in blue) in a weak (Kd in the lower µM), but specific interaction. No 
density was seen for H3 residues 1 to 4 and 11 to 15, suggesting that they 
are not directly involved in binding. left: The peptide inserts into the chromo 
domain in an extended conformation, forming a β-strand that completes the β 
sandwich architecture of the CD. right: The methylammonium group of lysine 
9 is coordinated by three aromatic residues (Y24, W45, Y48; shown in purple), 
the "aromatic cage". Mutation of any of these completely abolishes binding.
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         Di- and trimethylation of H3 lysine 9 can be found at pericentric 
heterochromatin in virtually all higher eukaryotes and is considered 
a hallmark of silenced chromatin (Grewal and Jia, 2007). The enzyme 
mainly responsible for this methylation is the histone methyltransferase 
Su(var)3-9, as first shown with the S. pombe homolog Clr4 (Rea et 
al., 2000), and then confirmed with the mammalian homolg SUV39H 
(Peters et al., 2001) and the Drosophila homolog Su(var)3-9 (Schotta 
et al., 2002). Like HP1, Su(var)3-9 is a suppressor of PEV, confirming 
its importance in the formation of pericentric heterochromatin. By 
methylating H3 at lysine 9 through its C-terminal SET domain (Rea et 
al., 2000), Su(var)3-9 "writes" the histone mark that the HP1 CD then 
reads.
Interestingly, the amino acid context of H3K9 ("ARKS", Figure 1.8A) 
is found in identical or similar form at multiple other sites in histones 
and other proteins. In several of these instances the corresponding 
lysine has been found to be a methylation site as well. Moreover, even 
recruitment of interaction partners with chromo domains has been 
shown (e.g. H3K27: ARKmeS binds Polycomb, Fischle et al., 2003c; 
H1K26: ARKmeS binds HP1, Daujat et al., 2005; G9aK165: ARKmeT 
binds HP1, Sampath et al., 2007), and additional modifications such 
as lysine acetylation and serine phosphorylation are known to happen 
in this sequence stretch. Thus, ARKS and related sequences are typical 
examples of "modification cassettes" that are found in multiple proteins 
and confer the ability for the recruitment of specific binding partners 
(Fischle et al., 2003a).
The crystal structure of the HP1 chromo domain bound to 
a methylated H3 peptide shows that the main structural features 
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of the chromo domain are an antiparallel three-stranded β-sheet 
packed against an α-helix (Figure 1.8B). Of critical importance for the 
interaction of the CD with the methylated lysine are three aromatic 
amino acids within the chromo domain (the "aromatic cage", marked 
by green asterisks in the alignment of Figure 1.7 and shown in purple 
in the crystal structure of Figure 1.8B; Jacobs and Khorasanizadeh, 
2002; Nielsen et al., 2002). Mutation of any of these residues results in 
loss of methyl-K9 binding in vitro and functional defects in vivo (Platero 
et al., 1995).
Biophysical measurements by fluorescence anisotropy have 
determined dissociation constants for the binding of the CD of Drosophila 
and human HP1s to methylated H3 tail peptides (Fischle et al., 2005; 
Fischle et al., 2003c). The Kd values are in the low micromolar range and 
little difference is observed between the chromo domains of the three 
isoforms. However, there is some discrimination between the level of K9 
methylation: the affinity of the HP1 CD for H3K9me3 and H3K9me2 is 
about five- to tenfold higher than for H3K9me1.
Binding of the chromo domain to the modified H3 tail is essential 
for recruitment of HP1 to chromatin, and disruption of this interaction 
by mutations in the CD or removal of the H3K9me mark results in 
mislocalization of HP1 in flies, S. pombe and mammals (Fischle et al., 
2003c; Platero et al., 1995; Stewart et al., 2005; Thiru et al., 2004).
Besides its interaction with H3K9me, the HP1 CD has been 
reported to bind components involved in nuclear architecture and to 
Psc3, a subunit of the mitotic cohesin complex in S. pombe (see Table 
1.4 for references).
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Table 1.4: Examples of HP1 interactions 
 
(Adapted from Kwon and Workman, 2008; Li et al., 2002; Lomberk et al., 2006.) 
 
Chromo domain: 
Interaction partner Shown with References
H3K9me Swi6, DmHP1a, 
mHP1, mHP1, 
mHP1
Bannister et al., 2001 
Lachner et al., 2001 
Jacobs et al., 2001 
Nakayama  et al., 2001
Lamin B, LAP2beta mHP1 Kourmouli et al., 2000
Psc3 Swi6 Nonaka et al., 2002
 
Chromoshadow domain: 
HP1 Swi6, mHP1, 
mHP1, mHP1
Le Douarin et al., 1996 
Brasher et al., 2000 
Cowieson et al., 2000 
Thiru et al., 2004
Su(var)3-9 DmHP1a, mHP1, 
mHP1, hHP1
Aagaard et al., 1999 
Yamamoto and Sonoda, 2003 
Schotta et al., 2002
TIF1alpha mHP1 Nielsen et al., 1999 
Le Douarin et al., 1996
KAP-1/TIF1beta mHP1, mHP1, 
mHP1, hHP1, 
hHP1
Nielsen et al., 1999 
Le Douarin et al., 1996 
Lechner et al., 2000
Rb mHP1, hHP1 Nielsen et al., 2001b 
Su(var)3-7 DmHP1a Cleard et al., 1997 
Delattre et al., 2000
CAF-1 (p150) mHP1, mHP1, 
hHP1
Murzina et al., 1999 
Brasher et al., 2000 
TAFII130 hHP1, hHP1 Vassallo and Tanese, 2002
AF10 DmHP1a Linder et al., 2001 
ORC1-6 (CD+CSD) DmHP1a Pak et al., 1997
Ku70 hHP1 Song et al., 2001
ATRX mHP1, mHP1 McDowell et al., 1999
Su(z)12 hHP1, hHP1 Yamamoto et al., 2004
Ki67 mHP1, mHP1. 
mHP1 
Scholzen et al., 2002 
PIM1 hHP1 Koike et al., 2000 
SP100B hHP1, hHP1, 
hHp1 
Lehming et al., 1998 
Seeler et al., 1998 
Lamin B receptor hHP1, hHP1, 
hHP1 
Polioudaki et al., 2001 
Ye et al., 1997 
 
(continued on next page)
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Hinge: 
RNA mHP1, mHP1 Muchardt et al., 2002 
INCENP hHP1, hHP1 Ainsztein et al., 1998 
H1b hHP1 Hale et al., 2006 
 
Interacting HP1 domain not determined: 
Dnmt3a/b mHP1, mHP1, 
hHP1, hHP1,  
Lehnertz et al., 2003 
Bachman et al., 2001 
Fuks et al., 2003 
Histone H3 core hHP1, hHP1, 
hHP1 
Nielsen et al., 2001a 
Su(var)4-20 mHP1, mHP1, 
mHP1 
Schotta et al., 2004 
 
B. Chromoshadow domain
Distantly related to the chromo domain in primary amino acid sequence 
(Aasland and Stewart, 1995), the chromoshadow domain (CSD) is also 
highly conserved between HP1 proteins of different organisms. The 
structure of the CSD bears some resemblance to the chromo domain 
structure (a three-stranded β sheet packed against two α helices; 
Cowieson et al., 2000). However, it does not engage a histone modification, 
but rather mediates a wide array of protein interactions. More than 
three dozen different molecular interactions of the HP1 chromoshadow 
domain have been identified to date (see Table 1.4 for examples).
Of particular interest among the interactions of the chromoshadow 
domain is the interaction with HP1 itself: as shown for Drosophila and 
mammalian HP1, the HP1 CSD mediates homodimerization with the 
same HP1 isoform as well as heterodimerization between different 
HP1 isoforms. The finding has been observed by various independent 
methods, such as two hybrid interaction assay (Gaudin et al., 2001; 
Le Douarin et al., 1996), in vitro pull-downs (Cowieson et al., 2000; 
Ye et al., 1997), gel filtration, equilibrium sedimentation analysis, and 
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structural studies (Brasher et al., 2000; Cowieson et al., 2000; Thiru et 
al., 2004). The dimer interaction is quite tight (Kd < 150 nM). Even so, it 
can be disrupted by single point mutations (e.g. I161E, Y164E in HP1β; 
Brasher et al., 2000).
Dimerization of HP1 through the CSD is an intriguing observation, 
because it suggests a mechanism how HP1 could achieve condensation 
and silencing of specific chromosomal domains. As depicted in 
Figure 1.9A, HP1 may crosslink H3K9-methylated nucleosomes, thus 
condensing regions of chromatin through a "handcuffing" mechanism 
(Jenuwein and Allis, 2001). Direct testing of this hypothesis by point 
mutations has been difficult, though, because deletions of the CSD 
or mutations abolishing HP1 dimerization also affect HP1 chromatin 
association in general (Thiru et al., 2004; Vogel et al., 2006).
A phage display screen carried out with the HP1 CSD identified 
a pentapeptide motif PXVXL/I (X = any amino acid) that interacts 
specifically with the chromo shadow domain (Smothers and Henikoff, 
2000). The peptide motif was subsequently shown to be present in 
many of the molecules reported to bind the HP1 CSD, for example in 
KAP-1 (Brasher et al., 2000), Su(var)3-7 (Delattre et al., 2000), CAF-1 
p150 (Brasher et al., 2000), the TAFII130 component of TFIID (Vassallo 
and Tanese, 2002), and AF10 (Linder et al., 2001). Binding of proteins 
with the PXVXL/I motif to HP1 requires dimerization of the CSD, which 
generates a hydrophobic groove that the peptide motif associates with 
(Thiru et al., 2004).
As described above, Su(var)3-9 functionally interacts with the 
chromo domain of HP1: It methylates H3K9 and thus generates a 
binding site for the HP1 CD that is essential for HP1 recruitment to 
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chromatin. However, it has been found that Su(var)3-9 also interacts 
physically with HP1. In co-immunoprecipitation experiments, it was 
shown that mouse HP1β binds the mouse homolog of Su(var)3-9, 
SUV39H1 (Aagaard et al., 1999). The interaction was mapped to the 
CSD of HP1 and the extreme N-terminus of SUV39H1 (residues 1 – 42, 
outside of the chromo domain of SUV39H1 as well as its SET domain; 
Melcher et al., 2000).
The interaction between SUV39H1 and HP1 has potentially far-
reaching biological implications, because it suggests a mechanism for 
the spreading and maintenance of heterochromatic structures and 
epigenetic gene silencing. According to this model, SUV39H1, the histone 
H3 tail and HP1 collaborate to form a self-sustaining loop: methylated 
H3K9me recruits HP1, which in turn directs more SUV39H1 histone 
methyltransferase to chromatin, enabling further methylation (Figure 
1.9B).
Besides dimerization and the interaction with Su(var)3-9, several 
transcriptional regulators have been shown to bind to the HP1 CSD, 
such as the transcriptional repressors TIF1α, KAP-1/TIF1β, and Rb (Le 
Douarin et al., 1996; Nielsen et al., 1999; Nielsen et al., 2001b). This 
could provide means for initial recruitment of HP1 to specific regions of 
chromatin. Rb, for example, has been reported in human cells to recruit 
HP1β to the cyclin E promoter and induce tri-methylation of H3K9 by 
SUV39H1 (Nielsen et al., 2001b). The reported interaction of the HP1 
chromoshadow domain with class II HDACs (Zhang et al., 2002; reports 
of HP1 interaction with HDACs also in S. pombe, Yamada et al., 2005) 
may contribute to gene repression and the initiation of stable silencing 
through hypoacetylation of histones H3 and H4 and deacetylation of 
H3K9, which allows for K9 methylation.
34
A
B
1.9
M
M
M
M
M
M
M
M
Crosslinking of
adjacent nucleosomes
“Discontinuous” crosslinking
of nucleosomes
M
M
M
CD
M
HP1
CSD
SUV39H1
SET
M
MM M
M
M
M
M
M
CD
CSD
H3K9me
Figure 1.9: Models for HP1-mediated chromatin condensation and the 
spreading of heterochromatic domains.
a: Model for chromatin condensation through nucleosome crosslinking via HP1 
dimerization. According to this model, HP1 binds to the H3K9me mark (small red 
dot) through its chromo domain (blue). Dimerization of HP1 molecules through the 
CSD (in pale red) can bridge individual adjacent nucleosomes, thus preventing a 
more open chromatin conformation of loci carrying H3K9me (left). "Discontinuous" 
bridging between different chromatin fibers could even cause condensation of larger 
heterochromatic domains (right). The structures may then be further stabilized by 
interactions with additional heterochromatic factors.
B: Model for the spreading of heterochromatin by interplay of SUV39H1, histone 
H3, and HP1. The histone mark H3K9me (small red circle "M") recruits the effector 
protein HP1 via its chromo domain (CD) to chromatin, possibly with the contribution 
of other stabilizing interactions. HP1 crosslinks nucleosomes and forms condensed, 
heterochromatic structures. In addition, however, HP1 also recruits the HMTase 
SUV39H1 (in yellow). Upon recruitment to chromatin, SUV39H1 methylates 
through its SET domain adjacent unmethylated H3 tails at lysine 9, forming new 
H3K9me binding sites for HP1. Thus, this three-component system could explain 
spreading and maintenance of heterochromatic gene silencing.
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In addition to these, various other molecular interactions of HP1 
have been described, ranging from histone chaperones over Su(var)3-7, 
a PEV modifier with an unknown molecular function, to proteins 
involved in replication, DNA repair and nuclear architecture. For more 
examples and references see Table 1.4.
C. Hinge region
Compared to the chromo and chromoshadow domains, the hinge 
region that connects them has received much less attention. The hinge 
is somewhat variable in length between the different isoforms (ranging 
for Drosophila, e.g., from 60 aa in HP1a to 23 aa in HP1c, Figure 1.6B). 
As can be seen from the Table in 1.6B, its sequence conservation is 
significantly lower than that of the CD or the CSD, with the notable 
exception of a few clusters of mostly basic amino acids (see alignment 
in Figure 1.7).
The sequence variation between the hinge regions of the different 
HP1 isoforms has led to the suggestion that the hinge may be the 
key to explain the differences that have been observed in localization 
and behaviour between the isoforms. Indeed, most of the molecular 
interactions that have been described for the hinge region so far have 
only been observed for specific isoforms (Ainsztein et al., 1998; Hale et 
al., 2006).
Despite its low level of sequence conservation, the hinge regions 
of all three isoforms have a common characteristic found in various 
organisms: a striking density of charged amino acids (K, E, D) and 
serines. The presence of multiple serine residues has led to speculation 
that this region of HP1 may be the site of phosphorylation (see below), 
but no phosphorylation sites in the hinge have been unambiguously 
identified so far.
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The hinge region is assumed to have no defined secondary 
structure, but instead is probably unstructured, in keeping with a very 
high accessibility by proteases (Ball et al., 1997). Even though much 
less is known about the molecular interactions of the hinge region than 
those of the CD and CSD, nevertheless several molecular interactions 
of this domain of HP1 have been discovered. Since much of my Ph.D. 
research focuses on the HP1 hinge, I will describe the interactions of 
the hinge in a little more detail.
The HP1 hinge binds to INCENP (inner centromere protein), a 
member of the chromosomal passenger complex (Ainsztein et al., 1998). 
The chromosomal passenger complex (CPC) is a mitotic kinase complex 
that shows very distinct localization changes during mitosis and plays an 
important regulatory role in multiple steps of chromosome segregation 
and cell division. After identification of human HP1α and HP1γ from 
a two hybrid screen with INCENP, the interaction was reproduced for 
HP1α in pull-down experiments with recombinant/in vitro translated 
components and has since been confirmed by co-IP from Xenopus egg 
extracts (Tseng, 2008). The interaction is not required for targeting 
of INCENP to centromeres, and the exact biological function of this 
interaction is currently still elusive.
An interaction of the HP1 hinge region with RNA was demonstrated 
in mouse cells by Muchardt and colleagues (Muchardt et al., 2002). 
Through immunofluorescence-overlay assays, it was shown that 
besides the chromo domain the hinge region and an RNA component 
was required for the proper localization of HP1 to regions of pericentric 
heterochromatin, in keeping with observations by Maison et al. (Maison 
et al., 2002). The hinge of HP1α and HP1γ directly interacts with RNA by 
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EMSA (electrophoretic mobility shift assay). Competition experiments 
showed that a mixture of nuclear RNA bound best, while control 
sequences (AU- and GC-rich RNA oligomers, tRNA, ssDNA, dsDNA) did 
not. This suggests that there may be a specific secondary structure or 
sequence motif that is present in some of the nuclear RNAs and that is 
specifically bound by the HP1 hinge, but to date nothing more is known 
about the nature and sequence of any RNAs HP1 may bind to.
Recently, it has been reported that the hinge region of human 
HP1 also interacts with the linker histone H1b, as shown by both in 
vitro binding and in vivo FRET experiments (Hale et al., 2006). The 
interaction, which was mapped to the C-terminal domain of H1b, is 
specific for the isoform HP1α (the HP1 isoform that also has been 
specifically linked to breast cancer metastasis, see below; Kirschmann 
et al., 2000). Interestingly, binding of H1b to HP1α is controlled by 
posttranslational modification of H1b. Phosphorylation of the histone 
by CDK2/cyclin E at late G1/S abolishes the interaction, a step that is 
required for efficient progression of the cell cycle, possibly because it 
leads  to a more relaxed structure that facilitates DNA replication.
Despite these published interactions, the HP1 hinge remains a 
region about which very little is known compared to the other domains of 
HP1. The identification of additional interaction partners, understanding 
the contribution of the HP1 hinge to the differences observed between 
isoforms, and potential phosphorylation of hinge serines remain wide 
open questions in the understanding of HP1.
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Cellular localization and functions of hp1
HP1 in heterochromatin
Thorough localization studies of HP1 in Drosophila and mammals have 
shown that HP1 proteins are localized primarily to regions of constitutive 
heterochromatin around the centromeres and at the telomeres, which are 
rich in repetitive DNA sequences. For example in polytene chromosomes of 
Drosophila, mainly the chromocenter (i.e. regions of pericentric chromatin) 
and the telomeres are stained with HP1 antibodies (Fanti et al., 1998; 
James and Elgin, 1986; Li et al., 2002). The S. pombe homolog Swi6 is 
found at silent mating-type loci, centromeres and telomeres (Ekwall et al., 
1995), and in mouse cells, colocalization of HP1 with DAPI-dense regions 
of constitutive heterochromatin is observed during interphase (Figure 1.9; 
Lachner et al., 2001).
As is evident from its function as a dominant suppressor of 
variegation, HP1 plays an essential role in the the formation of silenced 
domains of constitutive heterochromatin at pericentric regions, which in 
turn is crucial for the faithful segregation of chromosomes during mitosis. 
HP1 mutation also leads to defective telomere protection in Drosophila (it 
is required for telomere capping, silencing and telomere length control; 
Perrini et al., 2004) and loss of silencing at mating type loci in S. pombe.
But besides this role in gene silencing, HP1 also has a function in 
promoting gene expression within heterochromatin. Some genes located 
within pericentric heterochromatin require a heterochromatic environment 
for their normal expression, as first described for the "light" and "rolled" 
genes (Lu et al., 2000). These genes depend on HP1 to generate the 
heterochromatic structures needed for their proper expression, and similar 
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observations have by now been made for many other genes (de Wit et al., 
2007). Thus HP1 plays different, quite opposing roles within constitutive 
heterochromatin, which are not understood in mechanistic terms.
HP1 in euchromatin
However, it is well documented that HP1 does not only localize to regions 
of constitutive heterochromatin. A small fraction of HP1 is also found 
at sites within euchromatic regions of the chromosomes. In polytene 
chromosomes of Drosophila, e.g., HP1a is present at about 200 sites within 
the chromosome arms (Fanti and Pimpinelli, 2008; Li et al., 2002). This 
suggests that HP1 may also play a role in the repression of individual genes 
within euchromatin, an interpretation supported by reports demonstrating 
recruitment of HP1 by several transcriptional repressors (Le Douarin et al., 
1996; Nielsen et al., 1999; Nielsen et al., 2001b) and the observation that 
some HP1-bound genes in euchromatin are upregulated upon mutation of 
HP1a in Drosophila (Hwang et al., 2001).
Several experimental obervations argue that HP1 by itself can initiate 
heterochromatic structures and may indeed directly induce gene silencing 
within euchromatin. When HP1 is tethered to sites within euchromatic 
regions of Drosophila chromosomes through an ectopic binding domain, 
this is almost always sufficient to nucleate the formation of heterochromatin 
and silencing of nearby reporter genes (Li et al., 2003). In mammalian cells, 
targeting of HP1α through a GAL/lacR system to euchromatic regions leads 
to local condensation of the higher order chromatin structure (Verschure 
et al., 2005). These experiments suggest that HP1 could indeed play a role 
in gene repression within euchromatic regions of chromosomes.
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 However, the involvement of HP1 in the regulation of euchromatic 
regions is even more complex and goes beyond its well established role in 
gene silencing. Quite surprisingly, at some euchromatic loci HP1 association 
clearly correlates with increased gene expression, such as in some 
developmental (ecdysone-) and heat-shock induced chromosome puffs in 
Drosophila (chromosome puffs are morphological features caused by strong 
decondensation of chromatin due to high levels of gene expression). Upon 
induction of gene expression at these sites, Drosophila HP1a is specifically 
recruited to these decondensed regions of extremely active transcription 
(Piacentini et al., 2003), suggesting that HP1 can indeed promote gene 
expression without inducing heterochromatic structures. Support for this 
interpretation comes from recent high-resolution mapping of HP1 binding 
sites in Drosophila that finds HP1 at transcriptionally active loci (de Wit et 
al., 2007; Johansson et al., 2007), from the observation that HP1 deletion 
reduces mRNA levels of some euchromatic genes (Cryderman et al., 2005), 
and from ChIP (Chromatin immunoprecipitation) experiments in mouse 
cells that find HP1γ at actively transcribed regions (Vakoc et al., 2005). 
Thus, despite its name, HP1 seems to have functions in euchromatin that 
go beyond its role as an initiator of gene silencing and heterochromatin 
formation, at least at a subset of loci.
In addition to constitutive heterochromatin and sites of repressed and 
activated euchromatic genes, HP1 has also been detected at a few other 
cellular structures in mammalian cells, such as in PML nuclear bodies 
(discrete subnuclear structures of unknown function that are dirupted in 
acute promyelocytic leukemia; Everett et al., 1999; Seeler et al., 1998) or 
at the periphery of nucleoli (Minc et al., 1999).
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To further complicate the localization of HP1, in many instances 
subtle differences between the three HP1 isoforms are observed. It has 
repeatedly been noted, for example, that euchromatic localization and 
function is more pronounced in the case of HP1γ/HP1c than in the case 
of the other two isoforms (Hwang and Worman, 2002; Minc et al., 2000; 
Smothers and Henikoff, 2001; Vakoc et al., 2005). High-resolution mapping 
in Drosophila Kc cells confirms these findings: As opposed to HP1a, little 
enrichment of HP1c at pericentric regions is observed, but rather a focal 
distribution to a few "hotspots" near highly active genes, where HP1c 
colocalized with many transcription factors and other regulatory proteins 
(de Wit et al., 2007; Moorman et al., 2006). From a molecular point of view, 
differences between the isoforms are perhaps not completely surprising, 
because there is clear sequence variation between the three isoforms, in 
particular in the hinge region. Differences in the molecular interactions 
of the three isoforms (e.g. HP1α interacts with histone H1b, while HP1β 
and HP1γ do not), and in their involvement in human disease (e.g. HP1β, 
but not HP1α, is downregulated in the progression of human melanoma; 
Nishimura et al., 2006) have been known for a long time.
In summary, HP1 is clearly involved in multiple, sometimes seemingly 
opposing cellular events. It is a central player in the formation/maintenance 
of constitutive heterochromatin at pericentric regions and telomeres, which 
is crucial for the faithful segregation of chromosomes during mitosis, as 
well as for the normal expression of certain genes located within pericentric 
heterochromatin. Besides its function in heterochromatin, HP1 clearly also 
plays a part in euchromatin, where it represses transcription at some loci, 
while promoting gene expression at others. On a molecular level, little is 
known how HP1 fulfills these multiple functions.
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The paradigm that the presence of HP1 always accompanies and 
promotes constitutive heterochromatin is clearly not completely true, 
since ample evidence exists for both euchromatic localization and positive 
involvement in gene expression. However, by far the largest fraction of 
cellular HP1 is indeed localized to regions of constitutive heterochromatin by 
H3K9me-dependent mechanisms, where it is involved in heterochromatin 
formation and gene silencing.
Changes in hp1 localization during the cell cycle
Detailed studies of HP1 in cultured cells have revealed dramatic changes 
in HP1 localization during mitosis in Drosophila (Kellum et al., 1995) as 
well as human cells (Hayakawa et al., 2003; Minc et al., 1999; Murzina et 
al., 1999). When chromosome condensation is initiated during prophase, 
all three HP1 isoforms are released from their interphase binding sites on 
chromatin and become dispersed throughout the cytoplasm (see Figure 
1.10). No earlier than telophase/early G1 does the bulk of HP1 isoforms 
reassociate with chromatin.
Quite surprisingly, the binding site of HP1 at constitutive 
heterochromatin, methylated lysine 9 (K9) of H3, is not removed during 
this dissociation (Bannister et al., 2002). This is surprising, because in 
most other cases where release of a recruited effector protein is observed, 
this is achieved by removal of the histone mark. Before our work, the 
mechanisms of the reversible ejection of HP1 from chromatin during 
mitosis were thus still enigmatic.
Several studies have reported another subtlety of HP1 dynamics 
during mitosis observed in human cells: A small fraction of the HP1α 
isoform (and, according to some reports also of HP1β and HP1γ) reassociates 
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at metaphase with centromeric regions of chromosomes (Hayakawa et al., 
2003; Minc et al., 1999; Sugimoto et al., 2001). Hayakawa and colleagues 
demonstrated that this reassociation is chromo domain-independent and 
rather requires the CSD and part of the hinge region (HP1α 101-180). 
Recently, it has been reported that HP1 interacts with shugoshin, a factor 
that is required for protection of centromeric cohesins during mitosis/
meiosis (Yamagishi et al., 2008). The interaction is conserved in both S. 
pombe and humans, and shugoshin is mislocalized in the absence of HP1, 
suggesting that shugoshin recruitment may be the biological funtion of the 
reassociation of HP1α with centromeric regions of chromosomes during 
metaphase.
1.10
anti-HP1DNA
Interphase
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Overlay
Figure 1.10: Cellular localization of hp1 in mammalian cells.
Localization of HP1 in interphase and metaphase. Immunofluorescence staining 
of 3T3 mouse fibroblast cells. In interphase the HP1α signal colocalizes with 
densely staining regions of DNA, indicating that HP1α is concentrated at 
regions of pericentric heterochromatin. (Note: These striking dots of condensed 
heterochromatin are specifically observed in mouse cells and not seen as clearly 
in other, e.g. human, cells.) In metaphase, HP1α is dispersed throughout the 
cytoplasm and for the most part excluded from the condensed DNA, which is 
arranged in the metaphase plate. Similar observations are made with the other 
HP1 isoforms. DNA stained with DAPI.
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The mechanism of the reversible HP1 release has not been uncovered 
(or had not been uncovered at the time when I started with my thesis), and 
the biological function of the striking changes in HP1 localization during 
mitosis are completely unknown.
Molecular mechanism of hp1 recruitment
Essential role of CD-H3K9me interaction
Many studies have shown that the CD interaction with H3K9me is absolutely 
essential for the recruitment of HP1 to chromatin. If this interaction is 
abolished by point mutations or deletions of the chromo domain (e.g. 
Cheutin et al., 2003; Thiru et al., 2004) or by removal of the K9-methyl mark 
(Ekwall et al., 1996; Lachner et al., 2001), HP1 is not localized to pericentric 
heterochromatin anymore in several in vivo systems. Point mutations that 
abolish CD binding to H3K9me in flies exhibit the same phenotypic effects 
as HP1 deletions (suppression of PEV, homozygous lethality) and such 
constructs are incapable of rescuing the deletions (Eissenberg et al., 1990; 
Eissenberg et al., 1992; Platero et al., 1995).
Contribution of other mechanisms
However, several in vivo observations suggest that CD binding to H3K9me 
may not be sufficient for stable chromatin association of HP1 in the cell. 
The chromo domain alone is not targeted properly to heterochromatin 
in vivo and shows much lower resistance to extraction with detergents 
(Cheutin et al., 2003; Smothers and Henikoff, 2001; Thiru et al., 2004). 
Even certain point mutations in the chromoshadow domain are sufficient to 
reduce the stability of HP1‘s association with heterochromatin significantly 
(Fanti et al., 1998; Thiru et al., 2004). Moreover, the three HP1 isoforms 
45
have somewhat different localization patterns, even though their chromo 
domains bind H3K9me equally well in vitro. This suggests that additional 
molecular interactions contribute to HP1 chromatin association in vivo.
Several in vitro observations support the understanding that stable 
chromatin binding of HP1 involves additional interactions besides CD-
H3K9me binding, especially in the context of the nucleosome (in contrast 
to experiments with histone peptides). In pull-down experiments with 
recombinant GST-HP1, the CD alone could not pull down native soluble 
oligonucleosomes from chicken erythrocyte extracts (Meehan et al., 2003). 
Binding of bacterially expressed HP1 to mononucleosomes required the full-
length protein (Zhao et al., 2000). And, as Eskeland and colleagues reported, 
the association of recombinant Drosophila HP1 with highly methylated 
reconstituted chromatin was much weaker than with methylated peptides 
and presumably not sufficient to maintain a heterochromatic structure in 
vivo (Eskeland et al., 2007).
Considering the enormous increase in affinity that can be achieved 
through multivalency (Ruthenburg et al., 2007b), it seems possible that 
additional interactions besides CD binding to H3K9me could be the key 
to understand HP1 chromatin association in vivo. Several studies have 
proposed specific factors that may stabilize HP1 binding to chromatin. 
Eskeland and colleagues, e.g., found that the addition of the chromatin 
remodeler ACF1 (ATP-utilizing chromatin assembly and remodeling factor 
1) or the HMTase Su(var)3-9 increased binding of recombinant HP1 to 
methylated reconstituted chromatin arrays. Both factors are suppressors 
of variegation known to interact with the CSD of HP1, and the effect was 
independent of Su(var)3-9 HMTase activity, suggesting an increase in 
affinity through bimodal binding of HP1 to methylated chromatin (Eskeland 
et al., 2007).
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RNA is another molecule that has been implicated in HP1 chromatin 
association, based on the findings that RNase treatment of nuclei results 
in the release of HP1 binding in mammalian tissue culture cells (Maison 
et al., 2002), that HP1 recruitment to transcriptionally active heat-shock 
puffs depends on RNA (Fanti and Pimpinelli, 2008) and that HP1 interacts 
directly with RNA (Muchardt et al., 2002).
In addition, several other interactions of HP1 have been suggested 
to play a role in HP1‘s association with chromatin in vivo, such as the 
interactions with H1 and the histone H3 core (Meehan et al., 2003; Nielsen 
et al., 2001a) or with HOAP (Heterochromatin protein 1/origin recognition 
complex-associated protein; Badugu et al., 2003). However, the exact nature 
of these interactions is still quite enigmatic, and it seems there may be 
multiple factors among the huge number of HP1’s molecular interactions 
capable of contributing to HP1’s chromatin association.
H3K9me-independent chromatin association of HP1
As discussed above, the stabilization of HP1 on chromatin is a complex 
phenomenon and involves the CD-H3K9me interaction and additional 
interactions mediated by factors associated with HP1. However, the reality 
is actually even more complicated, because abundant observations show 
that there are also mechanisms of HP1 chromatin association that are 
completely independent of H3K9 methylation.
It has been noted, for example, that in Drosophila polytene chromosome 
stainings there is no full overlap of HP1 and H3K9me staining, indicating 
that particularly on euchromatic arms of chromosomes there are sites of 
HP1 binding that do not depend on the interaction with methylated lysine 
(Fanti and Pimpinelli, 2008; Li et al., 2002). In keeping with this, in chromo 
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domain point mutants that abolish K9me3 binding, association with sites 
on chromosome arms is still observed (Fanti et al., 1998). HP1 association 
with Drosophila telomeres is mediated by two mechanisms: One population 
of HP1 binds in a chromo domain-dependent fashion and is essential for 
silencing of telomeric sequences and telomere length control. The other 
fraction binds independently of the chromo domain and is required for 
telomere stability (Perrini et al., 2004).
While there are some hints about the mechanisms that could be 
involved in such K9me3-independent recruitment to chromatin (for 
example binding of the HP1 CD to H1K26me, Daujat et al., 2005); or HP1-
binding proteins with DNA-binding affinity, Nielsen et al., 1999), it seems 
that the enigmatic multiple functions of HP1 may be related to the many 
means by which the protein is targeted to its site of action. Clearly much 
more  careful research will be required to tease apart all of these different 
mechanisms of HP1 recruitment and chromatin binding.
Dynamics of HP1 binding
Even though the overall structure of heterochromatic domains is quite 
stable over time, HP1 binding to chromatin is actually highly dynamic. 
As  demonstrated by FRAP (fluorescence recovery after photobleaching) 
experiments in mammalian cells, HP1 association with chromatin is 
characterized by rapid on-off kinetics (Cheutin et al., 2003; Festenstein et 
al., 2003; Schmiedeberg et al., 2004). These experiments also showed that 
there are at least three different subpools of HP1 with different mobilities 
in heterochromatin.
As described in more detail later in this thesis, I observed in my own 
experiments with mammalian cells some differences in the fractionation/
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extraction behaviour of exogenous GFP-HP1 compared to endogenous 
HP1 (see Chapter 4). Thus, these results on HP1 dynamics have to be 
interpreted with caution.
hp1, heterochromatin nucleation and rnai
According to current understanding, heterochromatin nucleation is distinct 
from the subsequent steps of heterochromatin spreading and maintenance. 
Two alternative mechanisms seem to be involved in the nucleation process. 
One way is the recruitment of HP1 by factors with DNA-binding affinity, 
such as Rb or KAP-1 (see Section "HP1 domains and molecular interactions: 
Chromoshadow domain"). HP1 in turn recruits methyltransferase activity 
and mediates spreading/maintenance of heterochromatic structures. This 
appears to be the predominate mechanism for the repressive function of 
HP1 in euchromatic regions.
Formation of constitutive heterochromatin, however, seems to be 
mediated by other mechanisms. Besides DNA-binding proteins (Jia et 
al., 2004; Kim et al., 2004; Yamada et al., 2005), it can be mediated by 
mechanisms that require the presence of repetitive DNA elements and 
involves the RNAi machinery, as suggested by observations made in genetic 
experiments with S. pombe. Loss of/mutations in components of the RNA 
interference pathway (Argonaute 1, Dicer, RNA-dependent RNA polymerase) 
prevent heterochromatin-specific chromatin modifications (such as 
H3 K9 methylation), binding of Swi6 and formation of heterochromatin 
at centromeres and mating type regions (Hall et al., 2002; Volpe et al., 
2002). The result has been confirmed by similar findings in Tetrahymena 
(Mochizuki et al., 2002), Drosophila (Pal-Bhadra et al., 2004) and mouse 
(Kanellopoulou et al., 2005).
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Through a series of other observations, a pathway is emerging 
that involves transcription of repetitive elements within centric regions 
by RNA Polymerase II into double-stranded RNAs, processing of these 
dsRNAs into short interfering RNAs by the RNase Dicer, and the RNA-
induced transcriptional gene silencing complex (RITS). It is clear at 
this point that the repetitive elements are sufficient to nucleate Swi6-
dependent heterochromatin at ectopic sites. However, the exact molecular 
details of many steps of the pathway, and how siRNAs generated during 
this process localize histone-modifying activities, in particular the Clr4 
HMTase, is currently not understood (see Grewal and Jia, 2007 and Kwon 
and Workman, 2008 for more details and references).
hp1 phosphorylation
In several organisms, it has been reported that HP1 is multiply 
phosphorylated. These studies detected HP1 phosphorylation upon 
metabolic 32P-phosphate labelling of cells, and confirmed the presence 
of several differently charged isoforms by immunoblotting after 2D or 
acid urea gel electrophoresis, leading to the observation of seven to eight 
differently charged isoforms in  Drosophila (Eissenberg et al., 1994), four 
in Tetrahymena (Huang et al., 1999), and three (HP1α) and five (HP1γ) in 
human tissue culture cells (HP1β was found not to be phosphorylated in 
this study; Minc et al., 1999).
Changes in the phosphorylation state of HP1 correlate with specific 
biological events. The number of differently charged HP1 isoforms in 
Drosophila, e.g., increases at hour 1.5 – 2 of early embryonic development, 
around the time when cytologically visible heterochromatin appears and HP1 
concentrates in heterochromatin (Eissenberg et al., 1994). In Tetrahymena, 
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HP1 hyperphosphorylation correlates with chromatin changes induced by 
starvation (Huang et al., 1999). And in human HeLa cells, the number 
of charged isoforms is specifically increased during mitosis (Minc et al., 
1999).
Despite these interesting correlations, an in depth analysis of HP1 
phosphorylation and its role has turned out to be difficult. Due to the 
lability of the modifications and the challenges in purifying a protein 
that is strongly associated with heterochromatic structures, none of the 
phosphorylation sites have really been mapped in vivo to date.
A few sites have been proposed based on in vitro phosphorylation: 
Pim-1 kinase can phosphorylate HP1γ in the hinge region (the exact site 
was not mapped) in in vitro kinase assays (Koike et al., 2000). Three sites 
(one in the N-terminus at S15, two at the very C-terminus at S199 and 
S202; additional phosphorylation suggested in the hinge) were found 
phosphorylated in recombinant HP1a after incubation with  nuclear extracts 
from Drosophila embryos (Zhao and Eissenberg, 1999). While these may 
indeed represent sites of in vivo phosphorylation of Drosophila HP1a, due 
to the known promiscuity of kinases in the test tube these results have to 
be interpreted with caution.
Naturally, the lack of knowledge about the exact sites of 
phosphorylation has hindered an understanding of the biological function of 
HP1 phosphorylation beyond the described correlative data. Where results 
were obtained, they have often not been fully conclusive, despite some 
curious observations. For example, while Eissenberg and colleagues had 
found that HP1 becomes hyperphosphorylated at the stage of development 
when HP1 seems to localize to heterochromatin in Drosophila embryos 
(Eissenberg et al., 1994), another study reported that hyperphosphorylated 
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HP1a is extracted more easily with salt from chromatin of Drosophila 
embryos (Huang et al., 1998). When Zhao and Eissenberg tested mutants 
of phosphorylation sites for their effect on HP1 silencing, they found 
that both S to A and S to E mutation showed the same effect (reduced 
silencing; Zhao et al., 2001). However, another study mutated nine serine 
residues in the hinge region of Drosophila HP1a (most of these residues 
not conserved in other organisms), including the same sites as Zhao et 
al. In this case enhanced silencing activity for both S to G and S to E 
mutants was observed (Badugu et al., 2005). In addition, Badugu et al. 
reported that HP1 dimerization and binding to H3K9me were enhanced 
by the mutations, while interactions with components of the Drosophila 
Origin of Replication Complex were reduced. No other interactions besides 
these were tested.
In summary, the sites of HP1 phosphorylation have not been 
successfully mapped in any organism at this point, nor have the biological 
function(s) of HP1 phosphorylation been fully understood. This is 
particularly true for the human HP1 isoforms, where not a single site has 
been mapped so far. Similarly, the role of HP1 phosphorylation in mitosis 
has not been studied at all, despite the curious observation that HP1 
becomes hyperphosphorylated at this stage of the cell cycle. Some of these 
questions, I have tackled in my thesis project (see below).
open questions
In recent years, enormous progress has been made in our understanding 
of the general principles how chromatin is organized and functions within 
the cell. HP1 is today one of the best-studied factors among all chromatin 
components. Since its discovery in the 1980s, much has been learned 
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about its multiple important roles in the cell, the molecules it binds to and 
the pathways it interacts with.
However, there are still many fundamental questions in HP1 biology 
that have not been answered. For example, a full understanding of the 
different ways how HP1-dependent heterochromatin is nucleated, of the 
different roles of the three HP1 isoforms, of the regulation of HP1’s diverse 
molecular interactions, or of the exact molecular mechanism(s) of HP1-
mediated gene silencing will still require plenty of research. HP1 may have 
additional, still undiscovered roles in the cell, as suggested by its binding 
partners (e.g., structural components of the nucleus, implicating HP1 in 
nuclear organization). When I began my Ph.D., little was known about 
HP1’s posttranslational modifications beyond the fact that they exist. 
Furthermore, the molecular mechanisms underlying the relocalization of 
HP1 at the onset of mitosis and the biological reason for these striking 
localization changes remained exciting, but still unaddressed questions.
In the past few years, several studies have implicated genetic 
alteration of HP1 in the development of several types of human cancer. In 
highly invasive/metastatic breast cancer cells, HP1α (not HP1β or HP1γ) 
is down-regulated compared to poorly invasive/nonmetastatic breast 
cancer cells (Kirschmann et al., 2000). Similarly, HP1β downregulation 
correlates with the invasivess of several melanoma cell lines (Nishimura 
et al., 2006). The involvement of HP1 in human disease underlines the 
importance of learning more about this important chromatin protein. A 
better understanding of the multiple roles that HP1 plays in the cell and 
the molecular mechanisms underlying its functions will not only contribute 
hugely to our understanding of chromatin and its functions in the cell, 
but may also lead to insights that could one day be used for the benefit of 
human patients in the clinic.
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The research of my Ph.D. thesis focused on understanding the remarkable 
changes that HP1 undergoes during mitosis, both with respect to its 
localization and to its posttranslational modification profile.
Fascinated by the question of how reversible dissociation of HP1 
could be achieved without any changes to the histone mark that recruits the 
effector, in the first part of my thesis I sought to understand the molecular 
mechanisms of the mitotic chromatin dissociation of HP1. Through the 
combination of in vitro and in vivo experiments presented in this thesis, I 
show that the transient release of HP1 during mitosis is achieved by a novel 
mechanism, methyl-phos switching, in which two histone marks cooperate 
to bring about dynamic release of an effector protein: Phosphorylation of 
H3 at serine 10 at the onset of mitosis interferes with HP1 binding to 
methylated lysine 9 and thus ejects the effector protein from its binding 
site at chromatin. In vivo inhibition experiments show that methyl-phos 
switching is a necessary step for the mitotic release of HP1.
Prompted by observations made during the study of methyl-phos 
switching, in the second part of my thesis I set out to learn more about the 
dramatic changes in HP1’s posttranslational modification profile during 
mitosis. This led to purification/mass spectrometry identification of 
almost a dozen phosphorylations on the three human HP1 isoforms, most 
of which map to the HP1 hinge region and are upregulated in mitosis. 
For one particularly conserved site, I was able to identify Aurora B as 
the responsible kinase. In various attempts, no substantial evidence for a 
connection between mitotic HP1 phosphorylation and the mitotic release 
of HP1 or the reassociation of a subpool of HP1 to centromeres could 
be established. I conclude with in vitro data that suggests that mitotic 
phosphorylation of the HP1α hinge may play a role in the regulation of HP1 
association with RNA.
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In sum, my thesis has revealed that HP1's behavior and interactions 
in mitosis are regulated by posttranslational modifications on two levels: 
phosphorylation of histone H3 as well as phosphorylation of HP1 itself. 
Some of the mechanistic findings presented in this thesis may have 
implications even beyond the realm of chromatin biology.
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CHAPTER 2
MATERIALS AND METHODS
Reagents
Chemicals, media and recombinant proteins
Nocodazole, MG132, Microcystin LR, and Thymidine were purchased 
from Sigma, β-glycerolphosphate from Calbiochem, and propidium 
iodide from Molecular Probes. Calyculin A was from LC Laboratories. 
Hesperadin was received as a gift from Boehringer Ingelheim, Austria. 
Radiolabelled nucleotides were obtained from Amersham/GE Healthcare, 
and IPTG was from Acros Organics. Normal goat serum was from Jackson 
Immunoresearch. All tissue culture media and G-418 were purchased 
from Gibco. Recombinant MSK1, RSK2, and IKKalpha were from Upstate 
Biotechnology. Immunoprecipitated Xenopus laevis Chromosomal 
Passenger Complex was a kind gift of Boo Shan Tseng (Funabiki lab, 
Rockefeller University). All other reagents that were not generated by 
ourselves were from Fisher Scientific.
Peptides and peptide modification
Unmodified and posttranslationally modified peptides of the histone H3-
tail (residues 1-15 and 1-20) and of the HP1α hinge region (residues 83-
101) were synthesized either at the Baylor College of Medicine Protein 
Chemistry Core Laboratory or the Rockefeller University Proteomics 
Resource Center. For H3 peptides, a non-native tyrosine residue was added 
at the C-terminus (for concentration determination by UV absorption 
measurements). For pull-down experiments, an artificial biotin group was 
added to the C-terminus (H3 peptides) or N-terminus (HP1α peptides) 
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during synthesis. Peptides were purified by RP-HPLC (reversed-phase 
high-performance liquid chromatography) and characterized by MALDI-
MS (Matrix-assisted laser desorption/ionization mass spectrometry) by 
the Proteomics Resource Center.
 For fluorescence anisotropy measurements, peptides were labelled 
using fluorescein-5-EX succinimidyl ester (Molecular Probes) according 
to manufacturer's instructions and then purified by gel filtration (column: 
0.5 ml G10 Sephadex, Pharmacia; buffer: 100 mM KPO4 (pH 7.5)) and RP-
HPLC.
Bacterial media
Bacteria were grown in LB medium (1% tryptone, 0.5% yeast extract, 
1% NaCl), usually at 37° C. For selection, the following antibiotics were 
included in the media: ampicillin (100 µg/ml), kanamycin (50 µg/ml), or 
chloramphenicol (25 µg/ml).
Cell lines and tissue culture media
Human HeLa, HeLa S3, HEK293, HeP2, mouse NIH3T3, and 10T1/2 cell 
lines were all from ATCC. Cells were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM, with 4.5 g/l D-Glucose, L-Glutamine and 110 mg/l 
Sodium pyruvate; Gibco) supplemented with 10% fetal bovine serum (FBS, 
PAA Laboratories) and penicillin−streptomycin (10 000 U/ml and 10 000 
µg/ml, respectively; Invitrogen), at 37 °C in a humidified atmosphere with 
5% CO2. Cell monolayers were detached by one wash with PBS (phosphate 
buffered saline) followed by incubation in 0.05% trypsin/0.5 mM EDTA 
(Gibco).
Antibodies
For primary and secondary antibodies used, including dilutions, see Table 
2.1 and Table 2.2, respectively.
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Table 2.1: Primary antibodies 
Antibody Source Western IF
HP1S92ph1 
("Phos-HP1") 
gift of R. Urrutia (Mayo 
Clinic, Rochester, MN) 1:2 000 1:200 
Anti-HP1 MAB3446 (Chemicon) 1:7 500 --- 
Anti-HP1 
#05-689 (Upstate) 
(cl15.19s2) 
1:2 000 --- 
Anti-HP1 MAB3584 (Chemicon) --- 1:5 000 
Anti-HP1 MAB3448 (Chemicon) 1:10 000 1:7 500 
Anti-HP1 MAB3450 (Chemicon) 1:40 000 1:15 000 
Anti-H3K9me3  #07-442 (Upstate) 1:1 000 1:1 000 
Anti-H3S10ph #05-598 (Upstate) 0.5 μg/ml --- 
Anti-H3S10ph  #06-570 (Upstate) 1:5 000 --- 
Anti-H3S10ph #05-806 (Upstate) --- 1:4 000 
Anti-H3K9me3S10ph  #05-809 (Upstate) 1:1 000 1:1 000 
Anti-H3  Ab1791 (Abcam) 0.5 μg/ml --- 
Anti-H3  #06-755(Upstate) 1:1 000 --- 
Anti-GFP #11814460001 
(Roche) 1:10 000 --- 
Anti-Aurora B gift of S. Taylor 
(Ditchfield et al., 2003) --- 1:750 
Anti-Aurora B #611082 
(BD Biosciences) 1:250 --- 
Anti-Aurora A #603301(Biolegend) 1:500 --- 
Anti-Flag M2 F1804 (Sigma) 1:2 000 1:1 500 
Anti-HA (HA.11) MMS-101P (Covance) 1:1 000 1:1 500 
Anti-Cyclin B1 #05-373 (Upstate) 1:1 000 --- 
1 purified rabbit IgG against HP1 peptide 85-98 (SESNKRKSphNFSNSA) 
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Table 2.2: Secondary antibodies 
Antibody Source Western IF
Anti-rabbit(IgG)-HRP
Amersham/GE 
Healthcare 
1:2 500 ---
Anti-rabbit(IgG)-HRP
#PO399, 
Dakocytomation 
1:2 500 ---
Anti-mouse(IgG)-HRP
Amersham/GE 
Healthcare
1:2 000 ---
Goat-anti-rabbit 
AlexaFluor488
Molecular Probes --- 1:2 000
Donkey-anti-rabbit 
AlexaFluor488
Invitrogen --- 1:2 500
Sheep-anti-mouse-
Rhodamine Red X
Jackson 
ImmunoResearch
--- 1:1 500
Molecular Biology
Plasmids
Constructs were generated by standard techiques of DNA cloning 
(Sambrook and Russel, 2001 ; for a brief description see next section), 
using the commercially available vectors pET11a (Novagen) for His-tagged 
constructs, pEGFP-N and pEGFP-C (Clontech) for GFP-tagged constructs, 
and pGEX (Amersham/GE Life Science) for GST-tagged constructs.
To generate His6-tagged full-length or chromo domain constructs 
of the three HP1 isoforms, the full sequence of human HP1α (GenBank 
BC006821; residues 1-191), HP1β (GenBank BC002609; residues 1-185) 
and HP1γ (GenBank BC000954; residues 1-183), or regions encompassing 
the chromodomains (HP1α: 15-71, HP1β: 15-72, HP1γ: 24-81) were fused 
to His6-tags by PCR with EST (expressed sequence tag) clones as templates 
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(HP1α I.M.A.G.E. Consortium Clone ID 3448801; HP1β: I.M.A.G.E. 
Consortium Clone ID 5013102; HP1γ: I.M.A.G.E. Consortium Clone 
ID 3450099). PCR products were then cloned into the pET11a vector 
via the Nde I and BamH I restriction sites.
The vector pHD-N (N-terminal Flag-HA-Flag tag for expression 
in mammalian cells) for ligation-independent cloning (see below) was 
constructed by inserting an oligonucleotide cassette into the vector 
pIRESneo (Clontech) via the Nhe I and BamH I sites, pHD-C (C-terminal 
Flag-HA-Flag tag for expresion in mammalian cells) was generated by 
inserting a cassette into pIRESneo (Clontech) via the EcoR V and BamH I 
sites.
The GST-Aurora B plasmid (in pGEX, Amersham/GE Healthcare) 
was a gift of Ciaran Morrision (National University of Ireland, Galway). The 
His6-H1.4 plasmid (in pET16, Novagen) was a gift from Szabolcs Sörös 
(MPI for Biophysical Chemistry, Göttingen)
General DNA manipulation
For cloning and plasmid amplification, recombinase-deficient TOP10 
and XL1-Blue E. coli strains were used (see Table 2.3). Plasmid DNA 
was purified with the Quagen Mini and Midi prep kits (Qiagen). DNA 
digestions were carried out with restriction enzymes from NEB according 
to manufacturer’s instructions. DNA fragments were isolated with the 
QIAquick Gel extraction kit (Qiagen). Cut vectors were treated with calf 
intestine phosphatase (NEB) and then purified using the QIAquick PCR 
purification kit (Qiagen). Ligation of DNA was carried out with T4 DNA 
ligase (NEB) for 3 h at RT. Bacterial transformations were carried out by 
42° C heat shock according to standard protocols (Sambrook and Russel, 
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2001). All plasmid DNA constructs were fully sequenced, and sequencing 
was carried out by Genewiz Inc. Synthesized DNA and oligonucleotides for 
cloning and introducing mutations were purchased from Operon, Sigma 
Genosys, and GenScript.
Table 2.3: Bacterial strains 
Strain Genotype Source 
TOP10  
F- mcrA (mrr-hsdRMS-mcrBC) 80lacZM15 
lacX74 deoR recA1 araD139 (ara-leu)7697 galU 
galK rpsL (StrR) endA1 nupG 
Invitrogen 
XL1-Blue recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA 
lac[F’ proAB lacIqZM15 Tn10 (Tetr)] Stratagene 
BL21 F- ompT hsdSB(rB- mB-) gal dcm Stratagene 
RosettaBlue 
endA1 hsdR17(rK12-mK12+) supE44 thi-1 recA1 
gyrA96 relA1 lac pRARE (CmR) [F’ proA+B+ 
lacIqZDM15 ::Tn10(TcR)] 
Stratagene 
Rosetta(DE3)
pLacI 
endA1 hsdR17(rK12-mK12+) supE44 thi-1 recA1 
gyrA96 relA1 lac pLacIRARE (CmR) [F’ proA+B+ 
lacIqZDM15 ::Tn10(TcR)] (DE3) 
Stratagene 
 
PCR and mutation of plasmids
PCR to amplify DNA was carried out with Pfu polymerase (dPromega) 
according to manufacturer’s instructions. Typically, 50 µl reactions were 
set up with 10 ng template, 400 nM of each primer, 0.2 mM of each dNTP, 
5 µl 10X Pfu buffer, and 1 U of Pfu polymerase. A typical cycling program 
was 95°C/3:00min–[92/0:45–48/0:30–72/1:00]6x – [95/0:45–56/0:30–
72/1:00]26x–72/2:00–4/pause. PCR products were purified with the 
QIAquick PCR purification kit (Qiagen).
Mutations were introduced into plasmids with a protocol based on 
the "QuickChange Site-Directed Mutagenesis" procedure (Stratagene). Two 
primers of complementary sequence with the mutated bases in the middle 
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and about annealing 15-20 bases up- and downstream were designed 
with the QuikChange Primer Design software (at www.stratagene.com). 
The PCR product was purified with the QIAquick PCR purification kit 
(Qiagen), digested for 1 h at 37° C with Dpn I (NEB) and an aliquot used to 
transformed bacterial cells.
Ligation-independent cloning
Vectors were linearized with the blunt-end cutter BsaB I (NEB) and PCR 
purified (QIAquick PCR purification kit, Qiagen). Inserts were generated by 
PCR. Single-stranded ends for annealing ("sticky ends") are generated in 
this protocol through a T4 polymerase reaction in the presence of only one 
dNTP, which by its 3’→5' exonuclease activity removes the second strand 
to the first position where this nucleotide is in the sequence. The vector 
and the insert are constructed in a way that their resulting annealing 
sequences match and can be annealed. Because the annealing sequence 
is much longer than in standard ligations, the annealed sequences are 
so stable that no ligation enzyme is required. Vector "sticky ends" were 
generated by carrying out a T4 polymerase reaction (NEB) in the presence 
of dGTP, insert "sticky ends" in the presence of dCTP. The resulting vector 
and insert products were mixed (molar ratio or about 1:3), after 5 min of 
incubation at room temperatur EDTA was added to a final concentration 
of 10 mM. The annealing reaction was incubated for another 10 min at RT 
and then transformed into competent E. coli cells.
Cell-based methods
Mitotic arrest
To arrest HeLa cells in mitotis, 200 ng/ml nocodazole (Sigma) was added 
to culture media at 40-60% cell confluence. Cells were processed after 
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a 12 to 16 h incubation. Typical enrichment rates were about 70-80% 
mitotic cells.
Transfection of tissue culture cells and selection for stable cell lines
Transfection of DNA into HeLa cells was performed using Fugene 6 reagent 
(Roche) in accordance with the instructions of the manufacturer, typically 
using 3 µl Fugene reagent and 1 µg of DNA per 6-well. HEK293 cells 
were transfected by CaPO4 precipitation following established protocols 
(Sambrook and Russel, 2001).
Selection was started 5 days after transfection. HeLa cells were 
selected for four weeks with 0.5 µg/ml geneticin (G-418 sulfate; Gibco), 
HEK293 cells with 1 µg/ml. Untransfected cells were treated at the side 
as a control to verify that the treatment was working. No clonal selection 
was carried out and no clonal cells were used in this study (because this 
might have been a bias towards cells expressing the transgene at higher/
lower levels). For storage of cell lines, cells were frozen in fetal calf serum 
containing 10% DMSO (Sigma) and stored in a liquid nitrogen tank.
siRNA-mediated gene silencing
For a list of the siRNAs used, see Table 2.4. siRNA duplices (20 µM or 
100 µM) were stored at –80° C. For transfection with siRNAs, HeLa cells 
were grown for one day in DMEM/FBS without antibiotics/antimycotics. 
Transfection was carried out at 30-50% confluency in 24-well plates 
with Oligofectamine (Invitrogen), using 60 pmol siRNA duplices and 3 
µl Oligofectamine reagent per well. To optimize transfection efficiencies, 
BLOCK-iT fluorescent oligos (Invitrogen) were used and transfected cells 
analyzed by flow cytometry. Knock-down was analyzed by SDS-PAGE of 
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whole-cell extracts and subsequent immunoblotting. Pilot experiments were 
carried out to determine which time span of incubation after transfection 
resulted in maximal knock-down (for HP1 protein: 3.5 d).
Table 2.4: siRNA oligos  
Name Sequence Source
Aurora B 5’-AACGCGGCACUUCACAAUUGA-3’
Dharmacon 
(Lampson and 
Kapoor, 2005)
HP1 (5'-UTR) 5’-GGGACCUGGUGGCCUUAGUCUUUCA-3’
Dr. W. Fischle 
(MPI Göttingen, 
Germany)
HP1 5’-UGACACCAUAGAGGUGGCUUGAGAA-3’ Dr. W. Fischle
HP1 5’-GGUUACUUUGAACAAAUAA-3’ Qiagen
 
Cell synchronization by double thymidine block
To obtain a highly synchronized culture of HeLa cells, thymidine (2 mM 
final concentration was added to the medium of cultures grown to 20-
30% confluency (first block). After 15 h, cells were washed with PBS, 
fresh thymidine-free medium added and the cells grown for 9 h. Thymidin 
was re-added 2 mM f.c.) for another 15 h (second block). To release the 
second block, cells were washed in PBS and fresh thymidine-free medium 
was added. Cell synchrony was checked by light microscopy, by western 
blotting with mitotic markers, and by cell cycle flow cytometry.
Harvesting tissue culture cells
Cell were harvested commonly by scraping them off the plate with a cell 
scraper. For highly enriched mitotic cells, mitotic shake-off was carried 
out (i.e. rounded-up and detached mitotic cells were selectively pipetted 
off the plate). If cells were to be analyzed for phosphorylation, phosphatase 
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inhibitors (10 mM NaF, 2 mM Orthovanadate, 10 nM Calyculin A) were 
added, then cells were collected by centrifugation (500 g/5 min). Cells were 
washed once with PBS (including phosphatase inhibitors) and then flash 
frozen in liquid nitrogen and stored at –80° C until further processing.
Whole cell extracts were generated by resuspending the cells in protein 
sample buffer, heating the mixture for 5 min to 95° C, and subsequent 
shearing the the DNA by sonication in a BioRuptor (Diagenode) for 5 min 
at setting High.
Immunofluorescence staining and confocal microscopy
For analysis by immunofluorescence microscopy, tissue culture cells were 
grown on cover slips in 24-well plates. Where indicated, cells were treated 
with hesperadin (200 nM, in DMSO) for 1 h prior to fixation. Cells were 
fixed with 3.7 % parafomaldehyde in PBS for 15 min and permabilized 
with 0.2% Triton X-100/0.2% NP-40 in PBS. Where mentioned, the order 
was reversed, and the cells were first extracted with 0.2% NP-40 for 5 min 
and then fixed. Cells were blocked for 30 min in Blocking solution (PBS 
with 2.5% bovine serum albumine, 10% normal goat serum, and 0.1% 
Tween-20). Primary and fluorescently labelled secondary antibodies were 
applied in Blocking solution for 1 h at RT/over night at 4° C (primary 
antibodies) or for 30 min at RT (secondary antibodies), followed by three 
washing steps with PBS containing 0.1% Triton X-100. DNA was stained 
with DAPI (1 µg/ml in PBS; Sigma) for 30 seconds. The cover slips were 
mounted onto microscope slides with Prolong Gold Antifade (Molecular 
Probes). All steps were carried out at RT unless noted otherwise. 
Stainings were analyzed on an inverted LSM 510 laser scanning confocal 
microscope (Zeiss Axiovert 200) with a 63x/1.4 N.A. oil immersion lens 
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using a pinhole diameter of 1 Airy Unit. Image capture and processing was 
performed with the LSM 510 confocal software (Zeiss).
Cell cycle analysis and flow cytometry
Staining for cell cycle analysis was carried out following standard protocols 
(Darzynkiewicz et al., 1999). Cells were detached by trypsinization, collected 
by centrifugation (200 x g, 5 min), washed in PBS and resuspended to 
about 106 cells per 0.5 ml PBS. Ice-cold 70% ethanol was added under 
vortexing (to achieve a single cell suspension) and the cells were kept in 
fixative for at least 2 h on ice. Cells were centrifuged (500 x g, 5 min), the 
ethanol removed, and the cells washed in PBS. For staining of DNA, cells 
were resuspended in Propidium iodide staining solution, consisting of 
0.1% Triton X-100 in PBS with 0.2 mg/ml DNase free RNAse A (prepared 
by boiling RNase A for 5 min; Sigma) and 20 µg/ml of propidium iodide 
(Molecular Probes). After 30 min incubation at RT, the cells were analyzed 
on a FACSCalibur Flow Cytometry System (Becton-Dickinson). Cell cycle 
modelling was carried out with the software package FloJo (Tree Star) 
using the Watson Pragmatic Model.
Biochemical methods
Gel electrophoresis
SDS-PAGE was carried out according to the protocol by Laemmli (Laemmli, 
1970) with adaptions. Usually 12% or 15% Tris-glycine gels were used, 
for peptides 15% Tris-tricine gels (Schagger and von Jagow, 1987; Strom 
et al., 1993). Gel pouring and running was carried out with the Bio-Rad 
minigel system. For samples intended for mass spectrometry, the Novex 
precast system (Novagen) was used.
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Samples were boiled for 5 min in protein sample buffer (60 mM 
Tris (pH 6.8) 10% glycerol, 2% SDS, 140 mM β-mercaptoethanol, 0.03% 
bromophenol blue). Gels were run typically for 40 min at 200 V in SDS-
PAGE running buffer (25 mM tris base, 200 mM glycine, 0.1% SDS). Novex 
gels were run according to manufacturer's instructions in the provided 
MOPS or MES buffer systems. Gels were stained with Coomassie (10% 
acetic acid, 50% methanol, 0.05% Coomassie R-250) and destained with 
40% methanol/10% acetic acid.
Transfer of proteins to membrane and western blotting
Proteins separated by SDS-PAGE were transferred to PVDF membranes 
(Immobilon-P Millipore) in a semi-dry system (Hoefer) using Towbin 
buffer (192 mM glycine, 25 mM Tris-Cl, 0.1% SDS, 20% methanol, pH 
8.0). Alternatively, proteins were transferred to PVDF or nitrocellulose 
membranes by slot blotting, using the Bio-Dot SF microfiltration apparatus 
(Bio-Rad) following the manufacturer’s instructions.
Transferred proteins were visualized by Amido black staining (0.1 
% (w/v) amido Black, 40% methanol, 10% acetic acid). Membranes were 
blocked for 1 h at room temperature TBS-milk, which is 5% non-fat dry 
milk in TBS (20 mM Tris (pH7.6), 137 mM NaCl, 0.0015% phenol red). 
After incubation with primary antibody (dilutions see Table 2.1) for 1 h 
at RT, the membrane was washed three times for 5 min with TBS. The 
membrane was incubated with the HRP-coupled secondary antibody (see 
Table 2.2) in TBS-milk for 45 min at RT, and afterwards washed three 
times with TBS. Blot were developed with the ECL plus chemiluminescence 
detection system (Amersham Biosciences) and exposures were carried out 
with BioMax film (Kodak).
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Peptide competitions
For peptide competition experiments in western blotting, antibodies were 
preincubated in TBS-milk (20 mM Tris (pH7.6), 137 mM NaCl, 0.0015% 
phenol red, 5% non-fat dry milk) with 2 µg/ml peptide, tumbling for 1 h 
at room temperature. For peptide competitions in immunofluorescence 
stainings, antibodies were preincubated with 2 µg/ml peptide in Blocking 
solution (PBS with 2.5% bovine serum albumine, 10% normal goat serum, 
and 0.1% Tween-20) for 1 h rotating at RT. Afterwards, the preincubated 
antibodies were used for western blotting or immunofluorescence stainings, 
respectively, following the usual procedure.
Expression of recombinant proteins in E.coli
For expression of recombinant proteins, the recombination-deficient 
(and codon-optimized) E. coli strains BL21, RosettaBlue, and Rosetta-
Blue(DE3)pLacI were used (see Table 2.3). A single colony from a plate was 
used to inoculate a 50 ml culture of the respective bacterial strain in LB 
including the respective antibiotic for selection, and the culture was grown 
over night in a shaker-incubator (37° C, 250 rpm). The next morning, the 
overnight culture was used to inoculate a 2 l culture of LB (37° C, 250 
rpm). At an OD600 of about 0.6, the cells were induced with 1 mM IPTG 
final concentration. After induction, cells were usually grown for another 3 
to 5 h at 37° C. After harvesting the cells (6 000 rpm/10 min/4º C in SLA-
1500), the pellet was immediately frozen at –80° C.
Ni-NTA purification of His6-tagged proteins
The bacterial cell pellet was resuspended in 30 ml Lysis buffer (20 mM Tris 
(pH 8.0), 300 mM NaCl, 0.1 mM MgCl2, 0.1 % Triton X-100, 2 mM imidazol, 
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5 mM β-Mercaptoethanol, Complete EDTA-free protease inhibitor (Roche), 
1 mM PMSF), and the cells were lysed on ice with an Emulsiflex-C5 cell 
disrupter (10 000 psi, three passages). Insoluble cell debris was pelleted 
(15 500 rpm/15 min/ 4º C in SS34), meanwhile Ni-NTA beads (nickel 
nitrilotriacetic acid, Qiagen; 1 ml per 5 mg of expressed recombinant 
protein) were equilibrated with 50 ml Lysis buffer. The soluble supernatant 
of the disrupted cells was applied to the Ni-NTA beads and incubated 
rotating for 20 min at 4º C. After three washes "in batch" with Lysis buffer 
, the beads were transferred to a plastic chromatography column, washed 
with 4 column volumes of Column Wash buffer (20 mM Tris (pH 8.0), 
1 M NaCl, 0.1 % Triton X-100, 0.1 mM MgCl2, 30 mM Imidazol, 5 mM 
β-Mercaptoethanol). The recombinant protein was eluted with 6 column 
volumes of Elution buffer (20 mM Tris (pH 8.0), 300 mM NaCl, 0.1 mM MgCl2, 
150 mM Imidazol, 5 mM β-mercaptoethanol), dialyzed against Dialysis 
buffer (25 mM Tris (pH 8.0), 150 mM NaCl, 1 mM DTT) and concentrated 
with Centricon centrifugal filter units (Millipore). Protein concentrations 
were determined by absorbance spectroscopy using predicted extinction 
coefficients. Proteins were stored at 4º C or shock frozen and stored at 
–80° C.
Column chromatography
All protein purification chromatography with the exception of Ni-
NTA purification was carried out on ÄKTA Purifier fast protein liquid 
chromatography (FPLC) instruments (Amersham/GE Healthcare). Gel 
filtration as a second purification step for GST-Aurora B was performed 
with a Superdex 75 (Pharmacia; 20 mM imidazole (pH 8.0), 25 mM NaCl, 2 
mM DTT). Separation of RNA from the recombinant HP1 hinge was carried 
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out on a MonoS column (Amersham/GE Healthcare) with a linear gradient 
from 50 mM KCl to 1 M KCl. Purity was routinely confirmed by SDS-PAGE 
and Coomassie staining.
GST purification of Aurora B
GST-tagged recombinant Aurora B was prepared by GST purification 
according to the protocol from Dr. Ciaran Morrison, National University 
of Ireland, Galway. All steps of the procedure were carried out at 4° C. 
Briefly, bacterial cells were lysed in Lysis buffer (50 mM Tris (pH 8.0), 150 
mM NaCl, 50 mM EDTA, 1 mM DTT, 10% glyerol, 1 mM PMSF) with an 
Avestin EmulsiFlex C5 cell disruptor (three passages). Insoluble cellular 
debris was removed by centrifugation (15 500 rpm, 15 min, SS34 rotor). 
The supernatant was applied to Glutathione Sepharose (Fast flow 4B, 
Amersham/GE) and incubated on a rotator for 1.5 h. Unbound proteins 
were washed off (four washes with Lysis buffer), transferred into a plastic 
column (Bio-Rad) and eluted with Elution buffer (50 mM Tris (pH 8.0), 150 
mM NaCl, 10 mM EDTA, 1 mM DTT, 10% glycerol, 25 mM GSH (reduced 
glutathione), 1 mM PMSF). The eluate was eluted over night against 50% 
glycerol/50% XBE2 (10 mM K-HEPES (pH 7.7), 50 mM sucrose, 100 mM 
KCl, 2 mM MgCl2, 0.1 mM CaCl2, 2 mM K-EGTA, pH adjusted to 7.9). After 
protein concentration with a Centricon centrifugal filter units (Millipore), 
aliquots were flash frozen in liquid nitrogen and stored at –80° C.
Acid extraction
Cells were lysed by resuspending them directly in 0.2 M H2SO4 and agitated 
on a rotator for 1 h at 4° C. Insoluble matter was pelleted by centrifugation 
and the soluble proteins were precipitated by adding trichloroacetic acid 
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(TCA) to a final concentration of 25%. After 1 h incubation on ice, proteins 
were collected by centrifugation, washed once with acetone containing 
0.1% HCl, a second time with pure acetone, and dissolved in a buffer for 
further processing or dried and stored at –80° C.
Preparation of Dignam extracts
Nuclear extracts for peptide pull-downs with the HP1α (83-101) S92ph 
peptide were prepared following the procedure by Dignam and colleagues 
(Dignam et al., 1983). All steps were carried out at 4° C and protease 
inhibitors (Complete protease inhibitor cocktail, Roche) and phosphatase 
inhibitors (10 mM NaF, 5 mM Orthovanadate, Calbiochem Phosphatase 
Inhibitor Cocktail Set I [final concentrations  25 µM Bromotetramisole 
oxalate, 5 µM Cantharidin, 5 nM Microcystin-LF]) were used in all 
buffers.
The cell pellet was resuspended in 5 PV (pellet volumes) of buffer 
A (10 mM HEPES, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT, pH 7.9) and 
incubated on ice for 5 min to swell the cells. Then the cells were collected 
by centrifugation (750 rpm, 10 min), the supernatant was removed and 
the cells resuspended in 2 PV buffer A. Cell lysis was carried out with 
a Dounce homogenisator (pestle B) with 15 to 20 strokes. Nuclei were 
collected by centrifugation (1500 rpm, 7 min), and the supernatant flash 
frozen in liquid nitrogen (cytosolic fraction). The nuclei were resuspended 
in 4 ml buffer B (20 mM HEPES, 25 % (v/v) glycerol, 45 mM NaCl, 1.5 mM 
MgCl2, 0.2 mM EDTA, 0.5 mM DTT, pH 7.9) and broken by another round 
of douncing in this buffer. The suspension was centrifuged at 25000 x g 
for 30 min. The supernatant was dialyzed against buffer C (50 mM Tris-
Cl, 120 mM NaCl, 0.5 mM EDTA, 0.1% NP-40, 0.5 mM DTT, 1 mM PMSF, 
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pH 7.5) for 5 h. Aliquots were flash frozen in liquid nitrogen and stored at 
–80° C until further use.
Alternative biochemical fractionation of cells
As an alternative  to the Dignam protocol, the procedure of Mendez and 
Stillman was used to fractionate cells (Mendez and Stillman, 2000). All 
steps were carried out on ice and phosphatase inhibitors were included 
in all buffers (10 nM Calyculin A, 10 mM NaF, 5 mM Orthovanadate, 
Calbiochem Phosphatase Inhibitor Cocktail Set I [final concentrations  25 
µM Bromotetramisole oxalate, 5 µM Cantharidin, 5 nM Microcystin-LF]). 
HeLa cells (5⋅108 cells) were resuspended in 25 ml of Buffer A (10 mM 
HEPES (7.9), 10 mM KCl, 1.5 mM MgCl2, 0.34 M sucrose, 10% glycerol) 
including 0.2% NP-40 and incubated for 7 min on ice to lyse the cells. 
Cell nuclei were pelleted with a low-speed spin (1500 rpm, 5 min, in 
Eppendorf 5810R table-top centrifuge). While the supernatant (Cytosolic 
fraction) was transferred to a new tube and the salt concentration was 
adjusted to 250 mM NaCl, the nuclei were washed once with Buffer A 
(without NP-40) and then disrupted by resuspending them in 25 ml NoSalt 
buffer (3 mM EDTA, 0.2 mM EGTA). The nuclei were incubated for 30 
min on ice, interrupted by occasional vortexing. By centrifugation (3000 
rpm, 5 min, in Eppendorf 5810R), chromatin was collected as the pellet. 
The supernatant (soluble nuclear fraction and proteins stripped off the 
chromatin with NoSalt buffer) was adjusted to 250 mM NaCl. To solubilize 
most chromatin-bound proteins, the chromatin pellet was extracted with 5 
ml HighSalt solubilization buffer (50 mM Tris (8.0), 2.5 M NaCl), vortexed, 
and chromatin sheared with a BioRuptor sonicator (Diagenode) for 10 min 
at setting High. Unsolubilized material was pelleted (4000 rpm, 5 min) and 
the supernatant (solubilized chromatin proteins) diluted down to 250 mM 
NaCl.
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Peptide pull-down
Peptide pull-downs were carried out as previously described (Wysocka, 
2006; Wysocka et al., 2005). Typically, 100 µg of biotinylated peptide 
in PBS were prebound to 400 µl of avidin-coated beads (Pierce) for 5 h 
at 4° C with rotation. Unbound peptide was removed by three washes 
with PBS/0.1% Triton X-100. Immobilized peptides were incubated with 
cellular extracts for 3 h at 4° C. Beads were washed (six washes with 
Washing buffer (20 mM HEPES (pH 7.9), 150 mM KCl, 20% v/v glycerol, 
0.2 mM EDTA, 0.1% Triton X-100). For more or less stringent washing, 3 
washes with 300 mM or 50 mM KCl were carried out, respectively. In case 
phosphorylated peptides were used, phosphatase inhibitors (10 mM NaF, 5 
mM Orthovanadate, Calbiochem Phosphatase Inhibitor Cocktail Set I [final 
concentrations  25 µM Bromotetramisole oxalate, 5 µM Cantharidin, 5 
nM Microcystin-LF]) were included at all steps,. Protease inhibitors (Roche 
Protease inhibitor cocktail and 1 mM PMSF) were included from the point 
of adding the cellular extract. Peptides and bound proteins were eluted 
by boiling the beads in protein sample buffer. Samples were run on SDS-
PAGE gels and stained with Coomassie or by silver staining (SilverSnap 
Staining Kit, Pierce).
Anti-FLAG immunoprecipitation of tagged HP1 constructs / 
Immuno-precipitation of endogenous HP1
Immunoprecipitation of exogenous, Flag-tagged HP1 proteins expressed in 
HeLa cells was carried out with anti-Flag M2 beads (Sigma). Phosphatase 
inhibitors were included in all buffers (10 mM NaF, 2 mM Orthovanadate, 
10 nM Calyculin A). Beads were washed twice in Wash buffer (50 mM Tris-
Cl,pH 8.0, 150 mM NaCl, 0.05% NP-40), then the beads were incubated 
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with the extracts (Cytosolic, NoSalt-soluble and HighSalt-soluble) for 
45 min at 4° C. Beads were washed three times with 1M-Wash buffer 
(50 mM Tris-Cl, pH 8.0, 1 M NaCl, 0.1% NP-40), brought down in Wash 
buffer to a volume of 1 ml, spun down again and resuspended in Storage 
buffer (50 mM Tris-Cl, pH 8.0, 150 mM NaCl). Aliquots were taken during 
the whole procedure and the different steps subsequently analyzed by 
western blotting. Samples were shock frozen in liquid nitrogen, stored at 
–80° C, shipped to the Hunt lab on dry ice and analyzed there by mass 
spectrometry.
Immunoprecipitation of endogenous HP1 isoforms was carried 
out essentially by the same procedure, with a few minor differences: 
monoclonal HP1 antibodies (HP1α: MAB3584, HP1β: MAB3448, HP1γ: 
MAB3450 (Chemicon)) were immobilized on magnetic sheep-anti-mouse 
beads (M280 Sheep-anti-mouse IgG, Dynal Biotech). During washes, beads 
were collected not by centrifugation, but with a magnet.
RP-HPLC
Separation of acid extracted proteins was carried out by RP-HPLC 
(reversed-phase HPLC) on a C8 column (220 x 4.6 mm Aquapore RP-300 
(PerkinElmer) or Vydac 208TP510). A linear gradient of 35-60% solvent 
B (solvent A: 5% acetonitrile, 0.1% trifluoroacetic acid; solvent B: 90% 
acetonitrile, 0.1% trifluoroacetic acid) was applied over 75 min at 1.0 ml/
min flow-rate on a Beckman Coulter System Gold 126 Pump Module and 
166/168 Detector. Peptides were purified by a similar procedure on a C18 
column. Fractions were subsequently lyophilized and stored at –80° C.
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In vitro kinase reactions and analysis
Kinase reaction with H3 peptides (1-5 µM) or recombinant HP1 proteins 
(500 ng) were typically carried out in a 50 µl volume of Kinase Buffer (15 mM 
MOPS (pH 7.2), 30 mM MgCl2, 25 mM NaCl, 10 mM β-glycerolphosphate, 
2 mM EGTA, 1 mM DTT) with 150 µM ATP and 2-3 μCi [γ-32P]-ATP. 5 
µl of immunoprecipitated chromosomal passenger complex (CPC) (kindly 
provided by Boo Shan Tseng, Funabiki Laboratory, Rockefeller University), 
100 ng of commercial recombinant kinases (MSK1, RSK2, IKKα; UBI/
Millipore), or 2 µg of recombinant Aurora B kinase (own preparation) were 
used. Where indicated, hesperadin was added  at a final concentration of 4 
µM. Reactions were stopped after 60-90 min by adding acetic acid to 30% 
(v/v) and then either run on 15% Tris-Glycine or 20% Tris-Tricine gels for 
analysis by autoradiography or analyzed by filter binding assay.
For filter binding assays, the reaction mixture was spotted onto P81 filter 
paper (Whatman). The filter paper was washed three times with 0.75% 
phosphoric acid, once with acetone, dried and then analyzed by scintillation 
counting on the 3H-channel [sic] in a Beckman LS6000IC scintillation 
counter.
For non-radioactive kinase reactions with fluorescinated peptides, 100 nM 
peptide, 1 mM ATP and 10 μl CPC were used. The reactions were stopped 
with a final concentration of 0.5% (v/v) trifluoro acetic acid and peptides 
were analysed by MALDI-TOF mass spectrometry.
"Bioinformatics" methods
Alignments were generated with ClustalW (at www.ebi.ac.uk/ Tools/
clustalw2), graphic depictions of alignments with Boxshade (at http://
mobyle.pasteur.fr).
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Kinase predictions were carried out with the Group Based Prediction 
System (Xue et al., 2008). Depiction of crystal structures were generated 
with PyMol (DeLano, 2008). Extinction coefficients for recombinant proteins 
were calculated from their amino acid sequence using the ProtParam tool 
(ExPASy, http://ca.expasy.org).
Other methods
Fluorescence anisotropy binding measurements 
Fluorescence anisotropy binding assays were typically performed in a 100 
µl volume of 20 mM imidazole (pH 8.0), 25 mM NaCl, 2 mM DTT, and 100 
nM fluorescein-labelled peptide (Jacobs et al., 2004). Measurements were 
made on a Plate Chameleon multilabel counter (Hidex), and fluorescence 
polarization (P) values were converted to anisotropy (A) values by the 
equation A = 2P / (3-P). For the analysis of binding curves, non-linear least-
squares fitting of the data was carried out with the software KaleidaGraph 
(Synergy Software) using the equation A = [Af - (Ab-Af)]⋅[protein] / (Kd + 
[protein]) where Af and Ab are the anisotropy values of the free and bound 
peptides, respectively.
Mass spectrometry
Mass spectrometry analysis of HP1 proteins was carried out by Hillary 
Montgomery (Hunt lab, University of Virginia). Analysis of peptides was 
carried out by MALDI-TOF mass spectrometry on a Voyager RP STR 
instrument (ABI) in linear mode using hydroxy cinnamic acid as matrix.
Phage display screen
The phage display screen for proteins binding to HP1α in a manner 
dependent on HP1α S92 phosphorylation was carried out with the T7Select 
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system (Novagen). This screen was carried out by myself in the laboratory 
of Dr. Wolfgang Fischle (Goettingen, Germany).
Two commercially available cDNA phage libraries (T7Select Human 
Liver cDNA Library and T7Select Human Brain cDNA Library, Novagen) 
were used. Upon amplification of the libraries, an aliquot of the liver 
library was supplemented with a T7 phage with the HP1α gene cloned into 
it (kindly provided by Henriette Franz, Fischle lab) in a 1:106 dilution, to 
serve as a positive control in the screen. For amplification of T7 phages, 
BLT5403 E. coli cells grown in TB (12 g bacto tryptone, 24 g yeast extract, 
4 ml glycerol, 2.31 g KH2PO4 and 12.54g K2HPO4 per 1000 ml) were used. 
Phage concentration was determined by plaque assay (a diluted aliquot of 
the phage-containing solution was mixed with uninfected E. coli bacteria, 
plated, and incubated over night at 37° C; plaques of killed bacteria were 
counted the next day and phage titers calculated).
Biotinylated HP1α peptides (83-101, unmodified and phosphorylated 
at serine 92) and histone H3 peptides (1-20, unmodified and tri-methylated 
at lysine 9) were immobilized on avidin beads (Pierce). For the biopanning 
selection procedure, the phage mixture was incubated with the beads for 
2 h rotating at 4° C. Unbound phage was washed off (three washes with 
PBS including 0.05% Tween-20). During all these steps, buffers included 
25 mM NaF and 25 mM β-glycerolphosphate as phosphatase inhibitors. 
Phages selected in the pull-down were amplified by adding the beads with 
bound phages to a 50 ml culture of BLT5403 bacteria and growing the 
culture over night at 37° C. Phages obtained from this amplification were 
used for the next round of biopanning selection. Five rounds of biopanning 
were carried out.
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For a qualitative analysis of the selection procedure, a PCR reaction 
was carried out with (template: aliquots from the phage solution taken at 
each round of selection; primers" specifically designed to anneal at the 5’- 
and 3’-ends of the phage insert).
Electrophoretic mobility-shift assay (EMSA)
Electrophoretic mobility-shift assays (EMSA) were carried out as 
described (Akhtar et al., 2000). Briefly, single-stranded probe RNA was 
in vitro transcribed with the MEGAscript T7 Kit (Ambion) using a 500 
nucleotide fragment of the human cyclin E gene as template. The RNA 
was radioactively labeled by 5’-end-labeling with T4 Polynucleotide kinase 
(NEB) and [γ-32P]ATP and purified with the RNeasy kit (Qiagen). Binding 
reactions were carried out in 20 µl of Binding Buffer (20 mM HEPES (pH 
7.6), 100 mM KCl, 2 mM EDTA, 0.01% NP-40, 1 mM DTT) including 20 U 
RNasin Ribonuclease inhibitor (Promega), 10,000 cpm labelled RNA (about 
1 pmol). Reactions were incubated for 30 min on ice, and then run on a 
4% native 0.5x Tris-borate-EDTA gel (prerun for 30 min at 100V at RT) for 
3 h at 250 V at 4° C. Data was imaged with a FLA-5000 phosphorimager 
(Fujifilm).
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Chapter 3
regulation of the Chromatin assoCiation
of hp1 through phosphorylation of
histone h3: "methyl-phos switChing"
introduction
In recent years, it has become increasingly clear that dynamic changes in 
chromatin structure actively regulate all kinds of DNA-dependent processes, 
ranging from transcription and mitotic chromosome condensation to 
DNA-repair and apoptosis (Felsenfeld and Groudine, 2003). Functions 
of chromatin are controlled, among other ways, by posttranslational 
modifications of N-terminal histone tails (Kouzarides, 2007; Peterson 
and Laniel, 2004). These modifications can serve as binding sites for the 
recruitment of modification-specific binding proteins (effectors), which 
then direct downstream functions (de la Cruz et al., 2005; Strahl and Allis, 
2000).
Recruitment of binding partners to chromatin is often dynamic, and 
the ability to release effector proteins from their binding site enables the cell 
to react to changes in environmental cues (Felsenfeld and Groudine, 2003). 
In many cases, reversibility is achieved efficiently by the enzymatic removal 
of relatively short-lived posttranslational modifications. For example, 
removal of histone acetylation can be achieved by histone deacetylases 
(Keogh et al., 2006; Sterner and Berger, 2000). Alternatively, histone tails 
can be clipped proteolytically (Allis et al., 1980; Duncan et al., 2008) or even 
the complete histone can be replaced (Ahmad and Henikoff, 2002). What 
all these mechanisms have in common is that they result in elimination of 
the posttranslational modification that recruits the effector.
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However, there are also situations where a histone modification 
appears to be more stable, yet dynamic behaviour of an effector protein is 
nevertheless observed. This suggests the existence of other, so far unknown 
mechanisms to control the release of effector proteins from their binding 
sites at chromatin.
One such case where an effector protein dissociates from its binding 
site at chromatin, while the histone mark persists, is the mitotic release of 
Heterochromatin protein 1 (HP1).
HP1, an effector protein with important functions in heterochromatin 
formation and gene silencing, is recruited to chromatin by histone H3 
methylation at lysine 9 (H3K9me) (Bannister et al., 2001; Lachner et al., 
2001). In interphase cells, HP1 is tightly associated with chromatin. At 
the onset of mitosis, however, the protein is released from its binding site 
at H3K9me (see Introduction, Figure 1.10; Hayakawa et al., 2003; Minc 
et al., 1999; Schmiedeberg et al., 2004), even though the methyl-mark it 
binds to is not reduced. Although this phenomenon has been observed 
for years (Bannister et al., 2002), the mechanism of this dissociation was 
completely unknown.
In this chapter, I describe experiments that I carried out in 
collaboration with a postdoctoral fellow in the Allis laboratory, Dr. Wolfgang 
Fischle, to elucidate the mechanism of HP1 release from chromatin during 
mitosis. Other key experiments, using the Xenopus cell-free system, were 
carried out in collaboration with the laboratory of Dr. Hironori Funabiki 
(data not presented in this thesis). In a combination of biophysical in vitro 
and in vivo immunofluorescence experiments, we show that the mitotic 
release of HP1 from chromatin is mediated by histone H3 phosphorylation, 
thus implicating histone H3 phosphorylation in the regulation of HP1 
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chromatin association. Our findings define a novel mechanism to regulate 
binding of an effector protein, "methyl-phos switching", in which two 
modifications work together to bring about dynamic control of binding to a 
histone mark, with far-reaching implications, inside as well as outside of 
the realm of chromatin.
results
hp1 is released during mitosis, even though the h3K9me3 mark 
persists
We began our investigation into HP1’s chromatin association by reproducing 
the observation that HP1 is released from chromatin, while the H3K9me3 
mark persists (Bannister et al., 2002; Kellum et al., 1995; Minc et al., 1999). 
Immunofluorescence microscopy (IF) of mouse fibroblast cells (Figure 3.1A) 
clearly shows that HP1 dissociates from chromatin in mitosis, while the 
H3K9me3 signal is still observed at the DNA.
To analyze the levels of the H3K9me3 mark throughout the cell-cycle 
in a more quantitative way, we carried out western blotting experiments. 
Comparison of asynchronously growing HeLa cells with cells arrested in 
mitosis by nocodazole treatment clearly shows that the overall level of 
H3K9me3 in the cell does not change at the different stages of the cell 
cycle (Figure 3.1B).
Taken together, the IF and immunoblotting experiments confirm 
that HP1 is released during mitosis from chromatin, even though the 
mark that is largely responsible for its recruitment, H3K9me3, remains 
unchanged. Naturally, this finding raises the puzzling question of how an 
effector protein like HP1 can be released, when the histone mark mainly 
responsible for its recruitment is stable.
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figure 3.1: hp1 dissociates from chromatin during mitosis, even though the 
h3K9me3 mark persists (in collaboration with Dr. Wolfgang Fischle).
a: Immunofluorescence microscopy of mouse 10T1/2 fibroblast cells. In 
interphase, HP1β localizes to dot-like structures throughout the cell nucleus that 
coincide with H3K9me3 and DAPI-dense regions, indicating HP1's association 
with pericentric heterochromatin Maison and Almouzni, 2004. In mitosis, HP1β 
is dispersed throughout the cytoplasm, while the H3K9me3 signal still overlaps 
with the DNA aligned in the metaphase plate. Similar observations were made 
for HP1α and HP1γ. Overlay generated from HP1β and H3K9me3 channels. Scale 
bar, 10 µm.
B: Immunoblotting of extracts obtained from asynchronously growing (Interphase) 
or nocodazole-arrested (Mitosis) HeLa cells. Acid-extracted histones (H3K9me3, 
H3S10ph and H3 blots) or total cell extracts (HP1β blot) were treated with or without 
alkaline phosphatase and then analyzed by western blotting. The H3S10ph signal 
confirms the enrichment for mitotic cells upon nocodazole arrest. No significant 
changes in the global H3K9me3 levels or in the expression of HP1β through the 
cell cycle are observed (similar results obtained for HP1α and HP1γ).
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the Binary switching hypothesis
To explain this enigma of effector protein release from a stable histone 
mark, Drs. Fischle and Allis proposed a novel mechanism for how 
cells might control binding of effector proteins to posttranslational 
modifications. According to their "Binary Switching" hypothesis (Fischle 
et al., 2003a), dynamic regulation of the read-out of a stable histone mark 
can be achieved through an adjacent reversible modification. Addition of 
the reversible modification would interfere with the binding of the effector 
protein and thus releases the effector from its binding site. Removal of the 
reversible modification, on the other hand, would allow the effector protein 
to reassociate (Figure 3.2).
How could such a binary switch be constructed in the specific case 
of H3K9me3 and HP1? H3K9me3 might form a "methyl-phos switch" 
by collaborating with the adjacent phosphorylation of H3 at serine 10 
(H3S10ph), a mitotically robust histone mark that has been known for 
years (Hendzel et al., 1997).
H3S10 phosphorylation is a very prominent mark in all eukaryotic 
cells during mitosis, when it is observed globally and on all chromosomes 
(Hsu et al., 2000; Kaszas and Cande, 2000; Van Hooser et al., 1998; Wei 
et al., 1998; Wei et al., 1999). In fact, due to its abundance serine 10 
phosphorylation has been used widely as a general marker for mitosis. 
However, although this mark and the enzymes responsible for its steady-
state balance have been characterized quite well, the biological role of this 
modification is still elusive (Hsu et al., 2000; Prigent and Dimitrov, 2003; 
Wei et al., 1999). According to the binary switching theory, at least one of 
the biological functions of serine 10 phosphorylation in mitosis might be 
to regulate binding of the effector protein HP1 to H3K9me, a process that 
we refer to as "methyl-phos switching".
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Several observations suggested to us that this might indeed be the 
case. Firstly, we had evidence for the existence of the dual modification mark 
H3K9meS10ph in vivo through mass spectrometry. In collaboration with 
the laboratory of Dr. Donald Hunt (University of Virginia, Charlottesville), 
Dr. Fischle had examined the modification profile of histones obtained 
from mitotic HeLa cells. This had led to the identification of a novel 
dual modification mark, where lysine 9 methylation and serine 10 
phosphorylation are present at the same time on one and the same H3 tail 
(H3K9me1S10ph, H3K9me2S10ph, and H3K9me3S10ph).
Secondly, Dr. Fischle had validated the identification of this novel dual 
histone mark through an independent method. After raising an antiserum 
X
XX
P Reversible modificationStable modification
S S R
S R
3.2
figure 3.2: the Binary switching hypothesis.
According to the Binary Switching Hypothesis Fischle et al., 2003, dynamic read-
out of a stable histone mark can be achieved through an adjacent reversible 
modification. A stable modification S (blue circle) serves as a binding site to re-
cruit the effector protein X. Addition of the reversible modification R (pink pen-
tagon) immediately adjacent to the stable modification sterically interferes with 
the binding of X to the stable modification and therefore causes the release of 
the effector protein. Upon removal of the reversible modification, the effector X 
can reassociate with its binding site. Together the two modifications work like a 
switch for the recruitment and release of a specific binding protein. Such switch-
es are possible for various combinations of modifications, such as "methyl-phos", 
"acetyl-phos", or "methyl-acetyl" switches.
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that specifically recognizes the dually-modified H3K9me3S10ph epitope, 
western blotting confirmed that the dual-mark epitope is specifically 
detected on histones of mitotic cells, while it is not found in histones 
purified from asynchronously growing cells.
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figure 3.3: Binding of the hp1 chromo domain to h3K9me3 is likely to be 
impaired by the presence of h3s10ph.
Crystal structure of the Drosophila melanogaster HP1 chromo domain (23-76) 
interacting with the H3 tail tri-methylated at K9 (Jacobs and Khorasanizadeh, 
2002). Peptide in yellow, K9me3 and S10 shown in detail, Cβ of serine 10 in green. 
left: Electrostatic surface charge rendering of the HP1 CD (negative charge in 
red, positive charge in blue) interacting with an H3K9me3 tail peptide. H3 serine 
10 is close to a negative patch of the CD. From this depiction it is evident that 
phosphorylation of serine 10 will lead to steric interference with the CD, as well 
as repulsion between the negative charge of the phosphate and the negative patch 
of the CD. right: Ribbon depiction of the HP1 CD interacting with an H3K9me3 
tail peptide. The three caging residues of HP1 that coordinate trimethyl-K9 of H3 
are shown in purple. H3 serine 10 undergoes multiple hydrogen bonds with glu-
tamate 56 and a carbonyl group of the HP1 backbone (W55). Phosphorylation of 
S10 would prevent formation of this network of hydrogen bonds. The sum of these 
effects (steric hindrance, electrostatic repulsion, and loss of hydrogen bonds) is 
likely to abolish the interaction between the H3 tail and the HP1 chromo domain 
upon phosphorylation of H3 serine 10.
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Thirdly, a close examination of the co-crystal structure of the HP1 
chromodomain bound to a methylated H3 tail peptide (Fischle et al., 
2003b; Jacobs and Khorasanizadeh, 2002; Nielsen et al., 2002) revealed 
that serine 10 phosphorylation was likely to interfere with chromodomain 
binding by effects of steric hindrance, electrostatic repulsion, and loss of 
hydrogen bonds (see Figure 3.3).
Taken together, these observations all pointed in the direction 
that dissociation of HP1 from chromatin during mitosis might indeed be 
achieved by a binary switching mechanism involving the H3K9me3S10ph 
dual mark.
Reduced binding affinity of HP1 to H3K9me3S10ph peptides in vitro
As a first test of this hypothesis, we attempted to verify the prediction from 
the co-crystal structure that HP1 binding to H3K9me3 would be affected 
by the presence of adjacent serine 10 phosphorylation. In in vitro binding 
experiments by fluorescence anisotropy, we compared HP1 binding to 
a singly modified H3K9me3 peptide with binding to a peptide carrying 
the dual modification (H3K9me3S10ph). These experiments revealed 
that binding of HP1β to a dually modified H3K9me3S10ph peptide is 
significantly weaker than binding to a H3K9me3 peptide (Figure 3.4). 
Similar measurements were also made for the chromo domains of the 
other human HP1 isoforms and for full-length HP1 proteins (Table 3.1), 
therefore confirming that binding of HP1 to methylated lysine 9 is indeed 
impaired by phosphorylated serine 10.
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Figure 3.4: The binding affinity of the HP1β chromo domain to methylated 
H3 peptides is significantly reduced by the presence of serine 10 phospho-
rylation.
Binding curves determined by fluorescence anisotropy for interaction of the HP1β 
chromo domain with the indicated peptides. The HP1β chromo domain binds to 
a H3 (1-20) K9me3 peptide with the expected binding affinity in the low micro-
molar range (red plot). The interaction with a dually modified peptide H3 (1-20) 
K9me3S10ph was significantly weaker (> 500 µM; blue plot). (The Kd can be es-
timated from this graph as the concentration of HP1β CD for which the Fraction 
bound is 0.5.)
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Table 3.1: Dissociation constants (Kd) for the binding of human HP1 
chromo domains to different H3 peptides (data generated by Dr. Wolfgang 
Fischle) 
H3 unmodified H3K9me3 H3K9me3S10ph
HP1 CD > 500 13 ± 3 > 500
HP1 CD > 500 3 ± 1 360 ± 60
HP1 CD > 500 7 ± 2 500 ± 100
FL-HP1 > 500 18 ± 4 > 500
FL-HP1 > 500 6 ± 1 450 ± 80
FL-HP1 > 500 7 ± 2 > 500
(values in μM ± s.d.) 
Even though Kd values for the interaction of HP1 proteins with H3K9me3S10ph 
are not quite as low as for the unmodified H3 peptide, they are two orders of 
magnitude lower than for H3K9me3. Note that dissociation constants greater 
than 500 μM cannot be determined by this assay. H3 peptides: residues 1-20. 
CD: chromo domain. FL: full-length. 
reconstitution of the release mechanism in the test tube
While these results were encouraging, simple measurement of binding 
affinities does of course not at all reproduce the dynamic environment 
within the cell. Here, serine 10 would have to be phosphorylated by a 
kinase, while the neighboring H3K9me3 is engaged by HP1, and this 
phosphorylation would subsequently result in the release of the effector 
protein.
We realized that it would be almost impossible to tease apart the 
molecular mechanism of mitotic HP1 release directly by in vivo experiments. 
Redundancy among H3 genes (about a dozen in human cells, Marzluff 
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et al., 2002) and the enormous complexity of the cellular events during 
mitosis makes it very difficult to obtain more than correlative data in this 
question from the tissue culture system. Therefore, we decided to pursue 
an extreme reductionist approach, trying to reconstitute the complete 
release mechanism of HP1 with purified components in the test tube.
Identification of kinases capable of phosphorylating H3S10 in the 
presence of h3K9 methylation
As a first step towards this reconstitution, I sought to identify conditions 
for efficient and specific in vitro phosphorylation of H3 peptides. The 
mammalian kinase responsible for mitotic phosphorylation of histone H3 at 
serine 10 is Aurora B kinase, a component of the Chromosomal Passenger 
Complex (CPC) (Hsu et al., 2000; Vagnarelli and Earnshaw, 2004). However, 
it had been reported that Ipl1, the homolog of Aurora B in S. cerevisiae, is 
not capable of phosphorylating H3 in vitro, if lysine 9 is methylated (Rea 
et al., 2000). I therefore tested not only recombinant Aurora B kinase for 
its ability to phosphorylate H3 serine 10 in vitro, but also several other H3 
kinases, such as IKKα (IκB kinase α), MSK1 (Mitogen- and stress-activated 
kinase 1), and RSK2 (Ribosomal S6 kinase 2), that have been reported to 
phosphorylate serine 10 at specific genomic loci upon immediate early 
gene activiation (Anest et al., 2003; Sassone-Corsi et al., 1999; Strelkov 
and Davie, 2002).
To my surprise, all these kinases were capable of phosphorylating 
H3 peptides methylated at lysine 9 in radioactive in vitro kinase assays 
(Figure 3.5). Phosphorylation by recombinant Aurora B (even though 
with a rather low specific activity) was rather unexpected in light of the 
published findings on Ipl1 (Rea et al., 2000). We therefore compared the 
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activity of Aurora B on unmodified and methylated H3 peptides directly. 
Both peptides were phosphorylated by recombinant Aurora B with almost 
identical efficiency (Figure 3.6A).
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figure 3.5: phosphorylation activity of different h3 serine 10 kinases on 
methylated h3 peptides (In vitro kinase assays).
Radioactive in vitro kinase assay with different recombinant kinases. Phosphory-
lation of H3 peptides methylated at K9 (residues 1-15, 3 µM) was determined in 
filter binding assays by scintillation counting.
All four kinases tested were able to phosphorylate the positive control, recom-
binant H3 (2 µg; the high levels of phosphorylation observed for Aurora B are 
probably caused by Aurora B's ability to phosphorylate full-length H3 on multiple 
sites). The specific activity of recombinant Aurora B kinase is much lower than 
that of MSK1 and RSK2 (amounts of enzyme used in this experiment: 3 µg of 
Aurora B, 100 ng of IKKα, MSK1, RSK2). Aurora B, MSK1 and RSK2 also show 
significant activity on H3K9me3 peptides (in other experiments, a weak activity 
of IKKα on H3K9me3 peptides was detected as well). The H3K9me3S10A control 
proves that the phosphorylation of the peptides is specific for serine 10. Recom-
binant IKKα, MSK1, RSK2 from UBI, recombinant Aurora B from own purifica-
tion.
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figure 3.6: In vitro phosphorylation of methylated h3 peptides.
a: Radioactive in vitro kinase assay to determine the activity of recombinant Au-
rora B on unmodified and K9me3 H3 peptides (1-15). The methylated H3 peptide 
is phosphorylated almost as well as the unmodified peptide. Comparison of the 
K9me3S10A reaction with the No peptide control (---) reveals exquisite specificity 
of the peptide phosphorylation for serine 10; the low levels of background phospho-
rylation are mostly caused by autophosphorylation of the kinase.
B: Quantitative comparison of in vitro phosphorylation of different H3 peptides 
(1-15) by recombinant Aurora B (n=3; error bars indicate s.d.). Reactions were 
evaluated by filter binding assay and scintillation counting. Counts were corrected 
for background and exact peptide concentration (quantitative mass spectrometry), 
and normalized to the unmodified H3 peptide (100%). Unmodified H3 peptides and 
peptides mono-, di-, and tri-methylated at K9 are all phosphorylated by Aurora B 
with similar efficiencies in vitro. Phosphorylation of H3 serine 10 by the CPC is thus 
not inhibited by K9 methylation.
C: Reaction kinetics (radioactive filter binding assay) of the phosphorylation of un-
modified and K9-methylated H3 peptides (1-15) by Aurora B. Values corrected for 
autophosphorylation of the kinase and background peptide phosphorylation. The 
unmodified (blue) and H3K9me3 (red) peptide are phosphorylated with very similar 
kinetics (n=3, error bars show s.d.).
D: Similar experiment as in panel B carried out with the Chromosomal Passenger 
Complex immunoprecipitated from Xenopus egg extracts (provided by Boo Shan 
Tseng, Funabiki laboratory, Rockefeller University). Again, unmodified and mono/
di/tri-methylated H3 peptides are phosphorylated with very similar efficiencies.
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Rea and colleagues had used dimethylated H3 peptides (Rea et 
al., 2000), while I used trimethylated peptides. Although an effect of this 
difference would be unexpected, I directly compared the phosphorylation 
of H3 peptides with different stages of K9 methylation. To make sure my 
measurements of peptide concentration were not affect by degraded peptide 
(photometric measurement through a tyrosin added to the C-terminal end 
of the peptides), the exact peptide concentrations was determined in these 
experiments by quantitative mass spectrometry. Once again, my results 
showed that peptides of all methylation stages are phosphorylated by 
Aurora B about equally well (Figure 3.6B).
The discrepancy between my findings with mammalian Aurora B 
and the published observations with the yeast homolog could be explained 
by an effect of reaction kinetics: If phosphorylation of unmodified and 
methylated H3 peptides proceeds at a very different rate, then samples 
taken at an early time-point will show quite different phosphorylation 
levels; the end point of the reaction, however, would in both cases be a 
fully phosphorylated peptide. I therefore carried out an experiment that 
followed the kinetics of the peptide phosphorylation by Aurora B kinase 
(Figure 3.6C). Unmodified H3 peptide and H3K9me3 peptide were found to 
be phosphorylated with almost identical kinetics.
Aurora B phosphorylates peptides of all methylation stages equally 
well, and no differences were observed in the phosphorylation kinetics 
of unmodified and K9me3 H3 peptides. Thus, it seems that the observed 
differences between mammalian Aurora B and its yeast homolog Ipl1 in 
their ability to phosphorylate serine 10 in the presence of K9-methylation 
are probably a real distinction between these enzymes rather than an 
artifact of the experimental conditions. It should be noted that S. cerevisiae 
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chromatin does not have H3K9 methylation (Briggs et al., 2001). Thus, it is 
possible that the mammalian kinase or the complex that it resides in (see 
below) has acquired the ability to phosphorylate serine 10 in the presence 
of K9 methylation, while its yeast homolog has not.
While recombinant Aurora B kinase was capable of phosphorylating 
H3 peptides, the specific activity was extremely low. In particular 
recombinant MSK1 showed similar site specificity and phosphorylated 
all methylation stages equally well, but with a much (about 100-fold) 
higher specific activity, making MSK1 the most efficient serine 10 kinase 
for H3K9me3 peptides among all enzymes tested. Since an in vitro test of 
the "methyl-phos switching" mechanism of course represents an artificial 
system anyway and the higher activity of MSK1 might be quite helpful for 
a principal test of the feasibility of binary switching, we decided to also 
proceed with this kinase.
We subsequently found that the Chromosomal Passenger Complex 
immunoprecipitated from Xenopus egg extracts (kindly provided by Boo 
Shan Tseng, Funabiki lab, Rockefeller University) had a several-fold 
higher specific activity on H3 peptides than recombinant Aurora B. It is 
unclear whether this increased activity is due to the presence of other 
complex members or reduced activity of bacterially expressed Aurora B. 
Like recombinant Aurora B, Xenopus CPC phosphorylated H3 peptides 
irrespective of their methylation status (Figure 3.6D). Moreover, the complex 
could be easily removed after kinase reactions, due to its immobilization 
on beads from the immunoprecipitation. We therefore decided to use the 
immunoprecipitated Xenopus CPC rather than recombinant Aurora B 
for our attempt to reconstitute the release mechanism of HP1 in the test 
tube.
93
reconstitution of the "methyl-phos switching" mechanism in the 
test tube
In contrast to the situation in these in vitro kinase experiments on methylated 
peptides, operation of a "methyl-phos switching" mechanism inside of the 
cell involves an additional level of complexity: The phosphorylation site at 
serine 10 may often not be freely accessible to the CPC, since methyl-K9 
recruits HP1 which in turn might prevent access to serine 10. Thus, to 
complete the in vitro reconstitution of "methyl-phos switching", HP1 was 
included in the reaction.
The activity of the CPC on H3K9me3 peptides in the presence of the 
effector protein was again measured by radioactive kinase assay. In these 
experiments, the kinase complex was able to efficiently phosphorylate 
H3K9me3 peptides. The efficiency declined at higher HP1 concentrations 
(probably due to competitive inhibition by HP1 at concentrations resulting 
in stoichiometric binding), but even in the presence of a significant excess 
of the chromo domain, there was still considerable phosphorylation of the 
peptide observed, as observed for all three HP1 isoforms (Figure 3.7A, C, 
E).
In parallel, we examined with fluorescein-labelled H3K9me3 
peptides whether phosphorylation of H3S10 would eject the HP1 chromo 
domain from its binding site. Upon addition of CPC, the effect of serine 
10 phosphorylation on HP1 CD association was monitored over time 
by fluorescence anisotropy measurements. In keeping with the binary 
switching hypothesis, phosphorylation of a H3K9me3 peptide by the CPC 
in the test tube results in dynamic loss of HP1 CD binding, an observation 
made with the CD of all three isoforms α, β, and γ (Figure 3.7B, D, F).
94
figure 3.7: In vitro reconstitution of release mechanism by "methyl-phos 
switching": the hp1 chromo domain is released from h3K9me3 upon serine 
10 phosphorylation by the CpC in vitro.
a, C, e: Phosphorylation of H3K9me3 peptides in the presence of HP1α chromo 
domain (A), HP1β chromo domain (C) and HP1γ chromo domain (E). H3 peptides 
(1-15, 1 µM) were incubated in in vitro radioactive kinase assays with [γ-32P]ATP 
and CPC (immunoprecipitated from Xenopus egg extracts) in the presence of in-
creasing concentrations of recombinant HP1 chromo domain (1 to 67.5 µM). Re-
actions were run on SDS-PAGE, stained with Coomassie (top) and analyzed by 
autoradiography (bottom). Brackets and arrow heads indicate where the HP1 CD 
and the peptide runs on the gel, respectively.
Reactions with a pre-phosphorylated peptide (H3K9me3S10ph) or in the pres-
ence of the Aurora B-inhibitor hesperadin confirm the specificity of the reaction. 
Even in the presence of a large molar excess of the HP1 CD, significant phospho-
rylation is observed.
B, D, f: Fluorescence polarization measurement of HP1 release upon serine 10 
phosphorylation. Different concentrations of recombinant HP1α chromo domain 
(B), HP1β chromo domain (D), HP1γ chromo domain (F) were mixed with the indi-
cated fluorescein-labelled H3K9me3 peptides (100 nM). CPC immunoprecipitated 
from Xenopus egg extracts was added in the presence or absence of the Aurora B 
inhibitor hesperadin (4 µM). By fluorescence polarization, the dissociation of the 
HP1 CD from the peptide over time was recorded (end point after over night reac-
tion shown; n= 3, error bars indicate s.d.).
In the presence of hesperadin (no serine 10 phosphorylation) the peptide remains 
associated with the HP1β chromo domain (yellow plot). Without hesperadin (ser-
ine 10 becomes phosphorylated), the chromo domain dissociates from the pep-
tide (blue plot), approaching the curve observed for the H3K9me3S10ph peptide 
(red plot).
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Figure 3.8: Additional specificity controls for in vitro reconstitution of release 
mechanism by "methyl-phos switching" (Controls for hp1β CD shown).
a: Control reaction carried out with H3K9me3S10A peptides, which cannot phos-
phorylated by the CPC. Addition of the CPC has no effect on the binding of the 
HP1β chromo domain. (H3K9me3S10A peptides generally show about fivefold 
reduced affinity for the HP1β chromo domain compared to H3K9me3 peptides.)
B: Mass spectrometric analysis (MALDI-TOF) of CPC reactions from Figure 3.7D 
containing 50 µM of HP1β chromo domain. In the absence of the Aurora B inhibi-
tor hesperadin, the H3K9me3 peptide (*) becomes completely phosphorylated to 
H3K9me3S10ph (**). As expected, there is no effect on the H3K9me3S10A control 
peptide.
C: Samples of the reactions analyzed in Figure 3.7D were run out on SDS-PAGE 
and stained with Coomassie, proving that the HP1β chromo domain is not de-
graded in the course of the experiment. Bracket indicates position of HP1β chro-
mo domain.  Note: Identical controls as presented here for the HP1β CD were also 
carried out for the reactions with all other isoforms, with very similar results.
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The release of the HP1 chromo domain from the H3K9me peptide is 
dependent on the kinase activity of the CPC, since no such changes are 
observed if Aurora B activity is inhibited with the small molecule inhibitor 
hesperadine (Hauf et al., 2003; Figure 3.7B, D, F) or if an unphosphorylatable 
H3K9me3S10A peptide is used (Figure 3.8A). Mass spectrometry confirmed 
that the peptide was indeed phosphorylated specifically at serine 10 (Figure 
3.8B). Aliquots of the reactions were subsequently run out on SDS-PAGE 
gels, to exclude the trivial explanation that the HP1 CD had simply been 
degraded during the incubation (Figure 3.8C).
"methyl-phos switching" in the test tube with full-length hp1
Taking these observations made with the chromo domains of HP1 a step 
further, we attempted to repeat the analysis with full-length HP1 proteins. 
However, in pilot experiments we observed that full-length HP1 itself was 
subject to in vitro phosphorylation by the CPC. While it is not clear whether 
this curious observation actually reflects a real in vivo event, it of course 
represents a problem for the analysis of the "methyl-phos switching" 
mechanism in the test tube, because it makes it difficult, if not impossible to 
specifically attribute dissociation of the effector protein to phosphorylation 
of the H3 tail. Closer analysis of the in vitro phosphorylation of full-length 
HP1 by the CPC revealed, however, that the phosphorylation was isoform-
specific (Figure 3.9). Only full-length HP1α and HP1γ were phosphorylated, 
while full-length HP1β was not. Thus, we could avoid the problem of HP1 
in vitro phosphorylation by focusing our analysis to the β isoform of HP1.
Our experiments with full-length HP1β showed ejection by serine 10 
phosphorylation very similar to the observations with the CDs (Figure 3.10). 
This proves that the release of HP1 from H3K9me3 in our reductionist in 
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vitro system is not just limited to the isolated chromo domain, but can also 
happen in the context of the full-length protein.
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Figure 3.9: Isoform-specific phosphorylation of HP1 by the CPC in vitro.
Isoform-specific in vitro phosphorylation of HP1 by the CPC (radioactive in vitro 
kinase reaction followed by autoradiography). Recombinant full-length HP1α 
and HP1γ are phosphorylated by the CPC. No phosphorylation is observed for 
full-length HP1β. Bracket indicates position of full-length HP1 isoforms (addi-
tional bands are mostly degradation products), arrow head indicates position of 
the control peptide.
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figure 3.10: full-length hp1β is released from h3K9me3 upon serine 10 
phosphorylation by the CpC in vitro.
An experiment analogous to the one described in Figure 3.7 was carried out with 
full-length HP1β (see Figure 3.7 for experimental details). left: The radioactive 
kinase assay shows that H3K9me3 peptides are phosphorylated even in the pres-
ence of high concentrations of full-length HP1β. right: Fluorescence anisotropy 
measurements indicate that, as the HP1 CDs, full-length HP1β dissociates from 
H3K9me3 peptides upon serine 10 phosphorylation by the CPC.
All the controls depicted in Figure 3.8 were carried out for this experiment as 
well, showing no effect of CPC treatment on the association of full-length HP1β 
with H3K9me3S10A peptides (fluorescence anisotropy), specific phosphorylation 
of serine 10 (mass spectrometry), and little degradation of the effector protein in 
the course of the reaction (SDS-PAGE).
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"methyl-phos switching" in the test tube with msK1
While our controls clearly show that Aurora B-dependent phosphorylation 
of serine 10 is required for the release of HP1 in this reconstituted system, 
they cannot exclude that there are additional effects caused by the 
presence of other components in the test tube. In particular, it is possible 
that the other complex members of the CPC, which are always present in 
the reactions as well, also play a part.
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Unfortunately, the very low specific activity of recombinant Aurora B 
made it difficult to carry out similar experiments with the isolated kinase. 
However, taking advantage of our identification of MSK1 as another kinase 
capable of phosphorylating H3K9me3 peptides in vitro, we were able to 
reproduce the CPC results with this kinase: MSK1 was capable of efficiently 
phosphorylating H3K9me3 peptides in the presence of the HP1 chromo 
domain (Figure 3.11A), and the phosphorylation resulted in the ejection of 
the chromo domain from its binding site on the methylated H3 tail (Figure 
3.11B). This proves that the release of the HP1-H3K9me3 interaction 
by serine 10 phosphorylation does not require any of the other complex 
members of the CPC, but that serine 10 phosphorylation is sufficient for 
the release of CD binding in our reductionist in vitro system.
reversibility of "methyl-phos switching" in the test tube
In the cell, the release of HP1 from its binding site is reversible, and the 
protein reassociates with chromatin at the end of mitosis. To test the 
assumption that this reversibility could be achieved by "methyl-phos 
switching", we examined the reverse reaction and sought to find out if this 
observation could be reproduced in our in vitro system. In these experiments, 
removal of serine 10 phosphorylation from H3K9me3S10ph peptides by 
PP1, a phosphatase known to dephosphorylate H3S10ph (Prigent and 
Dimitrov, 2003), resulted in reassociation of the HP1β chromo domain to 
the peptide (Figure 3.12). The effect can be abolished by inclusion of the 
phosphatase inhibitor microcystin LR, showing that it indeed depends on 
the dephosphorylation.
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figure 3.11: Dissociation of the hp1β CD from h3K9me3 upon serine 10 
phosphorylation by msK1 in vitro.
a: H3K9me3 peptides are phosphorylated by MSK1 even in the presence of a 
large excess of HP1β chromo domain (radioactive kinase experiment). In addition 
to the analysis by SDS-PAGE and autoradiography, peptide phosphorylation was 
quantified by filter binding assay and scintillation counting. While high concen-
trations of the HP1β chromo domain slow down the peptide phosphorylation, 
there is still significant phosphorylation activity observed. Bracket, arrow head 
and asterisk indicate positions of HP1β CD, peptide and MSK1, respectively.
B: Release of the HP1β CD from H3K9me3 peptides upon treatment with the ser-
ine 10 kinase MSK1 (fluorescence anisotropy). Phosphorylation of H3K9me3 pep-
tides by MSK1 shifts the binding curve to the right, close to the curve observed 
with a H3K9me3S10ph control peptide. This indicates dissociation of the chromo 
domain from the peptide.
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figure 3.12: reassociation of the hp1β CD upon phosphatase treatment of 
h3K9me3s10ph peptides.
Dephosphorylation of a H3K9me3S10ph peptide results in restoration of the in-
teraction with the HP1β chromo domain. Binding of the HP1β chromo domain 
to a fluorescein-labelled H3K9me3S10ph peptide was measured by fluorescence 
anisotropy. In the absence of the phosphatase inhibitor microcystin LR, the phos-
phatase (recombinant PP1, NEB) removes serine 10 phosphorylation (as deter-
mined by mass spectrometry, data not shown) and binding of the HP1β chromo 
domain to the peptide is restored (blue plot). In the presence of the microcystin, 
serine 10 phosphorylation is unaffected by phosphatase treatment and no reas-
sociation is observed (red plot).
Taken together, the presented data demonstrate that in our reductionist 
system enzymatic phosphorylation of serine 10 results in the release 
of HP1 from methylated H3 peptides, while removal of S10ph causes 
reassociation. Thus, these experiments unambiguously demonstrate the 
operation of a "methyl-phos switching" mechanism for the dynamic and 
reversible regulation of HP1 binding to the stable K9-methyl mark in the 
test tube.
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h3s10 phosphorylation coincides with the release of hp1 in vivo
The described in vitro findings suggest that the "methyl-phos switching" 
mechanism could account for the observations made in vivo and that 
transient, reversible phosphorylation of serine 10 during mitosis might 
also be the mechanism how the dynamic interaction between HP1 and 
H3K9me3 over the cell cycle is achieved within the cell. To test this 
hypothesis, we turned to a combination of inhhibition experiments and 
microscopy.
figure 3.13: the mitotic release of hp1 coincides with the appearance of 
h3K9me3s10ph in vivo.
Immunofluorescence analysis of 10T1/2 mouse fibroblasts. The dual 
H3K9me3S10ph epitope occurs at late G2, at the same time when the typical 
dot-like staning pattern of HP1β starts to become diffuse and HP1β is released 
from chromatin. Only at telophase, when the dual epitope is removed again, does 
HP1 start to reassociate with chromatin. Similar observations were made in HeLa 
cells and with the HP1 isoforms α and γ. DNA stained with DAPI. Figure courtesy 
of Dr. Wolfgang Fischle.
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Taking advantage of the dual-epitope(H3K9me3S10ph)-specific 
antiserum that he had generated, Dr. Fischle carried out a careful IF 
analysis in cultured mammalian cells, comparing the time of dual epitope 
appearance with the release of HP1. This analysis revealed a close temporal 
correlation between the occurrence of the H3K9me3S10ph mark and the 
dissociation of HP1 from chromatin at late G2 (Figure 3.13). Significant 
H3K9me3S10ph staining is only observed in mitotic cells that have lost the 
characteristic chromatin-associated HP1 localization pattern and instead 
show diffuse HP1 staining throughout the cytoplasm. Thus, there is a 
close link between the temporal and local occurrence of the dual epitope 
in mitosis and the dissociation of HP1 from chromatin.
inhibition of aurora B kinase prevents the release of hp1 in vivo
The observed close correlation between S10 phosphorylation and HP1 
dissociation prompted us to carry out a direct in vivo test to see if there was 
a causal link between mitotic serine 10 phosphorylation and the release of 
HP1 (experiments carried out by Dr. Fischle).
To this end, asynchronously growing HeLa cells were treated with 
hesperadin and the effect of this inhibition on the mitotic dissociation of 
HP1 was studied by immunofluorescence microscopy. We found that upon 
inhibition of Aurora B, all three HP1 isoforms were retained on mitotic 
chromosomes (Figure 3.14A).
Since these observations were dependent on stainings with HP1 
antibodies, we reproduced the experiment with cells expressing GFP-
tagged HP1 isoforms. Similar to endogenous HP1, GFP-HP1 was retained 
at chromatin upon hesperadin treatment (data not shown). Thus, our 
experiments with GFP-HP1 confirm the findings with endogenous HP1 and 
exclude the possibility that our in vivo observations are simply a peculiar 
artifact of epitope masking.
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figure 3.14: retention of hp1 on chromatin upon inhibition of mitotic ser-
ine 10 phosphorylation in vivo (Figure courtesy of Dr. Wolfgang Fischle).
a: Upon inhibition of Aurora B kinase activity, endogenous HP1 isoforms are re-
tained on mitotic chromatin. 10T1/2 cells were either mock treated or treated with 
hesperadin (200 nM), and then analyzed by immunofluorescence microscopy with 
the indicated antibodies. In cells treated with hesperadin, no H3K9me3S10ph 
signal is observed and HP1 does not dissociate from chromatin at metaphase. 
DNA stained with DAPI. Bar, 10 μm.
B: Retention of HP1 on mitotic chromatin upon knock-down of Aurora B kinase 
by RNA interference. HeLa cells either mock treated (Control) or treated with Au-
rora B siRNAs (Aurora B RNAi) were analyzed by IF microscopy. Aurora B RNAi 
resulted in loss of the dual epitope and failure of HP1β to dissociate from mitotic 
chromatin. Staining for HP1α and HP1γ gave very similar results. DNA stained 
with DAPI. Overlay generated from HP1β and DNA channels. Bar, 10 μm.
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Retention of HP1 on chromatin in vivo upon Aurora B inhibition 
was also confirmed by biochemical fractionation experiments with HeLa 
and 10T1/2 cells arrested in mitosis with nocodazole. Upon Aurora B 
inhibition, we observed increased association of all three HP1 isoforms 
with chromatin. At the same time, there was no change in the levels of 
HP1, H3K9me3 or the acetylation of H3 at lysine 14 (data not shown).
Since all these observations depended on the use of hesperadin, 
it was possible that our observations were just the result of unspecific 
side-effects of this small molecule inhibitor. To exclude this possibility, 
we examined the effect of Aurora B depletion by RNA interference on 
HP1 dynamics in mitosis. In keeping with the results obtained from the 
inhibition experiments, knock-down of Aurora B prevented the dissociation 
of HP1 from chromatin during mitosis (Figure 3.14B), while not affecting 
the localization of HP1 in interphase cells.
In sum, these in vivo experiments strongly suggest that serine 10 
phosphorylation of H3 is a necessary step for the release of HP1 from 
chromatin in mitosis.
hp1 binds to metaphase chromosomes lacking h3 serine 10 
phosphorylation in Xenopus egg extracts
We realized that the tissue culture system offers only very limited 
possibilities to manipulate experimental parameters in order to investigate 
the molecular mechanism of mitotic HP1 release. An experimental system 
that allows for detailed examination and highly controlled experimental 
manipulation of cell cycle events are Xenopus egg extracts. Therefore, we 
collaborated with Boo S. Tseng and Dr. Hironori Funabiki, experts in the 
use of this cell-free system (who had actually already independently made 
observations related to "methyl-phos switching" in Xenopus egg extracts).
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In keeping with our observations in tissue culture cells, Boo Tseng 
and Dr. Funabiki demonstrated simultaneous occurrence of the dual mark 
K9me3S10ph and release of GFP-tagged Xenopus HP1 from chromosomes 
in egg extracts entering mitosis (data not shown).
Upon removal of Aurora B through immunodepletion of the CPC, 
as expected H3 serine 10 phosphorylation was clearly diminished, while 
the levels of H3K9me3 were unaffected. Most notably, however, binding of 
HP1α to chromosomes was significantly increased in extracts depleted of 
the CPC compared to control extracts. This retention of HP1 on chromatin 
was dependent on the chromodomain-H3K9me3 interaction, since the 
interaction could be competed with an H3K9me3 peptide (no effect of 
unmodified H3 peptide) and since mutation of one of the caging amino 
acids (W57A) drastically reduced the amount of bound GFP-xHP1α in ∆CPC 
extracts. Thus, these data show clearly that HP1 cannot bind to metaphase 
chromosomes when H3 is phosphorylated at serine 10, in the absence of 
serine 10 phosphorylation, however, it associates through mechanisms 
that depend on chromo domain-binding to H3K9me3.
Discussion
A novel mechanism how histone modifications control the 
recruitment of effector proteins
With the described experiments, I have, together with my collaborators, 
provided answers for two longstanding questions. Firstly, we have identified 
a biological role for mitotic H3 serine 10 phosphorylation (H3S10ph), a 
prominent mitotic histone mark with so far elusive biological function. 
We have demonstrated that H3S10 phosphorylation plays a crucial role 
in the regulation of the chromatin association of Heterochromatin protein 
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1 (HP1), an effector protein with important functions in the formation 
of heterochromatic structures that dissociates from chromatin during 
mitosis.
Secondly, the experiments presented here led to the discovery of the 
mechanism underlying the mitotic release of HP1 from chromatin. They 
show that the reversible dissociation of HP1 from its binding site at histone 
H3 during mitosis is achieved through histone phosphorylation.
Reconstitution of the release mechanism with purified components in 
the test tube and subsequent inhibition studies in vivo clearly demonstrated 
that Aurora B phosphorylation of H3 at serine 10 at the onset of mitosis 
is crucial for the ejection of HP1 from mitotic chromatin. H3 serine 10 
phosphorylation sterically and electrostatically interferes with binding of 
HP1 to its binding site at methylated lysine 9 of histone H3, resulting in the 
release of the effector protein. Thus, in this "methylation-phosphorylation 
switching" mechanism, two histone modifications collaborate to control 
association of an effector protein with chromatin (Figure 3.15). While the 
actual binding site (the methylation mark) is stable, the dynamic histone 
phosphorylation mark serves to regulate dynamic binding and release of 
the effector protein.
"Methyl-phos switching" is a novel mechanism how two histone 
modifications collaborate to bring about dynamic regulation of effector 
binding, that defines a new class of cross-talk between histone modifications 
in general (Fischle et al., 2003c; Fischle et al., 2003d). Our findings have 
been confirmed by other investigators (see below), and it is becoming 
increasingly clear that there are broader implications for this mechanism 
within the field of chromatin and beyond.
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In the following, I will briefly discuss different aspects of mitotic 
"methyl-phos switching" of HP1, "methyl-phos switching" in other cellular 
contexts and binary switching in general in light of the literature. In the 
first part of this discussion, I will briefly address what the responsible 
phosphatase might be and if there may be other supportive mechanisms 
besides "methyl-phos switching" that contribute to the mitotic release 
of HP1. In the second part of the discussion, I will go into the general 
implications of our findings.
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figure 3.15: "methyl-phos switching" controls hp1 dissociation during mi-
tosis.
A "methyl-phos switching" mechanism controls the dynamic release of HP1 dur-
ing mitosis. Model summarizing the mechanism of mitotic HP1 dissociation by 
"methyl-phos switching", as it is established by the experiments described in 
chapter 3 of my thesis.
HP1 is recruited to chromatin by methylated lysine 9 on the histone H3 tail. 
During mitosis, H3 serine 10 is phosphorylated by the Chromosomal Passenger 
Complex (CPC) with its kinase Aurora B. This sterically interferes with binding 
of HP1’s chromo domain to H3K9me, resulting in HP1 dissociation. At the end of 
mitosis, serine 10 phosphorylation is removed by phosphatases and HP1 bind-
ing to H3K9me is restored. Thus, serine 10 phosphorylation allows for a revers-
ible release of HP1 from chromatin, even though its binding site at H3K9me3 is 
stable.
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identity of the phosphatase responsible for the removal of h3s10ph 
in vivo
Observations in vivo indicate that the mitotic dissociation of HP1 is a fully 
reversible process. In our in vitro reconstitution system, the methylation-
phosphorylation switch could be readily reversed by phosphatase treatment, 
and removal of serine 10 phosphorylation by phosphatase PP1 resulted in 
full reassociation of the HP1 chromo domain with H3K9me3 (Figure 3.12). 
The responsible phosphatase in vivo, however, is still unknown. Even so, 
there are some interesting observations and worthwhile speculation.
One of the genes identified in PEV screens, Su(var)3-6, has been 
shown to encode a catalytic subunit for type 1 serine-threonine protein 
phosphatases (PP1; Baksa et al., 1993). Interestingly, mutation of this gene 
leads not only to strong PEV suppression, but also to abnormal mitosis, 
mitotic defects, and hyperploidy. Considering the role that HP1 "methyl-
phos switching" plays in the mitotic dissociation of HP1 and (possibly) in 
the definition of boundaries of heterochromatin (see below), this phenotype 
comes very close to what would be expected for a phosphatase that is 
involved in "methyl-phos switching" of HP1.
potential contribution of other mechanisms to the mitotic release of 
hp1 in vivo
The existence of the "methyl-phos switching" mechanism and its importance 
for the mitotic dissociation of HP1 has been confirmed by multiple groups, 
in vitro and in vivo, and in both mammalian cells and S. pombe (Chen et al., 
2008; Hirota et al., 2005; Kloc et al., 2008; Sabbattini et al., 2007; Terada, 
2006).
In extreme reductionist systems (only H3 peptides and the HP1-CD) 
"methyl-phos switching" is always sufficient for HP1 release (Fischle et al., 
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2005; Terada, 2006), allowing to study the mechanism without overlapping 
other effects and thus establishing binary switching as a mechanism for 
the regulation of effector protein association with histone marks in general. 
However, in more complex systems there seem to be other effects that also 
affect experimental observations. Already when full-length HP1 proteins 
are used instead of the isolated chromo domain, "methyl-phos switching" 
is not always sufficient. We have shown that full-length HP1β is released 
from H3 peptides upon serine 10 phosphorylation, while Terada reports that 
full-length HP1α does not dissociate in very similar experiments (in parallel 
control experiments, the HP1α CD was ejected; Terada, 2006). Thus, there 
are differences between isoforms, and additional binding mechanisms seem 
to prevent the release of full-length HP1α after "methyl-phos switching". 
This raises the question whether "methyl-phos switching", while clearly a 
necessary step, is also sufficient for the release of HP1, particularly in an 
in vivo context where HP1 undergoes may different interactions.
By Aurora B inhibition and depletion in various experimental systems, 
in vivo experiments have clearly demonstrated the importance of "methyl-
phos switching" for the release of HP1, for example in mammalian cells 
(Fischle et al., 2005; Sabbattini et al., 2007; Terada, 2006), in Xenopus egg 
extracts (Fischle et al., 2005) and in S. pombe (Kloc et al., 2008). Further 
support came from a different approach, the overexpression of an exogenous 
H3 protein with a S10A mutation in mammalian cells, which also led to 
increased retention of HP1 at chromatin (Terada, 2006). However, these 
experiments can only prove that "methyl-phos switching" is necessary for 
the release of HP1, while they do not address whether it is sufficient.
When HP1 binding to full-length H3 or chromatin was tested in 
the presence of cellular extracts, binding of HP1 in spite of serine 10 
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phosphorylation of H3 has been reported. In pull-downs with recombinant 
full-length HP1γ from acidic-soluble cellular extracts, for example, Fass 
and colleagues found that serine 10 phosphorylation does not prevent H3 
binding (Fass et al., 2002), suggesting that the reversal of the CD-H3K9me 
interaction is not sufficient for the release of HP1 from chromatin in vivo. 
Such a conclusion is also supported by an experimental observation made 
by our collaborators Boo Shan Tseng and Dr. Hironori Funabiki. In Xenopus 
egg extracts, exogenous HP1 with a mutation in the chromo domain still 
showed partial retention on chromosomes (in extracts depleted of CPC), 
even though mutation of the chromo domain abolishes H3K9me-dependent 
binding of HP1, therefore mimicking the effect of complete "methyl-phos 
switching" (Fischle et al., 2005).
HP1 is known to undergo various molecular interactions and bind to 
chromatin by multiple different mechanisms in vivo. Considering the clear 
evidence for a role of other interactions in stable chromatin association of 
HP1 (see Introduction), it is very likely that there may be other interactions 
besides the CD-H3K9me interaction that have to be reversed for the mitotic 
release of HP1. It is therefore expected that other mechanisms besides 
"methyl-phos switching" do play a part in the mitotic dissociation of HP1 
from chromatin in vivo. Interestingly, there are indications in mammalian 
cells that HP1 becomes multiply phosphorylated during mitosis (Minc 
et al., 1999). While the sites of these phosphorylations had not been 
mapped and little, if anything, was known about the function of these 
mitotic phosphorylations, it is tempting to speculate that mitotic HP1 
phosphorylation could provide a mechanism for the reversal of molecular 
interactions of HP1 and thus contribute to the release of the protein during 
mitosis.
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"methyl-phos switching" of hp1 at h3 lysine 9/serine 10 outside of 
mitosis
As shown in this chapter of my thesis, in the regulation of mitotic HP1 
dissociation "methyl-phos switching" plays a central role. However, there are 
other instances where there are indications that "methyl-phos switching" 
may regulate HP1 behaviour.
In a recent publication by Sabbattini and colleagues (Sabbattini et 
al., 2007), it was reported that H3 S10 phosphorylation by Aurora B in 
postmitotic cells leads to delocalization of HP1β. While HP1β is localized 
to regions of facultative heterochromatin in activated B cells, it becomes 
displaced from facultative heterochromatin in an Aurora B-dependent 
fashion during the differentiation process to terminally differentiated 
postmitotic plasma cells. The displacement of HP1 may allow binding of 
other chromatin proteins involved in transcriptional silencing to these 
regions of the genome. The study thus establishes a non-mitotic role for 
"methyl-phos switching" in differentiation.
Another instance, where "methyl-phos switching" of HP1 may play a 
role, is meiosis. H3 serine 10 phosphorylation has been reported in meiosis 
as well, and it is possible that HP1 might have to be released for accurate 
progression of meiotic divisions (Kaszas and Cande, 2000; Wei et al., 1998; 
Wei et al., 1999).
"Methyl-phos switching" of HP1 could also be involved in 
transcriptional activation. It is well established that HP1 has, besides its 
function in heterochromatin, also a role in the repression of euchromatic 
genes (see Introduction, Section "Cellular Localization and Functions of 
HP1"). This is reflected by the multiple interactions HP1 undergoes with 
transcriptional repressors, such as TIF1α (Le Douarin et al., 1996), TIF1β/
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KAP1 (Nielsen et al., 1999), Rb (Nielsen et al., 2001), or E2F (Ogawa et 
al., 2002). In keeping with this interpretation,  it has been reported that 
transcriptional activation of a silenced transgene array in human cells 
involved the dissociation of associated HP1 proteins (Janicki et al., 2004). 
Clearly, HP1-mediated gene repression is reversible, and mechanisms 
must have evolved to overcome this form of gene silencing. Interestingly, 
H3 serine 10 phosphorylation has also been observed in connection with 
gene activation. During a process called immediate early gene response 
which involves the rapid induction of gene expression and cell growth 
upon treatment of quiescent mammalian cells with mitogens (Mahadevan 
et al., 1991), a burst of H3 serine 10 phosphorylation is observed at 
specific loci that are activated during this process (e.g. Chadee et al., 1999; 
DeManno et al., 1999; Yamamoto et al., 2003). Several kinases involved 
the phosphorylation or serine 10 during this process have been identified 
(MSK1, RSK2, IKKα; Anest et al., 2003; Sassone-Corsi et al., 1999; Strelkov 
and Davie, 2002).
Interestingly, in my experiments on HP1 "methyl-phos switching" in 
vitro, the immediate early kinase MSK1 was capable of ejecting the HP1 
chromo domain from its binding site at H3K9me3 (see Section "Methyl-phos 
switching" in the test tube with MSK1"). Thus, while it is not clear at this 
point if HP1 really participates in the regulation of immediate early genes, 
it remains an interesting hypothesis to test if "methyl-phos switching" of 
HP1 by serine 10 phosphorylation is indeed a step in the activation of 
these genes.
"Methyl-phos switching" of HP1 may also be the key to explain another 
curious observation in Drosophila cells. Reduced levels of the H3S10 
kinase JIL-1 lead to spreading of HP1 and H3K9 methylation to ectopic 
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locations along the arms of chromosomes (Zhang et al., 2006). A possible 
explanation for this finding is that in a wild-type situation JIL-1 controls 
HP1 association by "methyl-phos switching", preventing HP1 association 
at specific target sites, blocking the spreading of heterochromatin, and 
thus defining heterochromatic domains through "methyl-phos switching".
All in all, there are multiple pieces of evidence suggesting an 
involvement of HP1 "methyl-phos switching" in biological processes outside 
of mitosis.
"methyl-phos switching" of hp1 at other sites
HP1 chromatin association is mediated by the interaction of the chromo 
domain with H3K9me. However, lysine 9 and serine 10 of H3 are part a 
sequence motif "ARKS", which is a typical "modification cassette" (Fischle et 
al., 2003a), a sequence motif that is multiply posttranslationally modified. 
A brief review of the predicted human proteome shows that there are 
almost 70 proteins with an “ARKS” motif in the human genome (A. Basu, 
personal communication), thus conferring to these proteins the ability to 
undergo regulated molecular interactions with binding partners. At several 
instances, it has been reported already that the "ARKS" motif or related 
motifs are methylated at the lysine and/or phosphorylated at the serine 
or threonine. Examples have been found in the H3 tail at K9 and K27, 
in H1.4 at K26, in G9a at K165, and in the hinge of macroH2A at K157. 
Intriguingly, HP1 itself contains a very similar "KRKS" motif (see Chapter 
4 of this thesis). In several cases HP1 binding to these sites has been 
reported (Daujat et al., 2005; Sampath et al., 2007).
The linker histone H1.4 contains an "ARKS" cassette (Figure 3.16, 
top). Lysine 26 within this motif is methylated by the HMTase Ezh2 in 
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vivo, and in reporter assays methylation of this site is necessary for Ezh2-
mediated transcriptional repression (Kuzmichev et al., 2004). In a recent 
publication, Daujat et al. report that HP1 binds through its chromo domain 
to H1K26me in vitro and in pull-downs from cellular extracts (Daujat et al., 
2005). It is tempting to speculate that H1K26 methylation may be one of the 
suspected ways of H3K9me-independent recruitment of HP1 to chromatin 
(see Introduction). However, it has also been found that the neighbouring 
S27 is subject to phosphorylation (Garcia et al., 2004), and the interaction 
of HP1 with H1.4K26me is abolished by simultaneous phosphorylation 
of the neighbouring  serine 27, as shown in various pull-down and 
competition experiments (Daujat et al., 2005). The observations raise the 
intriguing possibility that release of HP1 from H1.4K26me by "methyl-phos 
switching" may be the explanation for observed decondensation effects of 
S27 phosphorylation (Roth and Allis, 1992).
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figure 3.16: examples of hp1 "methyl-phos switching" at sites other than 
h3K9me3s10ph.
top: Histone H1.4 contains a modification cassette "ARKS" that is methylated 
at K26 and binds HP1. Phosphorylation of the neighbouring S27 abolishes HP1 
association (Daujat et al., 2005). Bottom: The histone methyltransferase G9a 
contains an "ARKT"motif that is methylated at K165 and recruits HP1. A phos-
phorylation of T166 right next to the methylated lysine prevents HP1 binding.
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Another case of possible HP1 "methyl-phos switching" is G9a, a histone 
methyltransferase that methylates H3 at lysine 9 (Tachibana et al., 2001). 
G9a contains an "ARKT" motif (Figure 3.16, bottom), and autocatalytic 
methylation of lysine 165 within the G9a sequence generates a binding site 
that HP1γ associates with in vivo (Sampath et al., 2007). In in vitro binding 
assays, this interaction is reversed by phosphorylation of the adjacent 
threonine 166. While the biological function of G9aK165 methylation and 
the existence of T166ph in vivo still have to be established, this may turn 
out to be another case of HP1 "methyl-phos switching" in the cell.
Thus, H3K9meS10ph is not the only site where "methyl-phos switching" 
of HP1 is observed. Several other proteins, both in histones and in non-
histone proteins, have modification cassettes that give them the ability to 
recruit HP1 in a manner that is regulated by "methyl-phos switching".
Binary switching as a general mechanism in the cell
From these examples, it is clear that "methyl-phos switching" is a versatile 
mechanism that is used by the cell in many different contexts, for the 
regulation of HP1 binding in mitosis, during differentiation, or during for 
the definition of boundaries of heterochromatin, and for the association 
with different histones and non-histone proteins alike.
However, the demonstration of binary switching has even broader 
implications. Since various different histone marks serve as binding sites to 
recruit effector proteins, it is obvious that the mechanism will not be limited 
to HP1 and "methyl-phos" switching, but that various other proteins binding 
to different types of modifiations may be regulated by this mechanism and 
variations of the mechanism with other combinations of marks will occur, 
such as "acetyl-phos", "methyl-acetyl", or even "methyl-methyl" switching.
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figure 3.17: regulation of the chromatin association of the chromatin re-
modeller ChD by a "methyl-phos" and a "methyl-methyl" switch.
Example of a "methyl-phos" and "methyl-methyl" switch involving the chromatin 
remodeller CHD. CHD binds to methylated lysine 4 in the H3 tail. Both phospho-
rylation of theronine 3 (top, "methyl-phos switch") and methylation of arginine 2 
(bottom, "methyl-methyl switch) abolish association of CHD with H3K4me.
This is illustrated by the example of CHD (chromo-ATPase/helicase-
DNA-binding), a nucleosome remodeling factor with two chromo domains 
(Figure 3.17). Cooperating with each other in a tandem arrangement, these 
two CDs bind to H3K4me, a hallmark modification of active chromatin 
(Flanagan et al., 2005). The two neighbouring residues of H3, threonine 3 
and arginine 2, have both been found to be modified in vivo as well. H3 T3 
is phosphorylated during mitosis by the kinase haspin, a modification that 
is required for proper chromosome alignment in metaphase (Polioudaki 
et al., 2004). H3 R2 is the site of methylation by the methyltransferase 
CARM1 and plays a role in transcriptional activation (Chen et al., 1999). 
In fluorescence anisotropy experiments, it was found that the presence 
of either additional modification (i.e. a dual epitope H3R2meK4me or 
H3T3phK4me) significantly reduces binding of CHD to H3K4me (Flanagan 
et al., 2005). Thus, binding of the chromatin remodeller CHD to H3K4me 
is another case of binary switching, which in this case involves both a 
"methyl-phos" and a "methyl-methyl switch" and may control recruitment 
of the chromatin remodeller.
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Figure 3.18: High density and clustering of posttranslational modifications 
in the histone h3 tail.
The histone H3 tail shows a very high density of posttranslational modification 
sites, many of which cluster together. This suggests the existence of other binary 
switches within the H3 tail. Red circle: (mono/di/tri-) methylation. Green square: 
phosphorylation. Yellow star: acetylation.
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Within the histone tails, there are many regions with a very high 
density of clustered histone marks (see Figure 1.3 for an overview). This 
is exemplified by the histone H3 tail (Figure 3.18). Within the first 30 
amino acids of the H3 sequence, there are multiple regions of very densely 
clustered histone marks found. For many of these sites, binding proteins 
have been found, and thus it seems very likely that other cases will be 
discovered in the future where chromatin effector proteins are regulated 
by this mechanisms (Fischle et al., 2003a).
While the recruitment of effector proteins by histone marks has 
received a lot of attention in recent years, the regulation of protein 
interactions by posttranslational modifications is a general principle that 
has been studied intensely for years (Pawson, 1995; Seet et al., 2006). 
Many of the principles observed with histones have also been found in 
non-histone proteins. It is therefore likely that the mechanism of binary 
switching will be found in many interactions between non-histone proteins 
as well. Future research will tell how far beyond the field of chromatin 
biology the consequences of this novel mechanistic principle will reach.
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Chapter 4
regulation of hp1
through effeCtor phosphorylation:
phosphorylation of the hp1 hinge region
introduction
The recruitment of specific effector proteins by posttranslational histone 
modifications represents a key mechanism for controlling chromatin 
structure and function. The elusive mechanisms for how these effector 
proteins are directed to chromatin and released, and how they fulfill 
their functions in the dynamic environment of the nucleus, remain major 
challenges for the field of chromatin biology.
Arguably one of the more famous of these effector proteins, 
Heterochromatin Protein 1 (HP1) has over the last few years been the focus 
of intense research. This has led to a number of key findings, and has not 
only provided insights into the functions and mechanisms of action of 
this important chromatin factor, but has also shaped our understanding 
of chromatin in general. For example, as described in previous chapters, 
the discovery that chromo domains are modules for methyl-lysine binding 
provided a paradigm for how proteins can be recruited to modified histones 
(Bannister et al., 2001; Jacobs et al., 2001; Lachner et al., 2001).
However, despite the progress made, a number of important 
questions in HP1 biology remain unresolved, such as a full understanding 
of the interplay of the different mechanisms involved in HP1 recruitment to 
chromatin, the different roles of the three HP1 isoforms, the exact sites and 
function of HP1 posttranslational modifications (especially in mammalian 
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cells), or the mechanisms that regulate HP1’s multiple molecular 
interactions. Addressing these questions will be of vital importance for 
a full comprehension of the biological role of HP1 as well as for a deeper 
understanding of the mechanisms that control chromatin structure and 
function.
In Chapter 3, I presented data that finally provides the mechanism 
of reversible HP1 dissociation from chromatin at the onset of mitosis. HP1 
is released by a mechanism called methyl-phos switching, through which 
the interaction of the HP1 CD with methyl-K9 H3 is reversibly abolished 
by transient phosphorylation of the histone at serine 10. An essential step 
in the ejection of HP1 from mitotic chromatin, this release mechanism 
illustrates how HP1 and its dynamics during mitosis are controlled by 
histone phosphorylation.
But histone phosphorylation may not be the only way how 
posttranslational modifications control HP1 behaviour. Indeed, it has been 
observed in various organisms that HP1 itself is subject to phosphorylation. 
Highly intriguing changes in HP1 phosphorylation at specific stages of the 
cell cycle suggest that phosphorylation may be a critical mechanism to 
control the protein’s function, making HP1 phosphorylation an important 
frontier that urgently needs to be addressed.
Studying the posttranslational modifications of HP1 may also be 
of more general interest. Much has been learned in recent years about 
the mechanisms of how histone modifications recruit effector proteins to 
chromatin to bring about specific effects. However, far less attention has 
been given to the possibility that the functions of effector proteins may also 
be controlled by posttranslational modifications of the effector proteins 
themselves. It is tempting to speculate that such a regulation on side of the 
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effector proteins may exist as well, since it would allow the cell to modulate 
the read-out of the histone code. Indeed, it has been observed that the 
"modification cassettes" that are found in histone proteins are also present 
in non-histone proteins (sequences closely related to the "ARKS" motif in 
H3 are present, e.g., in the histone methyltransferase G9a or even in HP1; 
see Chapter 3, Discussion, section "Methyl-phos switching at other sites"). 
Modulation of the read-out of histone marks by modification of effector 
proteins would add yet another layer of complexity to the regulation of 
chromatin structure and function. Phosphorylation of HP1 may be a good 
model to address this fundamental question.
While carrying out in vitro kinase experiments for the reconstitution 
of methylation-phosphorylation switching in the test tube (Chapter 3), I 
made the observation that the Chromosomal Passenger Complex (CPC, 
a mitotic kinase complex with important regulatory roles in mitotic 
chromosome segregation and cell division) phosphorylates not only histone 
H3, but also full-length HP1 in vitro. This phosphorylation is isoform-
specific, since only HP1α and HP1γ are phosphorylated, while there is 
no phosphorylation observed for HP1β (Figure 4.1). The finding appeared 
immediately intriguing, because it is in keeping with an observation in 
the published literature that had suggested mitotic phosphorylation of the 
HP1 isoforms HP1α and HP1γ before.
In a paper published in 1999, E. Minc and colleagues for the first 
time presented evidence that HP1 is phosphorylated in human cells (Minc 
et al., 1999). When they immunoprecipitated HP1 from HeLa cells grown 
in the presence of radioactive phosphate, they found that HP1α and HP1γ 
were radioactively labelled in IPs from both interphase and mitotic extracts, 
while no labelling was observed for HP1β. Following up on this finding, 
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they carried out 2D gel electrophoresis to analyze the number of charged 
isoforms of HP1 (Figure 4.2). In mitosis, additional species with more 
negative charge (either due to gain of negative charge or neutralization 
of positive charge through posttranslational modification) appeared 
for HP1α and HP1γ, suggesting that the proteins acquired additional 
posttranslational modifications such as additional phosphorylations. It 
was never confirmed whether these sites are indeed phosphorylations, 
where the sites of modification lie within the HP1 sequence, or what the 
biological function of such curious hyperphosphorylation of HP1 during 
mitosis might be.
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figure 4.1: In vitro phosphorylation of hp1 by the Chromosomal passenger 
Complex.
Isoform-specific phosphorylation of HP1 by the Chromosomal Passenger Com-
plex in vitro. Recombinant HP1α, HP1β and HP1γ were incubated with X. laevis 
Chromosomal Passenger Complex (a gift from Boo Tseng, Funabiki lab) in radio-
active in vitro kinase assays. Autoradiography shows that the isoforms HP1α and 
HP1γ are phosphorylated in this reaction, while HP1β is not. Bracket indicates 
position of full-legth HP1 isoforms on the gel. Faster migrating bands are prob-
ably degradation products.
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In light of the findings reported by Minc and colleagues, several 
lines of evidence suggested that my in vitro observations might reflect a 
real in vivo event: (1) The observed in vitro phosphorylation showed the 
same isoform-specificity as the metabolic labelling described by Minc et al. 
(2) In the cell, the Chromosomal Passenger Complex is active specifically 
in mitosis and could therefore indeed be responsible for the additional 
charged HP1 species observed by Minc et al. in mitotic samples. And (3) 
an interaction of HP1α and HP1γ with INCENP, a component of the CPC, 
has been described in the published literature before (Ainsztein et al., 
1998). Therefore, I decided to follow up on my observation of HP1 in vitro 
phosphorylation by the CPC.
4.2
figure 4.2: indications for in vivo phosphorylation of hp1 in the literature 
(Figure from Minc et al., 1999).
HP1α and HP1γ may be hyperphosphorylated in mitosis in vivo. Total cell extracts 
from interphase (I) and mitotic (M) HeLa cells were separated by 2D gel electro-
phoresis, followed by immunoblotting for the different HP1 isoforms. Plus/minus 
signs indicate the orientation of the electrodes during the isoelectric focusing 
step. The black circle marks the place on the membrane where the interphase 
signal for HP1α was detected. The appearance of additional dots in the mitotic 
samples suggests that HP1α and HP1γ are modified by a posttranslational modifi-
cation that adds negative charge or reduces positive charge. Additional phospho-
rylations in mitosis could explain this observation.
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Focusing mostly on HP1α, in this chapter I summarize the 
mapping of this phosphorylation to a conserved site in the hinge region, 
confirmation and characterization of the mark in vivo, the identification of 
the responsible kinase, and experiments to elucidate the biological function 
of the mark. I also report the identification of a series of additional, novel 
phosphorylations in the hinge regions of all three HP1 isoforms by mass 
spectrometry, describe the tests I performed to ask if these modifications 
contribute to the regulation of HP1α dynamics during mitosis, and end 
with observations that suggest that the HP1α hinge phosphorylations may 
play a role in the regulation of RNA binding to HP1.
results
Mapping of hp1 in vitro phosphorylation by the CpC to a conserved 
cassette in the hinge region
Through a combination of in vitro kinase assays, deletion/mutation 
analysis and computer-based predictions, I succeeded in identifying the 
sites of the observed in vitro phosphorylation of HP1α and HP1γ by the CPC 
(Figure 4.3). The sites of modification are serine 92 in HP1α and serine 93 
in HP1γ1. These serine residues fall within the hinge region of HP1 that 
connects the chromo and chromoshadow domains. Recombinant Aurora 
B kinase (without the other CPC components) showed slightly reduced site 
specificity compared to the complex, but otherwise reproduced the results 
obtained with the CPC (data not shown).
1 For a long time it has been unclear, where exactly translation of the mammalian 
HP1γ open reading frame starts. By mass spectrometry, my collaborator Hillary 
Montgomery (Hunt lab, University of Virginia) and I could confirm the exact 
identity of the HP1γ N-terminus. In some other studies, a translation start ten 
amino acids downstream had been assumed. Thus, what I refer to as HP1γ S93 
by some other studies would refer to as HP1γ S83.
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In order to assess the sequence context and level of conservation 
of the serines identified as phosphorylation sites, I generated a sequence 
alignment of the human HP1 isoforms with the HP1 proteins of other 
organisms. As shown in Figure 4.4, the overall sequence conservation 
within the hinge region is rather low. HP1αS92ph/HP1γS93ph is part of 
a highly conserved region right in the middle of the hinge sequence. This 
sequence motif (KRKS) is found in HP1 proteins from mammals down 
to flies. Similar, though not identical, sequence motifs are found in S. 
pombe (SKRK, KSRK) and T. thermophila (RKS, KRS) (not shown in the 
alignment).
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figure 4.3: Mapping of the site of hp1α and hp1γ in vitro phosphorylation 
by the Chromosomal passenger Complex.
Radioactive in vitro kinase assays. Phosphorylation of HP1α and HP1γ is com-
pletely abolished by mutation of serine 92 and serine 93, respectively. Inclusion 
of hesperadin, a small molecule inhibitor of Aurora B kinase activity (Hauf et al., 
2003), completely prevents phosphorylation, indicating that phosphorylation is 
indeed caused by Aurora B activity and not by another component that copuri-
fied with the CPC during immunoprecipitation from X. laevis egg extracts. Aster-
isk indicates full-length HP1α/γ.
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In the human HP1β isoform, the serine is replaced with an 
alanine (KRKA), which explains the isoform-specificity of the observed 
phosphorylation. That the alanine is not always found in exactly the same 
isoforms (in X. laevis, HP1α has an alanine, while HP1β and HP1γ have 
serines; in flies KRKS is found in HP1a and HP1b, but not in HP1c) may 
indicate that in distinct organisms biological functions may be distributed 
differently between the isoforms.
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figure 4.4: sequence alignment of the hp1 hinge region.
Sequence alignment of the hinge regions of HP1 isoforms from different organ-
isms (equivalent to human HP1α amino acids 72-114). Overall, the conservation 
of the hinge region is not very high, with the exception of two conserved stretches 
of basic amino acids in the middle and in the C-terminal part of the hinge. HP1α 
S92 and HP1γ S93 (asterisk) are homologous residues and are part of a conserved 
sequence motive KRK(S) (blue box). hHP1: human, mHP1: mouse, xHP1: X. lae-
vis, dHP1: Drosophila melanogaster. Drosophila HP1b was not included, because 
the ClustalW algorithm used did not align its KRKS motive to the cassette in the 
other HP1s (compare to Figure 1.7).
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The KRKS motif resembles the Aurora B target site on histone 
H3 (ARKS around lysine 9 and lysine 27). The ARKS sequence has the 
characteristics of a "modification cassette" (Fischle et al., 2003a) that 
includes sites of methylation, effector protein binding (HP1 and Polycomb, 
respectively; see Chapter 1), phosphorylation, and methyl-phos switching 
(see Chapter 3). Even in non-histone proteins, a closely related modification 
cassette has been found to be a site of methylation, and simultaneous 
phosphorylation of the neighbouring site leads to "methyl-phos switching" 
(the ARKT motif in the methyltransferase G9a seems to function as a 
"histone mimic", Sampath et al., 2007; see also Chapter 3, Discussion, 
section "Methyl-phos switching at other sites"). This suggested to me that 
the very similar, conserved KRKS motif might play an interesting role in 
the biology of the HP1 hinge.
Specific antibody for HP1αs92ph
To examine the phosphorylation sites in vivo, I decided to rely on 
modification-specific antibodies against the sites. An HP1αS92ph serum 
was made available to me through the generosity of Dr. Raul Urrutia (Mayo 
Clinic, Rochester, MN). This group had just carried out computer-based 
phospho-site predictions of HP1 for various cellular kinases. On this basis, 
they had generated several sera for predicted phospho-serines in the HP1 
sequence, and two of these sera were against HP1αS92ph and HP1γS93ph. 
To avoid direct competition, we decided to collaborate with a division of 
labor such that I would focus on the HP1α phosphorylation, while they 
would work on HP1γ.
 As a first step, I characterized the HP1αS92ph serum and tested 
its specificity in western blotting experiments with unmodified and in vitro 
phosphorylated HP1 isoforms. As shown in Figure 4.5A, the serum ("Phos-
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HP1α antibody") turned out to be quite specific for HP1αS92ph, with little 
cross-reactivity to the other HP1 isoforms or unmodified HP1α.
The HP1αS92ph antibody was also tested in peptide competition 
experiments with extracts of nocodazole-arrested HeLa cells (which carry 
the HP1αS92 phosphorylation; see following section). Again, in these 
experiments the antibody proved highly specific for its epitope (Figure 
4.5B).
hp1αs92 phosphorylation is a mitotic mark in vivo
Taking advantage of the HP1αS92ph antibody, I set out to test whether the 
S92 phosphorylation mark indeed also existed in vivo. Since I had observed 
in vitro phosphorylation of serine 92 with a mitotic kinase complex (the 
CPC), I decided to look for the signal in cells arrested in mitosis. These 
western blotting experiments from cellular extracts confirmed the existence 
of HP1α S92 phosphorylation in vivo and showed that HP1αS92ph is 
specifically enriched in cells arrested in mitosis (Figure 4.6A).
Similar observations were made in immunofluorescence experiments 
carried out with HeLa cells. In these experiments mitotic cells were stained 
strongly, while for interphase cells only a very weak background staining 
was observed (Figure 4.6B). That the observed IF signal was indeed specific 
for the HP1αS92ph epitope was confirmed by IF peptide competition 
experiments (Figure 4.6C).
To study the kinetics of the HP1αS92ph mark in more detail, I 
carried out a time-course experiment with cells synchronized by double-
thymidine block (Figure 4.6D). Consistent with my findings obtained with 
nocodazole-arrested samples, the HP1αS92ph signal was specifically 
observed in mitosis, showing similar kinetics as the mitotic marker H3 
serine 10 phosphorylation.
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4.5figure 4.5: Characterization of the hp1αs92ph antibody in immuno- 
blotting.
a: Recombinant HP1 isoforms were incubated with recombinant Aurora B kinase 
in the presence or absence of ATP. Immunoblotting of these samples shows that 
the HP1αS92ph antibody ("Phos-HP1α" antibody) distinguishes with exquisite 
specificity between the isoforms as well as between the phosphorylated and un-
phosphorylated form. Bracket indicates area where full-length recombinant HP1 
proteins run.
B: Peptide competition experiment with Phos-HP1α antibody. The antibody 
(1:2000) was preincubated with different peptides (2 µg/ml) and then used for 
immunoblotting of HeLa total cell extracts (asynchronous cells or cells arrested in 
mitosis with nocodazole). Only the phosphorylated HP1α peptide can compete the 
signal. HP1α peptides: amino acids 83-101. H3 peptide: amino acids 1-20.
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figure 4.6: hp1αs92 phosphorylation is a mitotic mark.
a: Whole cell extracts of HeLa cells (asynchronous or arrested in mitosis with no-
codazole) were analyzed by western blotting. The mitotic marker H3S10ph con-
firms enrichment for mitotic cells upon nocodazole treatment. While HP1α levels 
do not change, HP1α serine 92 phosphorylation is specifically observed in mitotic 
cells.  
B: Immunofluorescence microscopy of HeLa cells. The mitotic cell shows intense 
HP1αS92ph staining, while the interphase cell next to it is not stained at all. 
General HP1α staining confirms that this observation is not simply explained by 
changes in the levels of HP1α or differences in antibody accessibility.
C: Peptide competition. The HP1αS92ph antibody (1:200) was preincubated with 
different peptides (2 µg/ml) and then used for immunofluorescence staining of 
HeLa cells. Competition with a phosphorylated HP1α peptide completely abolishes 
the observed signal, while control peptides (unmodified HP1α peptide, H3S10ph 
peptide with the very similar ARKS sequence) have no effect. HP1α peptides: 
amino acids 83-101. H3 peptide: amino acids 1-20.
D: HeLa cells were synchronized by double-thymidine block. After removal of the 
second S-phase block, samples were taken at regular intervals and whole cell ex-
tracts analyzed by immunoblotting. The Phos- HP1α signal comes up in mitosis 
(around 12 h), at the same time as the mitotic marker H3 serine 10 phosphoryla-
tion. U: Unsynchronized cells; N: Nocodazole-arrested cells.
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Overall, these western blotting and IF experiments confirm that 
HP1α serine 92 is indeed a site of phosphorylation in vivo, and that this 
site is specifically phosphorylated in mitosis.
Detailed characterization of hp1αS92ph by immunofluorescence 
microscopy
In order to take a closer look at the temporal correlation between HP1αS92ph 
and the well characterized mitotic marker H3S10ph, I carried out an IF 
costaining of HP1αS92ph and H3S10ph by (Figure 4.7A). This analysis 
confirmed that there is a close temporal correlation in the appearance 
of the two marks (both at late G2/early prophase). The staining of both 
antibodies disappears slowly around the stage of cytokinesis (Figure 4.7A). 
At first sight, the localization of the HP1αS92ph signal with its exclusion 
from chromatin during mitosis looks very similar to stainings with general 
HP1α antibodies (data not shown).
Closer inspection of immunofluorescence stainings, however, yielded 
two intriguing observations (Figure 4.7B): The first is that the HP1αS92ph 
antibody stains two dot-like structures that look in their cellular position 
and their migration behaviour like spindle poles/centrosomes. The 
second, that at telophase there are differences between the stainings of 
the HP1αS92ph antibody and a general HP1α antibody (Millipore MAB 
3584) (see below).
presumed centrosomal staining
Dot-like structures suggestive of centrosomal staining had on occasion also 
been observed in prophase (Figure 4.7A) or even interphase (Figure 4.6C), 
even though these stainings were not very reproducible. To investigate 
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figure 4.7: Detailed characterization of the hp1αs92ph signal by immuno-
fluorescence microscopy.
a: Immunofluorescence microscopy of HeLa cells after costaining for HP1αS92ph 
and H3S10ph. The signal of the two antibodies appears with a very similar timing 
in early prophase. HP1αS92ph then follows the movement of HP1α as it dissoci-
ates from chromatin. The signal becomes weaker as mitosis proceeds, but is still 
visible untill cytokinesis.  
B: Immunofluorescence microscopy of HeLa cells after staining with the indicated 
antibodies. The HP1αS92ph antibody stains dot-like structures, most likely cen-
trosomes, in metaphase as well as cytokinesis. In cytokinesis, the general HP1α 
staining shows that most of HP1α has already reassociated with chromatin. How-
ever, HP1αS92ph staining is at this point still excluded from chromatin. Note 
that the general HP1α and Phos-HP1α stainings depicted in this figure are not 
co-stainings, but rather individual stainings.
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whether the spindle pole signal was the result of a small amount of highly 
phosphorylated HP1α at the centrosomes or just a crossreactivity of the 
HP1αS92ph antibody, I studied the effect of HP1α knock-down by RNAi on 
the staining of HeLa cells (Figure 4.8).
4.8
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figure 4.8: effect of hp1α rnai on centrosomal staining of the phos-hp1α 
antibody.
Immunofluorescence microscopy with HP1αS92ph and HP1α antibodies after 
transfection with HP1α or mock siRNAs. HP1α RNA interference clearly reduced 
the levels of HP1α, as well as the Phos-HP1α signal in the cytoplasm/nucleus. 
The dot-like structures seem less affected.
It is difficult to judge from these pictures to what extent the signal 
of the dot-like structures is affected by the RNAi, because partial removal 
of strong dot-like staining may be hard to detect and quantify, and the 
effects were somewhat variable. My overall conclusion is, however, that 
there is little if any effect of HP1α RNA interference on the dot-like staining. 
Because, in addition to this finding, I had never observed myself nor seen 
in the literature any reports of spindle pole/centrosome staining with any 
general HP1α antibody, I concluded that the centrosomal staining may 
be a crossreactivity and decided not to follow up on this observation any 
further.
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hp1αs92ph labels a pool of hp1α that is still excluded from chromatin 
at cytokinesis
The second curious observation made from the IF stainings of Figure 4.7B 
are the differences between HP1αS92ph and general HP1α stainings at 
the end of mitosis. In late telophase/cytokinesis, the majority of HP1α 
is already back at its binding site at chromatin, as can be seen from the 
staining with the general HP1α antibody. At the same time, however, the 
(fading) Phos-HP1α signal is still seen largely in the cytoplasm, indicating 
that HP1α molecules carrying the S92 phosphorylation mark have not yet 
reassociated with chromatin. Thus, it seems that the Phos-HP1α antibody 
marks a specific subpool of HP1α that has not yet re-engaged into a 
molecular interaction with chromatin.
The observation was confirmed by costainings in several human 
(HeLa, HeP2 cells; data not shown) as well as mouse cell lines (NIH3T3, 
10T1/2; see Figure 4.9A). In addition to reproducing the exclusion of the 
HP1αS92ph signal from chromatin at telophase/cytokinesis (see Figure 
4.9B for blow-up), these experiments also confirmed that HP1α S92 
phosphorylation exists in mouse cells and behaves exactly as in human cells. 
(In peptide competitions, the general HP1α signal (Monoclonal Antibody 
#3584 from Chemicon/Millipore) was unaffected by both unmodified 
and phosphorylated HP1α peptides in immunofluorescence and western 
blotting experiments (data not shown).)
That the S92 phosphorylation staining is excluded from chromatin 
is of course just a correlation and does not prove any causal link between 
this phosphorylation and the regulation of HP1α chromatin association. An 
alternative explanation would be for example the existence of a chromatin-
associated phosphatase that removes the phospho-mark as soon as HP1α 
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figure 4.9: Differences between hp1αs92ph and general hp1α stainings in 
telophase.
a: Detailed analysis of HP1αS92ph in mouse 10T1/2 fibroblast cells (IF). Kinet-
ics and localization of the HP1αS92ph staining are very similar to the stainings 
observed in human cells. (Note: The pronounced punctate staining of HP1α in 
interphase cells is a known characteristic of mouse cells.)
B: Blow-up from panel A with increased settings for sensitivity and contrast. As 
in human cells, Phos-HP1α labels in mouse cells specifically the pool of HP1α 
that has not yet reassociated with chromatin at telophase/cytokinesis.
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comes close. However, it is tempting to speculate that the exclusion of 
phosphorylated HP1α from chromatin may be indicative of a causal 
relationship, that S92ph controls HP1α chromatin association and that 
the phosphorylation has to be removed for stable reassociation of HP1α at 
the end of mitosis.
Experiments that I carried out to follow up on this observation are 
described below (Section "A role for HP1α serine 92 phosphorylation in 
regulating HP1α chromatin association?"). However, before I go into detail 
about these experiments, I will first present data in which I confirm that 
Aurora B is indeed the kinase responsible for S92 phosphorylation in 
vivo.
aurora B is the kinase responsible for hp1α s92 phosphorylation in 
vivo
As shown in Figure 4.7A, HP1α S92 phosphorylation and H3 S10 
phosphorylation take place at about the same time in late G2/early 
prophase, suggesting that Aurora B may be responsible not only for H3 S10, 
but also for HP1α serine S92 phosphorylation. In addition, the sequence 
context of HP1α serine 92 (KRKS) resembles known Aurora B target sites 
(e.g. in H3S10: ARKS), and Aurora B efficiently phosphorylates HP1 in 
vitro. Furthermore, HP1α (as well as HP1γ) has been reported to interact 
with another component of the Chromosomal Passenger Complex, INCENP 
(Ainsztein et al., 1998). Thus, I decided to directly test the hypothesis that 
Aurora B is responsible for HP1α S92 phosphorylation in vivo.
To begin, I turned to immunofluorescence costaining to show that 
Aurora B and HP1α indeed colocalized at the time of HP1α  phosphorylation. 
As expected for a chromosomal passenger protein, in prophase at the time 
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when HP1αS92 phosphorylation occurs, Aurora B was found all over the 
chromosomes, therefore significantly overlapping with the localization of 
HP1α serine 92 phosphorylation (data not shown). Encouraged by this 
correlative observation, I went ahead to test involvement of Aurora B in 
mitotic HP1α phosphorylation in a more direct way.
Aurora B inhibition with hesperadin
To test directly whether Aurora B is indeed the kinase responsible for 
mitotic HP1α phosphorylation in vivo, I carried out Aurora B inhibition 
experiments with the small molecule inhibitor hesperadin (Hauf et al., 
2003). However, Aurora B activity is required for multiple important steps 
in mitosis, and without it the spindle check-point does not function, 
preventing mitotic arrest by chemicals commonly used for this purpose. 
Since detection of HP1αS92ph in western blots requires enrichment for 
mitotic cells, I was forced to adapt a more indirect approach (Hauf et al., 
2003).
HeLa cells were arrested in mitosis by treatment with nocodazole for 
12 h. Then the arrested cells were treated with hesperadin. Simultaneously 
with hesperadin, the proteasome inhibitor MG132 was added to the cells, 
which precludes the degradation of anaphase inhibitor and thus prevents 
cells from leaving metaphase. After a brief incubation of 15 min with 
hesperadin/MG132, cells were harvested and tested by western blotting.
Generally, phosphatases are globally present and constitutively 
active, while kinases are highly regulated in their localization and activity. 
The phosphorylation of a specific site is determined by the balance between 
these counteracting forces. Consequently, if Aurora B is the kinase 
responsible for serine 92 phosphorylation, inhibition of this kinase should 
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shift the phosphorylation/dephosphorylation balance in the arrested cells 
towards the unphosphorylated form, resulting in a reduced HP1αS92ph 
signal.
With control immunoblots I verified that my basic experimental 
set-up was working (Figure 4.10). When I subsequently checked the 
effect of the hesperadin/MG132 treatment on HP1αS92ph, I found that 
the phosphorylation signal accumulated upon nocodazole arrest was 
significantly reduced and brought down to levels observed in unsynchronized 
cells. This strongly supports the hypothesis that Aurora B is indeed the 
kinase responsible for HP1α S92 phosphorylation in vivo.
figure 4.10: aurora B inhibition with the small molecule inhibitor hespera-
din decreases hp1αs92 phosphorylation.
HeLa cells were arrested in mitosis with nocodazole. Then they were either treated 
with hesperadin/MG132 or vehicle. Asynchronously growing cells (no nocodazole 
treatment) serve as control.
As expected, nocodazole arrest results in accumulation of the mitotic cyclin B1 
(asterisk indicates a crossreacting band) as well as increased levels of H3S10ph 
and HP1αS92ph. Blots with antibodies against general H3 and HP1α confirm 
equal loading. Upon treatment with hesperadin/MG132, the cyclin B1 signal per-
sists, proving that cells did not leave mitosis. Levels of H3S10ph and HP1αS92ph, 
on the other hand, are reduced upon hesperadin/MG132-treatment.
Nocodazole:
Hesperadin
& MG132:
H3S10phos
+- +
+- -
H3 general
Cyclin B1
HP1S92ph
HP1 gen.
4.10
*
141
However, it should be noted that the described inhibition experiment 
is based on a chemical compound, which might have unspecific effects 
on other kinases. Indeed, off-target effects of hesperadin have already 
been reported (e.g. on Aurora A, Hauf et al., 2003). I therefore decided 
to complement the small molecule inhibition experiment with a second, 
independent method.
Aurora B knock-down by RNA interference
To verify the observations made in the inhibition experiment through a 
second approach that was independent of a chemical compound, I carried 
out knock-down experiments of Aurora B by RNA interference.
Because Aurora B knock-down prevents the straightforward use of 
nocodazole to arrest cells in mitotis (see above), I generated a synchronized 
population of HeLa cells by double-thymidine block. Between the first and 
second block, the cells were transfected with siRNAs targeted at the Aurora 
B sequence. After the release of the second block and transition through 
S phase, the synchronized cell population was harvested upon entry into 
mitosis (as judged from cells deattaching and rounding up). Cell synchrony 
and enrichment for mitotic cells in samples transfected with Aurora B and 
mock siRNAs was confirmed by flow cytometry (Figure 4.11, left).
Western blotting shows that Aurora B RNAi resulted in almost 
complete removal of the kinase, while Aurora A protein levels were 
unaffected (Figure 4.11, right). When I examined how this specific removal 
of Aurora B affected mitotic HP1α S92 phosphorylation, I found a significant 
decrease in the levels of this mark. This strongly supports the hypothesis 
that Aurora B is indeed the kinase responsible for phosphorylation of HP1α 
serine 92 during mitosis in vivo.
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figure 4.11: aurora B rnai decreases hp1αs92 phosphorylation.
left: Analysis of DNA content of cells synchronized by double-thymidine block. 
Cells were stained  with propidium iodide, analyzed by flow cytometry and the 
data plotted as histograms. 2N: DNA content of diploid cell (before replication). 
4N: doubled DNA content after replication.
a: In a control population of unsynchronized HeLa cells, most cells are in G1 
phase (2N DNA content) and only few cells in S (between 2N and 4N) or G2 (at 4N). 
b: Positive control: HeLa cells in mitosis (arrested in prophase with nocodazole) 
uniformly have 4N DNA content. c: HeLa cells 2h after double-thymidine blot 
proceed through S phase as a homogeneous population. d, e: Cells synchronized 
by double-thymidine block, transfected with mock (d) or Aurora B siRNAs (e), 
and harvested at  mitosis. Most cells have 4N DNA content, indicating reason-
ably good cell synchrony. d) and e) are the samples used for analysis by western 
blotting, see on the right. f: Synchronized HeLa cells prevented from proceeding 
through mitosis by nocodazole block. Comparison of d and e with f shows that 
a small number of cells in d and e had already progressed through mitosis and 
reentered G1 at the time of harvesting. However, there is still significant enrich-
ment for mitotic cells observed in d) and e).
right: Western blots of synchronized HeLa cells treated with either Aurora B or 
mock siRNAs, and harvested when the majority of cells were in mitosis (see left, 
panels d and e). Aurora B RNAi efficiently reduces Aurora B protein levels, while 
not affecting Aurora A. Even though HP1α protein levels are similar in both sam-
ples, HP1α serine 92 phosphorylation is significantly decreased in the sample 
treated with Aurora B siRNAs.
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In sum, I have presented multiple experiments that all support the 
interpretation that Aurora B is the kinase responsible for mitotic 
phosphorylation of HP1α at serine 92. Colocalization of Aurora B and HP1α 
at the time of phosphorylation, chemical inhibition, knock-down of Aurora 
B by RNA interference, site-specific in vitro phosphorylation as well as 
the published observation reporting an interaction of HP1α with another 
member of the Chromosomal Passenger Complex, INCENP (Ainsztein et 
al., 1998), all point in the same direction. While it cannot be ruled out 
that there are other kinases that contribute to this phosphorylation at the 
onset of mitosis, the simplest interpretation of my data is that Aurora B is 
the main kinase responsible for HP1α serine 92 phosphorylation in vivo.
hypothesis: Does hp1α serine 92 phosphorylation play a role in 
regulating hp1α chromatin association?
The observation that HP1αS92ph specifically stains a subpopulation of 
HP1α which has not yet reassociated with chromatin is highly intriguing, 
because it raises the possibility that serine 92 phosphorylation may play a 
role in the regulation of HP1α chromatin association.
As conclusively shown by the findings described in Chapter 3 of my 
thesis, H3 serine 10 phosphorylation is essential for the mitotic release of 
HP1 from chromatin, and other groups have confirmed this observation 
(Hirota et al., 2005; Terada, 2006b). However, these different reports do 
not fully agree as to whether H3 serine 10 phosphorylation is actually also 
sufficient for HP1α dissociation. While in peptide binding assays reduced 
binding of the chromo domains of all three HP1 isoforms and of full-length 
HP1β to H3K9me3S10ph peptides was found (Fischle et al., 2005a; Hirota et 
al., 2005), H3S10 phosphorylation seems not sufficient to prevent binding 
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of full-length HP1α and HP1γ (Fass et al., 2002; Terada, 2006a). Differences 
in the experimental systems cannot fully account for these conflicting 
observations. One intriguing explanation to this conundrum is, however, a 
possible contribution of other HP1 domains besides the chromo domain to 
the association of full-length HP1α and HP1γ with chromatin. If in addition 
to the chromo domain-H3K9me interaction other molecular interactions 
contribute to stable association of HP1α and HP1γ with chromatin in vivo, 
then reversal of chromo domain-binding by methyl-phos switching may 
not be sufficient for the release of the full-length proteins.
This interpretation is supported by observations that our 
collaborators Boo Tseng and Dr. Hironori Funabiki made with Xenopus 
egg extracts during the study of methyl-phos switching. While exogenous 
full-length xHP1α was released from chromatin in the presence of CPC 
and retained upon depletion of the CPC, a point mutation that abolished 
the CD-H3K9me interaction displayed an intermediate effect and clearly 
some binding in CPC-depleted extracts (Fischle et al., 2005b).
Contributions of additional interactions besides the CD-H3K9me to 
HP1 chromatin interaction have been suggested repeatedly in the literature 
(Dialynas et al., 2006; Eskeland et al., 2007; Muchardt et al., 2002; see 
Chapter 1, Section "Molecular Mechanisms of HP1 Recruitment"). The 
molecular mechanism for the reversal of such interaction(s) may well be 
phosphorylation on the side of the effector protein HP1.
Given the phosphorylation of HP1α and HP1γ, it might seem surprising 
that HP1β is not phosphorylated. However, considering the differences in 
the interactions of the different isoforms, it is possible that HP1β does not 
require Aurora B phosphorylation, because it simply does not undergo 
the specific interaction that is reversed by HP1α/γ phosphorylation. Of 
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interest in this context, in none of the publications reporting interaction of 
full-length HP1 with H3 carrying serine 10 phosphorylations was retention 
of HP1β reported. In our own experiments full-length HP1β was readily 
released from H3K9me peptides upon S10 phosphorylation (Figure 3.7B).
Based on the observation that HP1αS92ph closely correlates with 
HP1α release and specifically stains a subpopulation of HP1α which is 
largely not associated with chromatin in immunofluorescence, and the 
possible importance to release other HP1 interactions besides the CD-
H3K9me interaction as described above, I formulated the hypothesis that 
HP1α S92 phosphorylation might play a role in the mitotic release of HP1α 
from chromatin in vivo (Figure 4.12).
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figure 4.12: hypothesis: hp1α serine 92 phosphorylation is a necessary 
step for the dissociation of hp1α from chromatin in vivo.
This hypothesis assumes that stable HP1α binding to chromatin invovles, in ad-
dition to chromo domain binding to H3K9me, a second interaction mediated by 
the hinge region (to an unknown chromatin component X). Efficient release of 
HP1α from chromatin during mitosis is therefore a two-step process and involves 
not only methyl-phos switching, but also HP1α serine 92 phosphorylation to re-
verse the hinge interaction. Stable reassociation of HP1α to chromatin at the end 
of mitosis, on the other hand, requires the removal of HP1αS92ph.
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s92 phosphorylation correlates with increased extractability of 
hp1α
Support for the hypothesis came from observations I made in biochemical 
experiments. Following a protocol commonly used in the Allis lab to prepare 
chromatin on a small scale, I extracted chromatin prepared from mitotic 
HeLa cells with a low-salt buffer (Mendez and Stillman, 2000). When I 
then compared the S92 phosphorylation of extracted and retained HP1α 
by western blotting, I found that the level of HP1αS92 phosphorylation 
correlates with the extractability of HP1α (Figure 4.13A).
a pool of hp1α associated with metaphase chromosomes is not 
recognized by the phos-hp1α antibody in if experiments
A second observation in support of the hypothesis that serine 92 
phosphorylation may play a role in HP1α chromatin association came 
from immunofluorescence microscopy. In metaphase cells, I observed on 
occasion a pool of HP1α that specifically localized to chromatin. However, 
this pool of HP1α was only detected by general HP1α staining and not with 
the Phos-HP1α antibody (Figure 4.13B).
One possible explanation for this finding is that some HP1α protein 
is not phosphorylated and therefore remains chromatin-associated 
throughout metaphase. This would be in keeping with the hypothesis that 
HP1α serine 92 phosphorylation plays a role in the release of HP1α from 
chromatin (for alternative explanations see below).
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figure 4.13: Biochemical and if experiments suggest that hp1α serine 92 
phosphorylation may indeed regulate hp1α chromatin association.
a: Mitotic HeLa cells were lysed with 0.2% NP40 and purified chromatin was 
extracted with a buffer of low ionic strength ("low-salt buffer": 2 mM KCl/3 mM 
EDTA/0.2 M EGTA). Serine 92 phosphorylation of extracted (S, soluble) and un-
extracted (I, insoluble) HP1α was compared by western blotting. Levels of phos-
phorylation are much higher in the extracted fraction. C: chromatin fraction be-
fore extraction; S: soluble in low-salt buffer; I: insoluble in low-salt buffer.
B: Immunofluorescence microscopy of HeLa cells. Staining with a general HP1α 
antibody labels a pool of HP1α that is associated with the mitotic chromosomes 
of metaphase cells. This pool of HP1α is not recognized by the Phos-HP1α anti-
body.
148
stable cell lines expressing hp1α with serine 92 point mutations
Encouraged by these findings, I decided to test the hypothesis that HP1α 
phosphorylation at serine 92 might be involved in the control of HP1α 
dissociation from chromatin directly. However, I did not have specific 
knowledge of which interaction(s) might be stabilizing HP1α's chromatin 
binding. In fact, the details of HP1 chromatin binding in vivo are exceedingly 
complex, possibly requiring several steps of binding and stabilization 
and multiple interactions (see Chapter 1). While it is clear that the CD-
H3K9me3 interaction is a particularly important interaction for binding 
of HP1 to chromatin, HP1 chromatin association in vivo is not completely 
understood. This made it impossible for me to set up an in vitro system 
of which I could be sure that it fully reflected the in vivo situation. Thus, 
I reasoned that the best way to test my hypothesis was the expression of 
HP1α constructs with S92 mutations in cultured mammalian cells. If the 
hypothesis in Figure 4.12 was correct, then an unphosphorylatable HP1α 
should be retained at chromatin (at least in the most extreme scenario). 
Similarly, an HP1α construct that mimics constitutive phosphorylation 
should not reassociate properly with chromatin at the end of mitosis. 
(Since the interaction controlled by S92 phosphorylation might be only of 
a stabilizing nature, it was possible that the phenotype would be a little 
less pronounced.)
To this end, I generated HeLa cell lines that stably expressed tagged 
HP1α with either wt (wild-type) sequence or with a point mutation at 
serine 92 (mutated to alanine to prevent phosphorylation; mutated to 
glutamate to mimic constitutive phosphorylation). Originally, I developed 
stable cell lines expressing HP1α fused with Green Fluorescent Protein 
(GFP). However, with these cells I observed significant differences in the 
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fractionation behaviour of wt GFP-HP1α and endogenous HP1α (data not 
shown). Thus, I generated a second set of cell lines with a much smaller 
FLAG-HA-FLAG tag. As a control for effects caused by the tag, I generated 
two sets of cell lines with the constructs tagged on the N-terminal and the 
C-terminal side of the protein, respectively.
In western blotting experiments, the cell lines for both N-terminally 
(Figure 4.14) and C-terminally tagged (data not shown) HP1α were 
characterized, proving expression of a protein of the expected size (Figure 
4.14, left). Tagged HP1α is phosphorylated with the same efficiency as 
endogenous HP1α (Figure 4.14, right), and in fractionation experiments 
as well as peptide pull-down experiments with H3 peptides tagged HP1α 
behaved like the endogenous protein (data not shown).
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figure 4.14: Characterization of hela cell lines stably expressing flag-ha-
tagged hp1α.
Cell line expressing N-terminally FLAG-HA-tagged HP1α shown. Whole cell ex-
tracts of cell lines were analyzed by immunoblotting. left: An additional band 
of the expected size is detected in the HP1α western blot, showing the expres-
sion level of the tagged HP1α. right: Upon nocodazole arrest, exogenous tagged 
HP1α is phosphorylated to the same extent as endogenous HP1α (compare with 
ratio of bands in HP1α blot). HP1α(N): HeLa cells stably expressing N-terminal-
ly FLAG-HA-tagged HP1α. wt: Unaltered HeLa control cells. Amidoblack shows 
equal loading of the lanes. Similar results were obtained with the C-terminally 
tagged constructs.
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no obvious effect of serine 92 mutation on hp1α localization
The effect of serine 92 mutation on the localization of HP1α was analyzed 
by immunofluorescence microscopy after staining with an HA antibody. 
Clearly, the tag did not alter the cellular localization of HP1α in these 
experiments, because tagged wt HP1α (no mutation) showed the same 
localization as observed before for endogenous wt HP1α (Figure 4.15, top 
row).
HP1 (N)
HP1 S92A (N)
HP1 S92E (N)
Inter Meta Ana Telo
4.15figure 4.15: no obvious effect of hp1α serine 92 mutations on hp1α local-
ization.
Immunofluorescence microscopy (anti-HA) of HeLa cell lines stably expressing 
FLAG-HA-tagged HP1α constructs with and without serine 92 point mutations. 
Typical stainings are shown. Point mutation of serine 92 does not have any clear 
effect on HP1α localization or dynamics at the different stages of mitosis.
Stages of mitosis are indicated above the panels. (Since only mouse interphase 
cells show clear heterochromatic dots, no such dots are observed in these HeLa 
cell stainings.) HP1α (N): HP1α with wt sequence, N-terminally tagged; HP1α S92A 
(N): HP1α with serine 92 mutated to alanine, N-terminally tagged; HP1α S92E (N): 
HP1α with serine 92 mutated to glutamate, N-terminally tagged. Comparable ob-
servations were made with the C-terminally tagged constructs.
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If serine 92 phosphorylation was indeed essential for the regulation 
of HP1α dissociation during mitosis, I reasoned that mutating this serine 
should affect the localization of HP1α during mitosis. Mutation of serine 92 
to alanine precludes phoshorylation and may therefore prevent the release 
of HP1α from chromatin; mutation of serine 92 to glutamate, on the other 
hand, might mimic constitutive phosphorylation (phosphomimic) and may 
thus delay or even prevent stable reassociation of HP1α with chromatin 
at the end of mitosis. However, my analyses failed to show any obvious 
effects of the serine 92 point mutations on HP1α localization or dynamics 
(Figure 4.15).
There are several possible explanations why these point mutations 
of serine 92 do not have any clear effect on HP1α localization. S92ph could 
be redundant with other phosphorylations or other covalent marks, or may 
need to cooperate with additional modifications in order to bring about an 
effect on HP1α's chromatin association (see below section "Redundancy / 
Requirement for cooperation"). But it is of course also possible that serine 
92 phosphorylation does indeed fulfill its function on its own, but that this 
function is simply not the regulation of HP1 chromatin binding. Serine 92 
phosphorylation could for example control a different molecular interaction 
of HP1α that has to be released/established during mitosis, but that does 
not affect the association of HP1 with chromatin.
hypothesis: hp1α serine 92 phosphorylation regulates the hp1α's 
association with a specific binding partner
If such an interaction exists, I reasoned that a yet unidentified binding 
partner would display differential binding to unmodified versus S92-
phosphorylated HP1α. Based on this assumption, I set out to identify 
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molecules that bound to the serine 92 region of HP1α if it was unmodified, 
but were abrogated, if S92 was phosphorylated, or vice versa.
Peptide pull-downs to identify protein interactions controlled by HP1α serine 
92 phosphorylation
My first approach to identify such phosphorylation-dependent binders 
was by peptide pull-down (Wysocka, 2006). Protein modules binding in 
dependence of a single modifications often recognize only a short sequence 
stretch around the modification site (Seet et al., 2006); thus, a peptide 
was generated that included the site of modification and about ten amino 
acids upstream and downstream (HP1α residues 83-101). Phosphorylated/
unmodified HP1α peptides were immobilized on avidin-coated agarose 
beads and incubated with cellular extracts. After washing steps, bound 
proteins were eluted and run out on SDS-PAGE gels, to identify specific 
bands after silver-staining. Since a binding protein might be a factor that 
is only expressed at a certain time during the cell cycle, extracts from 
both asynchronously growing and nocodazole-arrested HeLa cells were 
used. To minimize the risk of peptide dephosphorylation by phosphatases 
present in the extract, high concentrations of phosphatase inhibitors (25 
mM NaF, 25 mM β-glycerolphosphate, 6 mM Orthovanadate, CalBiochem 
Phosphatase Inhibitor Set (contains Cypermethrin, Dephosphatin, Okadaic 
acid, and NIPP-1); these are levels known to protect endogenous HP1α 
from dephosphorylation) were present at all times during the pull-down. 
However, no phospho-specific bands were detected reproducibly in these 
first pull-downs.
Several technical aspects of the experimental procedure could account 
for this. Therefore, I repeated the experiment under various conditions, 
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such as different methods of extract preparation, using HeLa S3 suspension 
cells (larger cell number results in higher extract concentration, in case 
the binding partner was only a low-abundance protein) and lowering the 
number and stringency of washing steps (to reduce the risk of washing off 
a low-affinity interactor). To make sure even weak specific binders were 
not missed in this complex protein mixture, whole gel lanes were analyzed 
by mass spectrometry (carried out by the MS facility of the Max-Planck-
Institute for Biophysical Chemistry in Göttingen, Germany). Subsequently, 
the complete lane was compared in its protein content and abundance 
with control pull-downs.
To validate the approach, I also included a positive control by using 
K9me3 and unmodified H3 peptides (Figure 4.16). As expected, in the 
H3K9me3 pull-down all three HP1 isoforms HP1α, HP1β and HP1γ were 
found. In contrast, no HP1 peptides were detected in the pull-down with 
unmodified H3 peptide. Thus, the control pull-downs specifically enriched 
for the expected modification-dependent interactors and verified the 
approach.
Comparison of the proteins in pull-downs with HP1α S92ph and 
unmodified HP1α peptides (see Figure 4.16 for example), however, did not 
lead to the identification of any convincing and reproducible candidates. 
Minor differences in the binding to the two peptides seemed either caused 
by handling (different keratins), unspecific binding of abundant and sticky 
cellular proteins (e.g. chaperonin, ribosomal proteins, actin, tubulin) or 
could be excluded due to their cellular localization (e.g. mitochondrial 
proteins).
Besides the possibility that S92 phosphorylation simply does not 
regulate a protein interaction at all, there are several other possible reasons 
why pull-down experiments may not have led to the identification of an 
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interactor. It could be that the binding partner was not present in sufficient 
abundance in the extracts used or that the affinity of the interaction is 
very low. Indeed, interactions depending on a single posttranslational 
modification have often been found to be rather weak (Fischle et al., 
2003b; Pawson, 1995; Ruthenburg et al., 2007). The low affinity may even 
be a prerequisite for dynamic regulation, and in the context of the full-
length protein such interactions could be stabilized by additional contacts 
with other partners. In this case a classical biochemical pull-down with 
a peptide may simply not be sensitive enough for the identification of the 
interaction partner.
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figure 4.16: peptide pull-down to identify phosphorylation-dependent bind-
ers of hp1α.
Peptide pull-down carried out with a nuclear extract of unsynchronized HeLa S3 
cells. (Similar experiments were completed with extracts from nocodazole-arrest-
ed cells.) Extracts were incubated with biotinylated peptides immobilized on avi-
din-coated agarose beads. After washes the beads were boiled in protein sample 
buffer, and the mixture was run out on an SDS-gel and stained with Coomassie. 
Lanes were subsequently cut into small pieces and subjected to analysis by mass 
spectrometry. Lanes 3 and 4 show the control pull-down with unmodified and 
K9-methylated H3 peptides. Some differences are so clear that they can even be 
seen in the coomassie staining. All three HP1 isoforms were subsequently identi-
fied specifically in the H3 K9me3 lane (asterisk marks a band that is most likely 
HP1γ). Lanes 5 and 6 show an example of an HP1α (83-101) peptide pull-down 
(unmodified vs. S92ph). Only little protein binds to the HP1α peptides (compare 
to lane 2), and banding patterns for the two pull-downs are virtually identical.
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Phage display screen for interacting proteins regulated by HP1α serine 92 
phosphorylation
To exclude that an interaction partner was missed due to these limitations 
of the biochemical pull-down, I applied a complementary approach by 
phage display screening, which I carried out (as some other experiments 
described in this thesis) in the laboratory of Dr. Wolfgang Fischle at the 
Max-Planck-Institute for Biophysical Chemistry in Göttingen (Germany). 
Its multiple rounds of clonal enrichment (see Figure 4.17) make this 
approach particularly suited for the identification of weak interactions 
with rare binding partners.
To verify that the screen was working as expected, control peptdides 
(unmodified H3 peptide and H3K9me3 peptide) were probed with a library 
containing minute amounts of an HP1-expressing phage (diluted 1:106). 
Within a few rounds of selection, the H3K9me3 peptide significantly 
enriched for the HP1-expressing phage (Figure 4.18, left), proving that 
this phage display screening protocol can indeed be used for efficient 
and highly selective enrichment for specific binders of posttranslational 
modifications.
The actual screen for binding proteins controlled by HP1α S92 
phosphorylation was carried out with two different phage libraries (from 
liver and brain tissue; Novagen), to increase the chances that a binding 
protein was found in the library. For every peptide I worked in duplicates, 
to estimate the reproducibility of the results. To my disappointment, the 
screening with the HP1α peptides did not result in the enrichment of 
any specific phages, as judged by a preliminary analysis by PCR (Figure 
4.18, right). Any follow-up experiments would have involved a significant 
investment in time and effort (screening of clones from last round of 
selection; sequencing of fused mammalian cDNA sequence; verification of 
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identified interactions). The preliminary analysis by PCR suggested that it 
was unlikely that a binding partner would be identified in the end (even 
though the positive control showed that the procedure was working in 
general). I therefore decided to abandon the phage display screen.
4.17
figure 4.17: principle of phage display screening.
Principle of the phage display screen for factors specifically interacting with 
HP1αS92ph. An immobilized HP1αS92ph peptide (1) is incubated with a library 
of phages expressing different cDNAs on their surface (2). After washing steps 
(3), phages binding to the peptide are released (4) and the eluted phages ampli-
fied in bacteria (5). The resulting mixture of phages is used for a second round 
of peptide binding (6). By successive rounds of binding and amplification phages 
expressing specific binding proteins are enriched, even if the interaction is rather 
weak and the binding protein present only at very low abundance in the original 
library (7).
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figure 4.18: phage display screen to identify phosphorylation-dependent 
binders of hp1α.
Phage mixtures eluted after different rounds of selection were analyzed by PCR 
(with sequencing primers annealing on both sides of the insert within the phage 
sequence). The appearance of specific bands indicates the enrichment for indi-
vidual phages. For each peptide, selection rounds 1 to 5 are shown, separated by 
a lane with DNA molecular weight marker.
left: Control. For the H3K9me3 peptide, a strong band of the expected size (as-
terisk) is observed within few rounds of selection, proving fast and strong enrich-
ment for phages expressing HP1. The unmodified H3 peptide shows no significant 
enrichment besides the band that is also seen in the beads-only control.
right: Actual screen. Neither with the unmodified HP1α peptide nor with the 
HP1αS92ph peptide specific bands (besides the band seen in the beads-only con-
trol) are observed.
redundancy / requirement for cooperation
At this point, I pursued several different approaches (and variations of these) 
in order to identify a phospho-dependent binding partner. Even though 
I had tried to anticipate and work around limitations of some of these 
approaches, there were of course still multiple trivial technical explanations 
possible why the experiments undertaken had not succeeded.
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It cannot be excluded, for example, that the length of the HP1α peptide 
used in these assays (19 aa) was simply not sufficient for stable binding, 
even though modules binding in dependence of a single posttranslational 
modification often recognize only a few amino acids around that mark (Seet 
et al., 2006). I carried out pilot experiments by passing cellular extracts 
over a recombinantly expressed HP1α hinge construct, but obtained 
protein mixtures too complex to analyze, possibly because the hinge region 
is not structured and therefore extremely sticky as an isolated domain. As 
an alternative explanation, it was also possible that a phosphorylation-
dependent binding partner existed, but that it was not a protein, but 
a nucleic acid and therefore not represented in the extracts/libraries I 
used.
However, besides these possibilities, there was another explanation 
for the failure to identify S92ph-dependent binding that seemed even more 
likely: Serine 92 phosphorylation may not fulfill its function on its own, 
but in concert with other modifications. This could even explain why no 
phenotype was detected upon S92 mutation in vivo.
If there are indeed multiple sites of posttranslational modification 
in mitosis and modification of some of these is already sufficient for HP1α 
dissociation (i.e. there is redundancy among the modifications), this could 
explain why S92A mutation does not prevent dissociation of HP1α. The 
interplay of several sites of posttranslational modification could also be 
the reason why S92E mutation has no detectable effect: If a threshold 
number of sites have to be modified simultaneously  to cause dissociation 
of HP1α from chromatin (i.e. a "requirement for cooperation" of several 
modifications), mutation of a single site to glutamate will not prevent 
HP1α from reassociating at the end of mitosis. Thus, the existence of 
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other modifications that collaborate with S92ph could explain the lack 
of a phenotype for point mutations of serine 92 despite all the intriguing 
correlative observations made.
As far as the type of posttranslational modification that may be 
collaborating with S92 phosphorylation is concerned, it could in principle 
be any kind. However, it seems particularly tempting to speculate about a 
role of phosphorylation. Additional phosphorylation would further increase 
the negative charge already introduced by S92ph, multiple kinases are 
known to be active during mitosis, and E. Minc et al. had already made 
observations suggesting that there may be more than one site of mitotic 
HP1α phosphorylation (Minc et al., 1999).
Studying the role of HP1α S92 phosphorylation in the context of 
such other mitotic phosphorylations is only possible, if these other 
phosphorylations (or modifications) are known. Therefore, I decided that 
it would be a worthwhile undertaking to examine the posttranslational 
modification profile of HP1 in detail.
Purification of HP1
In order to identify and map the sites of mitotic HP1 phosphorylation/
modification, I decided to purify the protein from cultured cells and 
determine the posttranslational modification profile by mass spectrometry 
(MS). Besides novel modifications, the MS approach also promised to 
confirm the existence of mitotic HP1α S92 phosphorylation in vivo through 
a completely independent method (in addition to the antibody-based 
methods I had already used), and might possibly even permit quantifying 
the abundance of the S92ph mark in mitotic and interphase cells.
Three different approaches for the purification of HP1 were 
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developed, which I briefly summarize below. In each of these cases, the 
actual mass spectrometric analysis was carried out by my collaborator 
Hillary Montgomery in the lab of Dr. Don Hunt at the University of Virginia 
(Charlottesville, VA).
(1) Acid extraction and HPLC enrichment of endogenous HP1 followed by 
analysis from SDS-PAGE gel
 I isolated endogenous HP1 by acid extraction from highly enriched 
mitotic HeLa cells (nocodazole treatment followed by mitotic shake-off, 
resulting in about 95% enrichment for mitotic cells).  Upon further 
separation by reversed phase HPLC (Figure 4.19A, left), HP1-containing 
fractions were run out on an SDS-PAGE gel (Figure 4.19A, right), and 
HP1 bands excised and analyzed by MS.
This approach led to the identification of three phosphorylations 
(HP1βS89ph, HP1γS93ph and HP1γS95ph), but unfortunately no 
convincing modification was identified for the isoform that I was most 
interested in, HP1α. Peptide coverage for all HP1 isoforms was low due 
to three technical aspects of the procedure: Firstly, acid extraction, 
even though the method of choice for enrichment of histones, is not 
very effective for the extraction of HP1, a finding that may be due to 
differences in isoelectric point (mammalian HP1 has a much lower pI 
than histones; note that this is in contrast to, e.g., Tetrahymena HP1, 
which has a pI more similar to that of histone proteins). Secondly, the 
approach requires proteolytic digestion and subsequent recovery of 
peptides from gel bands, which is often inefficient. And thirdly, in-gel 
digests are usually done with trypsin, and due to its richness in basic 
amino acids especially the HP1 hinge is cut by trypsin into pieces too 
small for most analyses.
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Figure 4.19: Purification of HP1 for analysis of modification profile by mass 
spectrometry.
a: Approach 1: Enrichment for of endogenous HP1 isoforms by acid extraction, 
RP-HPLC and gel electrophoresis.
left: Proteins acid extracted from mitotic HeLa cells were separated by RP-HPLC 
on an acetonitrile gradient. Fractions containing the HP1 isoforms were identified 
by slot blotting (the three isoforms eluted together, area between red lines). It is 
clear from the chromatogram that HP1 proteins are, in contrast to e.g. histones, 
only minor components in the extract. right: HPLC fractions containing HP1 
proteins were united and run on an SDS-PAGE gel, to cut bands for MS analysis. 
Asterisk: band containing (among other proteins) HP1α and HP1β. Arrow head: 
band containing HP1γ.
B: Approach 2: Purification of endogenous HP1γ by cell fractionation and immu-
noprecipitation (HP1γ shown because HP1α runs exactly behind antibody band).
left: HP1γ western blots after immunoprecipitation from the cytoplasmic frac-
tion of mitotic HeLa cells. Most of the HP1γ in the fraction is precipitated in the 
HP1γ IP, while the control IP shows that this is dependent on the HP1γ antibody. 
I: Input. U: Unbound. B: Bound. right: Coomassie-stained gel of the HP1γ IP 
and control IPs (25% ot total IPs loaded). Compared to the amounts of antibody, 
the levels of HP1γ (arrow head) in the IP are rather low . Note, though, that HP1 
peptides were not analyzed from the gel, but rather directly from the beads after 
limited proteolytic digest.
C: Approach 3: Purification of tagged, overexpressed HP1α from mitotic HeLa 
cells by cell fractionation and immunoprecipitation from the cytoplasmic fraction. 
Coomassie-stained gel (10% of total IP loaded). Arrow head: position of tagged 
HP1α. Asterisks: antibody bands.
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(2) Cell fractionation and immunoprecipitation of endogenous HP1 followed 
by analysis on the beads
To overcome these problems, I turned to a second approach for the 
purification of HP1. For more efficient extraction of HP1, cultured cells 
were subjected to biochemical fractionation (Wysocka et al., 2001), and 
all proteins subsequently stripped off of DNA with a high-salt buffer. 
The HP1 isoforms were further enriched by immunoprecipitation with 
monoclonal HP1 antibodies (Figure 4.19B, left). HP1 was then digested 
directly on the beads (not from the gel), and resulting peptides subjected 
to MS.
Even though only partial digests were carried out and I had 
verified saturation of the beads with HP1, a large excess of antibody was 
detected in these MS samples (see Figure 4.19B, right), most likely due 
to the procedure of antibody immobilization (I used anti-mouse beads to 
immobilize anti-HP1 monoclonals, and some of the antibody may have 
been bound in an inactivating fashion). MS analysis of HP1α against 
such a background of antibody protein fragments turned out to be next 
to impossible. Only upon inclusion of an additional enrichment step for 
phospho-peptides by IMAC (immobilized metal affinity chromatography) 
could novel HP1 modifications be identified.
The above altered approach resulted in the identification of 
multiple phosphorylations for all three HP1 isoforms (see below). It 
also led to the first proof by mass spectrometry for the existence of the 
S92ph mark in vivo. However, inclusion of the IMAC step made any 
quantification of the levels of phosphorylation impossible.
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(3) Cell fractionation, immunoprecipitation and on-beads analysis of 
exogenous tagged HP1
To reduce the amount of antibody in the sample, I took advantage of my 
cell lines expressing the three HP1 isoforms with a FLAG-HA tag and 
switched to anti-FLAG agarose beads, while still pursuing an approach 
of immunoprecipitation/on-beads analysis (Figure 4.19C). The samples 
obtained by this procedure turned out to be very well suited for the 
analysis by mass spectrometry and even allowed for quantification of 
phosphorylation levels.
To investigate whether the phosphorylation levels changed in 
the course of the cell cycle, I purified and analyzed HP1 from both 
asynchronously growing and mitotically enriched (nocodazole-treated) 
cell populations, and diverse fractions (cytoplasmic, nucleoplasmic, 
chromatin-associated). Overall, the analysis led to the identification of 
six phosphorylation sites on HP1α, one on HP1β and three on HP1γ (see 
Figure 4.20 and Figure 4.21 for example mass spectra; see Figure 4.23 
for summary of results). I will discuss these phosphorylations in detail 
in the section below entitled "Most phosphorylations cluster within the 
hinge region of HP1α".
Several other proteins were detected in the IPs that despite rigorous 
washing steps co-immunoprecipitated with the tagged HP1α. Especially 
the HP1α IPs were analyzed in depth, and we found that many of these 
coprecipitating proteins were published interaction partners of HP1α, 
such as HP1β, HP1γ, Su(var) 3-9, KAP-1, INCENP, CAF1 p150, Lamin B1, 
Lamin B Receptor, Ki-67, BRG1, and NIPBL (see Table 4.1). In addition, 
a few factors were detected that are members of complexes shown before 
to interact with HP1, for example Dasra B/Borealin, CAF1 p60, or NSL1 
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4.20
figure 4.20: tandem mass spectrum of a singly phosphorylated hp1α pep-
tide (s92ph) (Figure courtesy of Hillary Montgomery).
Tandem mass spectrum (MS/MS) of a singly phosphorylated HP1α peptide 
(S92ph), residues 87-108, fragmented by electron transfer dissociation (ETD). 
The peptide was generated by an on-beads digest of exogenous HP1α with endo-
proteinase Glu-C. A fraction of the resulting peptide mixture was analyzed by on-
line nanoflow high performance liquid chromatography micro-electrospray ion-
ization tandem mass spectrometry (nHPLC-µESI MS/MS). The instrument cycled 
through the acquisition of a full-scan mass spectrum (MS) and the top five most 
abundant masses in this initial MS scan were sequentially chosen for tandem MS 
(MS/MS) spectra (depicted in this Figure). Full sequence coverage was attained 
for this +6 charged peptide, 442.40 m/z. The spectrum provides evidence that 
the HP1α peptide is phosphorylated at serine 92. c’ and z’• fragment ions are de-
noted in blue and red, respectively.  Doubly-charged fragment ions are denoted 
with asterisks (*).
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4.21
figure 4.21: tandem mass spectrum of a doubly phosphorylated hp1α pep-
tide (s85phs92ph) (Figure courtesy of Hillary Montgomery).
Tandem mass spectrum (MS/MS) of a doubly phosphorylated HP1α peptide 
(S85phS92ph), residues 76-108, fragmented by electron transfer dissociation 
(ETD). Full sequence coverage was attained for this +7 charged peptide, 572.10 
m/z. The spectrum shows that this HP1α peptide is doubly phosphorylated, at 
serine 85 and serine 92. c’ and z’• fragment ions are denoted in blue and red, 
respectively. Doubly-charged fragment ions are denoted with asterisks (*).
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4.22figure 4.22: tandem mass spectrum of an hp1γ peptide defining the HP1γ 
n-terminus  (Figure courtesy of Hillary Montgomery).
Tandem mass spectrum (MS/MS) of the N-terminal peptide from HP1γ, residues 
2-24, fragmented by electron transfer dissociation (ETD). Full sequence coverage 
was attained for this +5 charged peptide, 522.10 m/z. The spectrum confirms the 
existence of an N-acetylated peptide ASNKTTLQKMGKKQN… in vivo. This implies 
that translation of HP1γ starts ten residues upstream of what is often assumed to 
be the N-terminus of HP1γ. c’ and z’• fragment ions are denoted in blue and red, 
respectively.  Doubly-charged fragment ions are denoted with asterisks (*).
168
Table 4.1: Known interaction partners of HP1 found in the HP1  IP 
Identified interaction Reference
HP1beta Le Douarin et al., 1996
HP1gamma Le Douarin et al., 1996
SUV39H1
Aagaard et al., 1999 
Czvitkovich et al., 2001
KAP1 Le Douarin et al., 1996
INCENP Ainsztein et al., 1998
CAF1 p150
Murzina et al., 1999 
Ryan et al., 1999
BRG1 Nielsen et al., 2002
Lamin B1 Kourmouli et al., 2000
Lamin B receptor Ye et al., 1997
Ki-67 Scholzen et al., 2002
NIPBL Lechner et al., 2005
 
SUV39H1: Suppressor of varieagation 3-9 homolog 1. INCENP: Inner 
centromere protein. CAF1: Chromatin assembly factor 1. BRG1: Brahma-
related gene 1 (also known as SWI/SNF-related matrix-associated actin-
dependent regulator of chromatin). NIBPL: Nipped-B like protein. 
Table 4.2: Proteins found in HP1 IP that are components of complexes 
known to interact with HP1 
Identified interaction Complex Reference
Dasra B/Borealin
Chromosomal Passenger 
Complex
Sampath et al., 2004 
Ainsztein et al., 1998
NSL1 Mis12 Complex
Euskirchen, 2002 
Obuse et al., 2004
CAF1 p60 CAF1 Complex Murzina et al., 1999
 
NSL1: NNF1 synthetic lethal. NNF1: Necessary for nuclear function 1. CAF1: 
Chromatin assembly factor 1. 
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(Table 4.2). Co-immunoprecipitation of these proteins can be considered 
as further validation that the tagged HP1α protein indeed undergoes the 
same interactions and behaves the same way as endogenous HP1α.
Of interest, from coimmunoprecipitated HP1γ, Hillary Montgomery 
and I could obtain specific information about the HP1γ N-terminus (Figure 
4.22), which settles a long-standing uncertainty about the exact translation 
start site of the protein. Detection of a peptide ASNKTTLQKMGKKQN… 
demonstrates that in Hela cells, translation of HP1γ starts (also) ten amino 
acids upstream of what is often assumed as the protein's N-terminus 
(MGKKQN…). We also found that the terminal methionine of HP1γ is 
actually processed, and that the protein is N-acetylated.
In addition to known interaction partners of HP1α, a number of 
other proteins were identified from these IPs. These include several 
transcriptional regulators (BCLAF, ERH, TRAP3), proteins involved in sister 
chromatid cohesion and cell division (Prohibitin 2, NDR1), and a protein 
phosphatase (PP1) (see Table 4.3). These proteins co-purified with tagged 
HP1α, but unfortunately there was no selection for phospho-dependent 
binders in this pull-down.
Most phosphorylations cluster within the hinge region of hp1
Most of the identified phosphorylation sites map to the hinge region 
of HP1 (Figure 4.23). This is intriguing, because it suggests that the 
phosphorylations may indeed collaborate to bring about a hinge-mediated 
effect, for example in the regulation of a molecular interaction. Thus, it 
provides support for the hypothesis that redundancy among the different 
HP1 phosphorylations may indeed be the reason why mutation of serine 
92 to alanine has no observed phenotypic effects.
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4.23Figure 4.23: Cartoon depiction of HP1 phosphorylation sites identified by 
mass spectrometry.
The phosphorylation sites identified by mass spectrometry are: S85, S87, S92, 
S95, S97, and S110 in HP1α; S89 in HP1β; and S93, S95, and S176 in HP1γ. 
Almost all phosphorylation sites fall within the hinge region of the HP1 proteins. 
Yellow star: acetylation site identified in the HP1α chromo domain (K24). Mass 
Spectrometry was carried out by my collaborator Hillary Montgomery (Hunt lab, 
UVA)
Table 4.3: Potential novel interaction partners of HP1 
Identified interaction Reference 
BCLAF Kasof et al., 1999 
ERH Isomura et al., 1996 
TRAP3 Fondell et al., 1996 
Prohibitin 2 Coates et al., 1997 
NDR1 Millward et al., 1995 
PP1 Trinkle-Mulcahy and Lamond, 2006 
 
BCLAF1: BCL2-associated transcription factor 1 (also known as Btf, . ERH: 
Enhancer of rudimentary homolog. TRAP3: Thyroid hormone receptor 
associated protein 3. NDR1: Nuclear Dbf2-related kinase (also known as Serine-
threonine kinase 38). PP1: Protein phosphatase 1. 
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Because of the striking density of serine residues in this region, the 
HP1 hinge has long been speculated to be phosphorylated (Badugu et al., 
2005). However, actual evidence for the existence of such phosphorylations 
has been lacking so far. The mass spectrometry data generated by Hillary 
Montgomery and me is the first time that definitive evidence is presented 
for the existence of such a series of phosphorylations in the hinge region. 
Compared to the other two domains of HP1, the hinge region has received 
much less attention. The discovery of these posttranslational modifications 
of the hinge may therefore contribute to our understanding of this 
understudied domain of HP1.
Conservation of phosphorylation sites
Sequence conservation of the serines identified as phosphorylation sites 
was assessed from an alignment of the human HP1 isoforms with the HP1 
proteins of other organisms (Figure 4.24). Outside of the conserved blocks 
of basic amino acids, the hinge regions of most HP1s have a high density 
of serines, glutamic acid and aspartic acid; however, the exact order of 
the serines and acidic residues is not conserved between organisms. But 
despite this low conservation at the level of the exact amino acid sequence, 
the composition and character of this region is well preserved across the 
different species.
The conservation of the basic and acidic (i.e. charged) character of 
these clusters makes it reasonable to assume that a molecular interaction 
mediated by these patches of positively and/or negatively charged amino 
acids could be conserved across different organisms. And if the target 
sequence for the kinase(s) responsible for the observed phosphorylations 
(besides serine 92) is defined simply by an acidic sequence context, it is 
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well possible that the phosphorylations as well as the responsible kinase(s) 
are conserved between different species.
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Figure 4.24: Alignment of the hinge regions of HP1 proteins from differ-
ent species indicating the position of the newly identified phosphorylation 
sites.
Low sequence conservation between the conserved blocks of basic amino acids 
makes it difficult to obtain a meaningful alignment. However, the character of 
these sequence stretches seems very well preserved between species. Identified 
phosphorylation sites in green. hHP1: human, mHP1: mouse, xHP1: Xenopus 
laevis, dHP1: Drosophila melanogaster HP1.
Higher levels of phosphorylation in mitosis
The IPs of tagged exogenously expressed HP1α allowed me to obtain 
quantitative data for several of the phosphorylation sites from both 
asynchronous and mitotic samples. Comparing the phosphorylation 
levels (see Table 4.4) clearly reveals that there is a significant increase of 
phosphorylation during mitosis at several of these sites. It seems possible 
that I have identified the sites for which indications had been found 
before by the Buendia lab (Minc et al., 1999). While the levels of mitotic 
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phosphorylation found in the quantitative MS analysis may not seem high, 
I assume that the values measured are artificially low due to technical 
aspects of the experimental procedure (such as incomplete enrichment 
for mitotic cells or phosphatase activity during extended incubations and 
handling). This is supported by other observations that I lay out in more 
detail in the Discussion at the end of this chapter.
In summary, our mass spectrometry analysis of HP1α posttranslational 
modifications revealed that the protein is multiply phosphorylated. The 
sites of phosphorylation specifically cluster in the hinge region in an area 
with a high density of serines and acidic amino acids between blocks of 
basic residues, a characteristic that is conserved between species. The 
levels of phosphorylation at most of these sites are specifically upregulated 
during mitosis.
Hypothesis: Multiple HP1α hinge phosphorylations collaborate to 
control the mitotic release of HP1α from chromatin
Having identified this series of novel phosphorylations in the HP1α 
hinge, I was now in a position to reevaluate the hypothesis that HP1α 
phosphorylation may play a role in the release of HP1α, this time taking the 
potential collaboration of multiple phosphorylations into consideration. For 
this purpose I generated stable HeLa cell lines expressing HP1α constructs 
in which all the sites of mitotic HP1α phosphorylation were mutated to 
alanine (six sites, see Figure 4.23; because I made the cell lines before 
our MS approach finally succeeded, the construct included an additional 
seventh mutation, S103A). To control for unwanted effects of the tag, two 
versions of this HP1α "aStA" construct (for "all Serines to Alanine") were 
generated, one with an N- and one with a C-terminal FLAG-HA-tag.
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By immunofluorescence microscopy I examined if there was any 
effect of the mutations on the localization or dynamics of HP1α in mitosis. If 
there was indeed a role of the hinge phosphorylations in the mitotic release 
of HP1α, then simultaneous mutation of all mapped phosphorylation sites 
should affect the dissociation of HP1α from chromatin despite redundancy 
among the phosphorylation sites. However, even simultaneous mutation 
of all serines in the HP1α hinge to alanine did not have any detectable 
effect on the localization of the protein, neither in interphase nor at any 
stage of mitosis (data not shown).
At first sight, this seems to reject the hypothesis that HP1α hinge 
phosphorylation might play any role in the control of mitotic HP1 dissociation 
from chromatin. However, upon more careful reflection, it became clear 
that even after ruling out redundancy of phosphorylations as a potential 
problem, there was still another major aspect of the experimental system 
that could significantly complicate the experimental read-out, namely HP1 
dimerization.
As described in the Introduction, it has been known that, through its 
chromoshadow domain, HP1α can both homodimerize and heterodimerize 
with HP1β and HP1γ (Platero et al., 1995; Smothers and Henikoff, 2000). 
The interaction is strong enough to be observed in pull-downs with 
recombinant components (Ye et al., 1997), and it is known that the different 
HP1 isoforms affect each other in their localization in vivo (Dialynas et al., 
2007).
In the tissue culture system that I was using for the analysis of 
the hinge mutations, endogenous unmutated HP1α, HP1β and HP1γ were 
still present in addition to the exogenous, mutated HP1α I was testing. 
Thus, it was possible that interaction with the endogenous, unmutated 
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HP1 isoforms had a significant impact on HP1 dynamics in mitosis and 
"masked" the effects of the mutations.
analysis of hp1α asta localization in cells devoid of endogenous 
hp1α, hp1β and hp1γ
Point mutations abolishing HP1 dimerization have been published by 
others before (e.g. HP1αI165E/HP1β161E, Brasher et al., 2000). However, 
these mutations also affect other interactions of the HP1 CSD (some of 
which actually depend on HP1 dimerization), and have been reported to 
significantly reduce chromatin association of HP1 and change its localization 
(Thiru et al., 2004). Thus, I reasoned that my best experimental option 
was a cell system in which the endogenous HP1 proteins were absent. 
Genetic knock-outs in mammalian cells have never been reported for any 
of the HP1 isoforms in the literature. Similarly, it is unlikely that a stable 
simultaneous knock-down of all three isoforms will be able to survive for 
extended periods of time, because knock-down of two of the three isoforms 
by RNA leads already to failure to segregate chromosomes faithfully during 
cell division (Obuse et al., 2004). Thus, I reasoned that the best way to do 
this experiment was by triple knock-down through simultaneous transient 
transfection of siRNAs against all three endogenous HP1 isoforms.
To make sure that only the endogenous HP1α was knocked down 
and not my mutated construct, I generated dsRNA oligos directed against 
the 5' untranslated region of the gene (a gift from Dr. Wolfgang Fischle, 
Goettingen; see Figure 4.25A). With fluorescent RNA oligos and flow 
cytometric analysis I optimized the transfection conditions until I reached 
efficiencies of >95% (data not shown). Even though successful transfection 
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figure 4.25: localization of hp1α hinge mutations after knock-down of en-
dogenous hp1 isoforms by rnai.
a: Strategy of specific RNAi against endogenous HP1α. HP1α siRNAs were tar-
geted against the 5' untranslated region of the HP1α gene, which is not present 
in the mRNA of the exogenous HP1α construct that carries the phosphorylation 
site mutations.
B: Immunoblots of cells at time of analysis by IF. Specific and almost complete 
knock-down of all three endogenous HP1 proteins is observed. Exogenous, tagged 
HP1α is unaffected by the RNAi. That there are sometimes traces of signal left 
after RNAi may be because of the small fraction of cells that were not transfected 
with the respective siRNA.
Asterisk: Exogenous HP1α. (Extended periods of culture led to a reduction in the 
expression levels of N-terminally tagged HP1α. The specific effects of the RNAi on 
the HP1 protein levels are therefore clearer in the C-terminally tagged cell lines.)
N: N-terminally tagged HP1α without mutations. N-aStA: N-terminally tagged 
HP1α with all S in hinge mutated to A. C: C-terminally tagged HP1α without mu-
tations. C-aStA: C-terminally tagged HP1α with all S in hinge mutated to A.
C: Immunofluorescence microscopy (anti-HA) of HeLa cell lines stably expressing 
HA-tagged HP1α constructs, either with wt sequence or with all serines in the 
hinge mutated to alanine, with or without triple knock-down of endogenous HP1 
isoforms (stainings shown are representative of what was commonly observed). 
No clear differences are seen at any of the cell cycle stages.
HP1α (N): HP1α with wt sequence, N-terminally tagged; HP1α "all S to A" (N): HP1α 
with all serines in the hinge region mutated to alanine, N-terminally tagged
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of individual cells cannot be tracked during the final experiment, these 
extremely high transfection efficiencies assure that 80-90% of cells will 
receive all three oligos.
For the actual experiment, cells were transfected with either HP1α/
β/γ siRNAs or random sequence siRNA. The day after the transfection, cells 
were split into two fractions and either seeded on cover slips for analysis 
by IF, or replated for biochemical analysis of the knock-down. Cells were 
harvested 3.5 d after transfection, according to pilot experiments the time 
of lowest protein levels (data not shown).
Immunoblotting proved efficient knock-down of all three endogenous 
HP1 isoforms, while the levels of exogenous HP1α protein were unaffected 
(Figure 4.25B). However, even with endogenous HP1 isoforms largely 
absent, I did not discover any clear differences in the localization of wt and 
mutated HP1α in my analysis of immunofluorescence stainings (Figure 
4.25C).
Theoretically, it is possible that the efficiency of the knock-down was 
simply not efficient such that the remaining traces of endogenous HP1 
isoforms were still sufficient to prevent an effect of the mutations. However, 
this scenario seemed not very likely. Despite a number of observations 
pointing in that direction, despite pursuing diverse experimental 
approaches, mutating all serine residues in the HP1α hinge, and even 
knocking down all endogenous HP1 isoforms simultaneously, I did not 
find any clear evidence to support the hypothesis that phosphorylation 
of the HP1α hinge controls the mitotic release of HP1α from chromatin. 
Of course my experiments do not completely rule out such a possibility. 
However, I decided that at this point that further follow-up experiments on 
the hypothesis were not justified and that it would be the best for me to 
reconsider other hypotheses.
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hypothesis: hp1α hinge phosphorylation regulates reassociation of 
hp1α with chromatin in metaphase
Alternatively, HP1α hinge phosphorylation may be the key to explain a 
curious experimental observation of HP1 biology that I also pointed out 
in the Introduction to this thesis: After the global release of HP1 from 
chromatin at the onset of mitosis, a small fraction of HP1α (and, possibly, 
also of HP1β and HP1γ) reassociates with the centromeric regions of the 
chromosomes in metaphase (Hayakawa et al., 2003; Minc et al., 1999). 
Hayakawa and colleagues mapped the region of HP1α that is required for 
the reassociation with centromeres during metaphase. They found that 
the above reassociation is independent of the chromo domain and rather 
mediated by a region comprising the C-terminal part of the hinge and the 
chromoshadow domain (aa 101-180).
Only a fraction of HP1α reassociates, and it has thus already been 
suggested that posttranslational modification might be the mechanism how 
this reassociation of HP1α is controlled (see Figure 4.26). While most of 
the identified phosphorylation sites lie just outside of this mapped binding 
region, due to tertiary structure effects or simply the immediate proximity 
to the binding region the addition of a series of negative charges to the HP1α 
hinge could prevent the interaction that causes this reassociation of HP1α 
with the metaphase chromatin. This interpretation is supported by previous 
observations, where serine 92 phosphorylation seems exclusive with the 
binding of a pool of HP1α to metaphase chromosomes (Figure 4.13B). This 
suggests HP1α hinge phosphorylation as the molecular mechanisms to 
keep the majority of HP1α from reassociating with metaphase chromatin.
181
For better visualization of the small pool of chromatin-bound HP1α 
against the large background of HP1α in the cytoplasm at metaphase, 
an alternative protocol of fixation and extraction for immunofluorescence 
microscopy was adapted (Figure 4.27A; Dormann et al., 2006). This protocol 
was then used to compare the reassociated, chromatin-bound pool of two 
HP1α constructs, one with all hinge phosphorylation sites mutated to 
alanine, the other to glutamate.
No differences in the staining intensity were observed (Figure 4.27B) 
suggesting that HP1α reassociation with chromatin is not significantly 
altered by phosphorylation of the identified sites within the HP1α hinge.
figure 4.26: hypothesis: hp1α hinge phosphorylation regulates reassocia-
tion of hp1α with chromosomes in metaphase.
Schematic overview of the hypothesis: After HP1α is globally released from chro-
matin by methyl-phos switching (and possibly other mechanisms), a fraction of 
HP1α reasociates with centromeric chromatin through chromo domain-indepen-
dent mechanisms. This reassociation may be controlled by HP1α hinge phos-
phorylation. Only the pool of HP1α that happens to remain unphosphorylated 
may be able to rebind, while HP1α hinge phosphorylation prevents the molecular 
interactions for reassociation with metaphase chromosomes.
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figure 4.27: Mutation of phosphorylation sites in the hp1α hinge has no 
obvious effect on hp1α reassociation with metaphase chromosomes.
a: IF of HeLa cells stably expressing HA-tagged HP1α. Comparison of different 
Fixation-Extraction procedures. If mitotic cells are fixed first and then extracted 
(top), the excess of HP1α in the cytoplasm is seen. However, if the order is changed 
and cells are extracted first and then fixed (bottom), all the unbound HP1α in the 
cytoplasm is removed and the small pool of HP1α bound to metaphase chromatin 
becomes visible.
B: Immunofluorescence microscopy (anti-HA) of HeLa cells stably expressing 
tagged HP1α mutants. Cells were first extracted and then fixed. As commonly 
observed, no difference in the HP1α pool associated with metaphase chromatin 
is observed.
HP1α "all S to A" (C): HP1α with all serines in the hinge mutated to alanin and 
C-terminal FLAG-HA tag. HP1α "all S to E" (C): HP1α with all serines in the hinge 
mutated to glutamate and C-terminal FLAG-HA tag. 
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Cell cycle faCs
In all the described IF experiments, mutated HP1α had shown the same 
cellular localization at the different stages of mitosis as wt HP1α. In light 
these observations, a direct involvement of HP1α hinge phosphorylation 
in the regulation of HP1's chromatin dissociation or reassociation seems 
unlikely. However, cells analyzed in IF experiments are "hand-picked" for 
being in specific mitotic stages. It is therefore possible that eventually the 
localization changes are the same for wt and mutant HP1α, but the kinetics of 
these localization changes are actually different. Cells expressing mutated 
HP1α constructs may simply take longer for their progression through 
mitosis. Interestingly, mutation/deletion of HP1 is connected to lagging 
chromosomes and delayed mitosis in several organisms (mostly of course 
because heterochromatin integrity is important for centromere function; 
Ekwall et al., 1995; Kellum and Alberts, 1995; Obuse et al., 2004).
To investigate whether mutations in the HP1α hinge region caused 
such delays in mitosis, I carried out cell cycle FACS analysis of HeLa cells 
expressing either wt or mutated HP1α. If the time for transition through 
one of the steps of mitosis was extended, the fraction of cells in mitosis 
would increase. However, my analysis of the flow cytometry data led only to 
the discovery of minor differences between the individual samples (Figure 
4.28). Since these differences showed no systematic pattern, they seemed 
rather caused by random fluctuations or by the fact that these stable cell 
lines that had been grown independently for a while, leading to minor 
differences in their growth characteristics.
To exclude that the presence of the endogenous wild-type copy of 
HP1α prevented the detection of a clear effect, I repeated the experiment 
with cells in which the endogenous HP1α protein had been knocked down 
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by RNAi. However, once again all the measurements fell within a rather 
narrow range (data not shown), indicating that even in the absence of 
endogenous HP1α there was no significant effect of the mutations on the 
progression of mitosis.
4.28figure 4.28: effect of hp1α hinge mutations on cell cycle progression.
Distribution of cell cycle stages of HeLa cell lines stably expressing various HP1α 
constructs. Upon RNase digestion and propidium iodide staining, the DNA con-
tent of asynchronously growing cultures was determined by flow cytometry, fol-
lowed by modelling of the culture's cell cycle distribution (Watson Pragmatic 
model, FloJo software package).
The cell cycle distribution of the different cell lines is very similar.
N: N-terminally tagged HP1α without mutations. N-aStA: N-terminally tagged 
HP1α with all S in hinge mutated to A. N-aStE: N-terminally tagged HP1α with all 
S in hinge mutated to E. C: C-terminally tagged HP1α without mutations. C-aStA: 
C-terminally tagged HP1α with all S in hinge mutated to A. C-aStE: C-terminally 
tagged HP1α with all S in hinge mutated to E. N w/ Noco: Control cells (N-termi-
nally tagged HP1α without mutations) arrested in mitosis with nocodazole.
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hypothesis: hp1α hinge phosphorylation regulates molecular 
interactions of the hinge region
My thesis data suggest that hinge phosphorylation controls neither mitotic 
HP1α dissociation from chromatin nor reassociation of a pool of HP1α 
with chromatin in metaphase. Mutations of the phosphorylation sites also 
do not affect progression through mitosis. However, the fact that these 
phosphorylations in the HP1α hinge specifically occur in mitosis still 
suggests that they may play a regulatory role at this phase of the cell 
cycle.
It is unlikely that the phosphorylations fulfill their function by affecting 
HP1α structure, because the hinge region is most likely unstructured (Ball 
et al., 1997). There is also no indication that mitotic HP1α phosphorylation 
affects protein stability; neither in the published literature, nor in any of 
my experiments with synchronized cell populations or nocodazole arrested 
cultures were changes in HP1α protein levels ever observed.
The identified modifications all cluster within a narrow region of the 
HP1α hinge, adding a significant amount of negative charge to a rather 
small patch of sequence. This suggests that HP1α hinge phosphorylation 
may control a molecular interaction with a binding partner that associates 
with this region of HP1α (Figure 4.29).
As outlined in the Introduction of my thesis, several molecules 
have been described to bind to the hinge region of HP1α and are therefore 
candidates: histone H1 (Hale et al., 2006), the chromosomal passenger 
protein INCENP (Ainsztein et al., 1998), and RNA (Muchardt et al., 2002). 
Since all these published reports included in vitro binding experiments, I 
decided to test through direct in vitro interaction assays, whether any of 
these interactions was affected by phosphorylation of the HP1α hinge.
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experiments to test if hp1α hinge phosphorylation controls hp1α's 
interaction with histone h1
In 2006, the lab of Rafael Herrera (Baylor College, Houston) 
reported a specific interaction of HP1α with H1b, a histone H1 isoform 
predominantly found in heterochromatin (Hale et al., 2006; Th'ng et al., 
2005). The interaction was mapped to the HP1α hinge, and it was shown 
that phosphorylation of H1b by CDK2 during interphase interrupts the 
interaction, possibly to allow disassembly of higher order chromatin 
structures for better access to the chromatin template (Roth and Allis, 
1992). Since already phosphorylation of a single site in the H1b C-terminal 
domain was sufficient to abolish the interaction, it is tempting to speculate 
that phosphorylations on the HP1α hinge may have a similar effect.
In order to address the question in the most direct way, I relied on in 
vitro binding experiments with recombinant proteins. However, although I 
tried this experiment under various conditions (H1b purified under different 
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figure 4.29: hypothesis: hp1α hinge phosphorylation controls a molecular 
interaction that has no connection to hp1 chromatin association.
Hypothesis: At the same time when methyl-phos switching releases HP1 chroma-
tin association at the onset of mitosis, HP1α hinge phosphorylation reverses (or 
establishes) a different molecular interaction with an unrelated molecule X.
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(denaturing and nondenaturing) conditions, various salt concentrations, 
presence/absence of BSA), I could never reproduce the reported specific in 
vitro binding of H1b to the HP1α isoform or the specificity of binding to the 
hinge region (data not shown).
My difficulties to repeat these experiments are mirrored by similar 
observations made by other labs, who also have only seen unspecific 
binding of H1b (Fischle, 2008). It cannot be ruled out that some minor 
difference between our experimental procedures (e.g. different tags) 
unexpectedly cause these conflicting observations. However, because 
multiple approaches by multiple labs had not been able to reproduce the 
reported results, I decided that it was advisable not to spend more time on 
the interaction of H1b with HP1α.
experiments to test if hp1α hinge phosphorylation controls hp1α's 
interaction with rna
The second molecular interaction of HP1α that I decided to examine was the 
interaction with RNA. Prompted by observations by Maison et al. (Maison 
et al., 2002), C. Muchardt and colleagues showed in 2002 in a series of 
experiments (overlay assays and electrophoretic mobility-shift assays) that 
HP1α and HP1γ bind RNA (Muchardt et al., 2002). While their in vitro 
experiments were carried out with a random bacterial RNA, competition 
demonstrated specificity with respect to the kind of RNA (competition by 
mammalian nuclear RNA; no competition by AU- or GC-rich oligomers, 
tRNA, or DNA). However, neither the nature nor the sequence of RNAs 
bound by HP1α in vivo has been studied so far.
Muchardt and colleagues mapped the RNA binding activity in vitro 
to residues 86 to 108 of HP1α (Muchardt et al., 2002), corresponding to 
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the C-terminal half of the hinge, which is rich in basic amino acid (and 
includes the KRKS sequence motif and most of the phosphorylation sites 
that I identified within the HP1α hinge). Mutation of three adjoining 
lysine residues within this sequence (K103, K104, and K105) to alanine 
completely abolished RNA binding of HP1α. If the removal of three positive 
charges by mutation entirely prevents RNA binding, then it seems quite 
possible that the addition of multiple negative charges to the same region 
by phosphorylation may have a similar effect. Thus, I hypothesized that 
the HP1α hinge phosphorylations may have a function in the regulation of 
RNA binding.
Further encouragement came from observations that I made while 
purifying recombinant HP1α domains. After affinity purification of HP1α 
hinge constructs (wt and with all serines in the hinge mutated to glutamate) 
from E. coli cells, I took a UV-Vis spectrum of the purified protein. To my 
surprise, the spectrum of the wt hinge had a significant peak at 260 nm 
(Figure 4.30A, left) that was not present in the spectrum of the mutated 
hinge construct (Figure 4.30A, right). Since the two samples had been 
prepared in parallel and undergone exactly the same manipulation, this 
suggested that a bacterial nucleic acid may be binding to and copurifying 
with the wt HP1α hinge, while it did not associate with the mutated 
hinge.
To verify the presence of the nucleic acid and learn more about 
its nature, I treated aliquots of the dialyzed protein mixture with DNase 
and RNase, respectively. Ethidium bromide staining after agarose gel 
electrophoresis revealed that the 260 nm peak was caused by RNA (Figure 
4.30B).
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figure 4.30: hp1α hinge phosphorylation may regulate the interaction of 
hp1α with rna.
a: UV-Vis spectra of bacterially expressed His-HP1α hinge (wt or with serines in 
hinge mutated to glutamate) after elution from Ni-NTA and dialysis. A peak at 
260 nm (arrow) indicates that a nucleic acid copurifies with the wt HP1α hinge. 
No such peak is observed in the spectrum of the mutated HP1α hinge.
B: The copurifying nucleic acid is RNA. Upon heat denaturing (5 min at 95º C), 
aliquots of the elution from panel A were treated with either DNase or RNase A. 
Only RNase treatmemt removes the nucleic acid.
C: Electrophoretic mobility shift assay to compare RNA binding of different HP1α 
wt and mutant domains (autoradiography). As expexted, the control chromo do-
main construct does not bind the RNA probe and leaves the RNA in the unshifted 
position (marked by an asterisk). While the wt HP1α hinge binds to and shifts the 
RNA, the mutated HP1α hinge does not. (The signal that is seen in all lanes at the 
top of the gel indicates that a fraction of the labelled RNA had aggregated.)
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This suggests that (possibly due to the absence of its normal target 
RNAs) the wt HP1α hinge associates by means of its RNA-binding capacity 
with bacterial RNA. Mutation of the HP1α hinge (all serines in the hinge were 
mutated to glutamate, introducing negative charges and thus mimicking 
constitutive phosphorylation), on the other hand, seems to abolish the 
ability of the HP1α hinge to bind RNA. Obviously, no conclusion can be 
drawn from this experiment about the size or nature of RNAs bound by 
HP1α in mammalian cells, because in this experiment nucleic acids were 
sheared during cell disruption and the interaction with bacterial RNAs is 
artifcial anyway. Nevertheless, the observation is completely in line with 
the exciting hypothesis that phosphorylation of the HP1α hinge region 
might indeed regulate the binding of RNA to HP1α.
As discussed above, so far little is known about the connection 
between HP1α and RNA in vivo. In particular, no RNAs that may bind 
HP1α in vivo have been identified yet. This makes it very difficult to design 
experiments that directly test the effect of HP1α hinge phosphorylation on 
RNA binding in the cell. Muchardt and colleagues used an in vitro method, 
electrophoretic mobility-shift assays (EMSAs), to learn more about the 
interaction they had observed in overlay assays (Muchardt et al., 2002). 
Therefore, I decided to apply the same technique and subject the hypothesis 
that HP1α hinge phosphorylation has an effect on HP1α's RNA binding to 
a first test by EMSA.
To obtain recombinant protein for use in the EMSA, I took HP1α hinge 
protein affinity purified from bacteria and then added an ion exchange 
chromatography step to separate the protein component from the bacterial 
RNA (data not shown). As RNA probe for these assays, a Drosophila mRNA 
sequence (500 nt of the cyclin E gene) was used. In pilot experiments, I had 
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established that this RNA probe reproduced the domain-specific binding 
to HP1α described by Muchardt and colleagues (collaboration with Dr. E. 
Bernstein, then a postdoc in the Allis lab; data not shown).
When I tested binding of the probe RNA to wt and mutated HP1α 
domains, I observed a striking difference. The unmutated wt hinge bound 
to and shifted the RNA probe. The mutated HP1α hinge (phospho-sites 
replaced by glutamate), however, did not shift the probe at all (Figure 
4.30C). While these experiments still are preliminary and have to be 
repeated and extended, they are fully in keeping with the interpretation 
that phosphorylation of the HP1α hinge region regulates the binding of 
RNA to HP1α.
Discussion
novel phosphorylations of hp1
In this chapter of my thesis, I have described the identification of a series of 
phosphorylation sites of HP1. Phosphorylation at these sites is specifically 
upregulated in mitosis, and most of them cluster in a short sequence 
stretch of the hinge region, a domain of HP1 that so far has received 
very little attention compared to the other domains of HP1. For one site, 
HP1αS92ph, which is conserved between different species, I carried out a 
detailed analysis with a modification-specific antibody and identified the 
Chromosomal Passenger Complex as the responsible kinase in vivo.
Intrigued by curious correlations (Figures 3.5, 3.6, 3.9), I tested various 
hypotheses about the function of these HP1 phosphorylations, ranging 
from an involvement in the mitotic release of HP1α and a regulatory role in 
the reassociation of a subpool of HP1α with metaphase centromeres to a 
function in mitotic progression or the regulation of molecular interactions 
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of HP1α, but no obvious effects were observed. In the last section, I present 
experimental observations that suggest HP1α hinge phosphorylation may 
regulate the interaction of the HP1α hinge with RNA.
The findings presented in this chapter of my thesis for the first time 
identify specific phosphorylation sites of human HP1 (actually, while I was 
working on this study, two other, non-mitotic phosphorylations of HP1 
have been identified by other groups, see Chapter 5, General Discussion).
In 1999, Minc and colleagues had published observations made 
from radioactive labelling experiments and western blotting after 2D gel 
electrophoresis that allowed some predictions about the number of human 
HP1 phosphorylations (Minc et al., 1999; see Figure 4.2). To what extent do 
my findings match with the number of phosphorylation sites and changes 
through the cell cycle suggested by the data of Minc and colleagues (Minc 
et al., 1999)?
The most detailed analysis Hillary Montgomery and I carried out with 
the HP1α isoform. For this isoform Minc and colleagues have indications 
for low phosphorylation in interphase and hyperphosphoylation in 
mitosis. This is fully in keeping with my findings (from their data, less 
phosphorylation sites are expected in mitosis, but it is possible that 
the two additional charged forms observed by Minc et al. are caused by 
multiple sites, or that some of the phosphorylations in their experiment 
were lost during handling). While my MS data on HP1γ is not as detailed, 
it is also in line with the predictions (several phosphorylations). A major 
discrepancy seems to exist, however, for HP1β, since I observed that HP1β 
is phosphorylated (at S89), while Minc et al. claim that it was not (Minc 
et al., 1999). Interestingly, MS data indicates that HP1β S89 is highly 
phosphorylated, and to the same extent in both mitocic and unsynchronized 
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samples (about 90%). Thus, it seems possible that the one spot in the 2D gel 
of Minc and colleagues is caused by this phosphorylated species. Note that 
Minc and colleagues claim that HP1β was not radioactively labelled, but do 
not show the data, while they show this data for HP1α and HP1γ. This may 
indicate that the HP1β labelling was ambiguous. Thus, it seems that my 
mass spectrometry findings are overall in reasonably good agreement with 
what was expected based on radioactive labelling and 2D gel electrophersis 
by Minc and colleagues.
While the MS data generated by Hillary Montgomery and me 
clearly shows an increase in phosphorylation during mitosis, the 
levels in mitosis still are not very high, never reaching more than 30% 
(see Table 4.4). However, for three reasons I suspect that the levels of 
mitotic phosphorylation within the cell may be significantly higher than 
suggested by our MS quantification. (1) The enrichment for mitotic cells 
was not perfect. MS quantification was done from mitotic samples that 
had not been further enriched by mitotic shake-off (to reduce the time 
of handling), resulting in only about 75% enrichment for mitotic cells. 
(2) Despite the use of phosphatase inhibitors there was probably some 
loss of phosphorylation during the fractionation and immunoprecipitation 
procedure. (3) In the samples obtained by approach 1 (higher enrichment 
for mitotic cells, all steps under denaturing conditions), it was possible 
to obtain quantitative data for one phosphorylation site, HP1γS93ph. 
This serine is the homologous HP1γ site to HP1αS92ph, and it was found 
phosphorylated to more than 70%. Unfortunately, no data for HP1αS92 
could be obtained from this approach. However, these data suggests that in 
vivo the homologous site HP1αS92 may have high mitotic phosphorylation 
levels as well. The longer incubation times required for approach 3 (the 
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approach used to purify HP1 for quantification of phosphorylation by MS, 
which includes a cell fractionation step; see Section "Purification of HP1") 
and the lower enrichment for mitotic cells in the starting material may 
result in significantly underestimated levels of phosphorylation, possibly 
at all sites.
intriguing new experimental directions
The findings presented in this chapter open up interesting new experimental 
directions. I identified Aurora B as the kinase responsible for HP1α S92 
phosphorylation in vivo, but it has not beem addressed yet which kinases 
are responsible for the other HP1 phosphorylations. Computational kinase 
prediction suggests enzymes with a known cell cycle dependence as possible 
kinases for HP1α hinge phosphorylation sites. For example, casein kinase 
2 (Litchfield, 2003) was predicted for S85, S87, S97, and S110 in HP1α. 
And S85 and S97 are predicted targets for the mitotic kinase PLK (Polo-
like kinase; Nigg, 1998). Thus, it will be very interesting to follow up on 
this question in the future.
The identification of serine 89 of HP1β as a phosphorylation site with 
high levels of phosphorylation (about 80%) in both interphase and mitosis 
raises the question what the biological function of this modification may 
be.
Besides phosphorylation, acetylation was discovered as another type 
of HP1 posttranslational modification: HP1α was found to be acetylated at 
lysine 24 (Figure 4.23). The levels of acetylation were rather low (<5%), and 
even though this site is close to the aromatic cage, there is no direct indication 
from the crystal structure that acetylation at this site will affect H3K9me 
binding of the chromo domain. However, considering that these samples 
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were prepared without deacetylase inhibitors and that K24 is solvent-
exposed, it is possible that K24 acetylation could regulate interactions of 
the chromo domain other than the CD-H3K9me interaction.
In our mass spectrometry analysis of tagged HP1α, several copurifying 
proteins were identified (see Table 4.3). Since the purification conditions 
were stringent, it is possible that these proteins might be novel interactors 
of HP1α.
Together with the reagents that I have generated (tagged HP1 cell 
lines, point mutants, recombinant HP1 constructs etc.), these data may be 
promising as a starting point for some graduate student in the future in 
the quest to expand our knowledge about HP1, the role of its modifications 
and the factors it interacts with.
hinge phosphorylation may regulate rna binding to hp1α
In vitro observations that I made during the purification of mutated HP1 
hinge constructs from bacterial cells and by electrophoretic mobility-shift 
assay suggest the intriguing possibility that HP1α hinge phosphorylation 
may be important for the regulation of the interaction of HP1 with RNA. 
Clearly, these data on HP1 phosphorylation and RNA binding are still of 
a preliminary character. They have to be repeated and extended in vitro, 
for example by a further characterization of the in vitro interaction by 
competition experiments. Several observations in the literature suggest 
an involvement of RNA in HP1-dependent heterochromatin, thus making 
the observation that HP1 phosphorylation may regulate RNA binding a 
very interesting alley of research to pursue further. In the next chapter of 
my thesis (General Discussion) I will suggest experiments to confirm my 
observation, outline possible follow-up experiments, and speculate on the 
biological role of this interaction and its regulation by phosphorylation.
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Chapter 5
General DisCussion
In my thesis studies, I have focused my attention on two different ways 
how phosphorylation regulates Heterochromatin Protein 1, an important 
chromatin effector protein and key factor in the formation of heterochromatin 
in eukaryotic cells (Figure 5.1): on the one hand, I discovered together 
with my collaborators that phosphorylation of histone H3, the histone that 
recruits HP1 to chromatin, is an essential step in the reversible ejection of 
HP1 from chromatin at the onset of mitosis. On the other hand, I identified 
several novel phosphorylations of HP1 itself, showed that these sites in 
the HP1 hinge region are hyperphosphorylated specifically in mitosis, and 
present observations suggesting that these mitotic phosphorylations may 
control HP1α's association with RNA.
In this chapter, I strive to briefly summarize the experimental findings 
presented in my thesis and then discuss important aspects in light of the 
literature. In addition, I will outline possible future directions, and suggest 
models that put my findings in a larger biological context.
"Methyl-phos switching"
release of hp1 from chromatin by phosphorylation of histone h3: 
"Methyl-phos switching"
Heterochromatin Protein 1 (HP1) is recruited to chromatin by binding to 
methylated lysine 9 of histone H3 (H3K9me) through its chromo domain, 
probably further stabilized by additional interactions. At the onset of 
mitosis, the bulk of the protein is released from its binding site to be 
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dispersed all throughout the cytoplasm (Hayakawa et al., 2003; Kellum 
et al., 1995; Minc et al., 1999), even though the H3K9me persists, an 
observation that was a long-standing conundrum in the field prior to this 
work.
5.1
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Figure 5.1: regulation of hp1α by phosphorylation on two different levels.
During mitosis, HP1 is regulated by phosphorylation on two different levels. Phos-
phorylation of histone H3 at serine 10 by Aurora B kinase results in the reversible 
release of the CD-H3K9me interaction by methyl-phos switching and (possibly in 
combination with other mechanisms) to dissociation of HP1 from chromatin. Si-
multaneously, phosphorylation of HP1α itself by Aurora B and other, currently 
unknown kinases in its hinge domain abolishes the interaction with an RNA com-
ponent (shown in green) that remains to be further characterized.
In experiments that I carried out in collaboration with Dr. Wolfgang 
Fischle, then a postdoctoral fellow in the Allis laboratory (now a faculty 
member at Max-Planck-Institute of Biophysical Chemistry, Göttingen), and 
with colleagues from the Funabiki lab, Boo Shan Tseng and Dr. Hironori 
Funabiki, I showed that the release of HP1 depends on phosphorylation of 
histone H3 at serine 10, a site that is phosphorylated by the Chromosomal 
Passenger Complex at the onset of mitosis. Serine 10 phosphorylation 
in immediate proximity to HP1’s binding site at methyl-K9 sterically and 
electrostatically interferes with binding of the chromo domain and therefore 
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ejects the chromo domain from the histone mark. Removal of serine 10 
phosphorylation at the end of mitosis, on the other hand, allows HP1 to 
reassociate with H3. In addition to providing important insight into the 
mechanism of mitotic HP1 release, these findings also identify a biological 
function for mitotic H3 serine 10 phosphorylation, a histone mark with so 
far elusive biological role (Nowak and Corces, 2004).
The data presented in my thesis is the first evidence for the existence 
of a novel "binary methylation-phosphorylation switch" mechanism, that 
controls the recruitment of effector proteins to chromatin through two 
collaborating histone marks (see Figure 3.12A). Even though the actual 
binding site of HP1, the methylation mark H3K9me, remains unchanged, 
addition or removal of the H3S10 phosphorylation mark results in a 
dynamic regulation of HP1 binding to chromatin.
Our findings close an important gap in the understanding of HP1 
behaviour. As outlined in detail in the Discussion section of chapter 3, 
they also have wide implications: "methyl-phos switching" is not limited 
to the mitotic release of HP1, but has also been observed for HP1 in other 
cellular contexts. Furthermore, examples of binary switching have been 
found in non-histone proteins as well, and with other combinations of 
modifications, such as "methyl-methyl switches" (see Chapter 3, Section 
"Discussion"). Thus, binary switching appears to be a mechanism that is 
employed by the cell in many different contexts. It will be very interesting 
to see in the next years where else this regulatory principle is used.
However, our findings also immediately open up a whole array of 
follow-up questions. Why does the cell use this peculiar mechanism to 
regulate the reversible dissociation of HP1? Is "methyl-phos switching" 
sufficient for the dissociation of HP1 from chromatin in vivo? And why 
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must HP1 be released from chromatin during mitosis? In the following, I 
will discuss these questions and speculate in light of the literature.
Why does the cell use a "methyl-phos switching" mechanism for the 
mitotic release of hp1?
It has been observed on many occasions, that binding of effector proteins 
to chromatin is often a dynamic and reversible process (Festenstein et 
al., 2003; McNally et al., 2000; Phair et al., 2004). Generally, effectors are 
recruited to chromatin by their interaction with specific histone marks 
(which are established by "writer" enzymes). The release of effector proteins 
appears to be accomplished by a number of different mechanisms. Besides 
binary switching, these include removal of the histone mark by enzymes 
(Lan et al., 2008; Yang and Seto, 2008), clipping of histone tails by proteases 
(Allis et al., 1980; Duncan et al., 2008, or even replacement of the modified 
histone as a whole (Ahmad and Henikoff, 2002). This of course raises 
the question why the mitotic release of HP1 proteins is accomplished by 
"methyl-phos switching" rather than by any of the other mechanisms. A 
closer look at "methyl-phos switching" reveals that this mechanism has 
certain characteristics that set it apart from all the other mechanisms.
In general, kinase function in the cell often controls rapid changes 
in protein-protein interactions, for example in the recruitment of adaptor 
proteins in signal transduction pathways (Seet et al., 2006), the control 
of enzymatic activity via conformational changes (Johnson et al., 1996), 
or the disassembly of the lamin network underlying the nuclear envelope 
during mitotic prophase (Moir et al., 1995). Considering the rapid and 
extensive changes that chromatin has to undergo to enable faithful 
progression through mitosis, a kinase reaction might be the best way for 
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the cell to achieve a fast global release of the HP1 effectors in a highly 
regulated manner. Phosphorylation and dephosphorylation are quite 
thermodynamically favorable and the kinetics of both enyzme classes are 
quite rapid relative to other ways to establish or remove posttranslational 
modifications.
Compared to the other mechanisms, "methyl-phos switching" 
provides specificity to a mechanism designed to release an effector protein. 
Since it interferes exclusively with the association of proteins binding 
in the immediate vicinity of the phosphorylation site, effector proteins 
associated with other regions of the histone remain completely unaffected. 
This is in stark contrast to, e.g., tail clipping or histone exchange. While 
these mechanisms allow to exchange the complete modification profile of 
a histone in a single step, this comes of course at the price of specificity: 
many different histone marks and all the interaction partners associated 
with them are removed at once.
"Methyl-phos switching" is energy-efficient as well. With mechanisms 
such as tail clipping or histone replacement, re-establishing HP1 association 
with chromatin comes at a significant engery cost for the cell, because 
it requires complete synthesis of a new histone and specific methylation 
of the newly synthesized H3. Reassociation mediated by "methyl-phos 
switching", in contrast, requires only a single kinase reaction and thus 
allows dynamic regulation of chromatin read-out at minimal energetic cost 
for the cell.
"Methyl-phos switching" also fully preserves the epigenetic information 
encoded in the methyl-marks. Enzymatic removal of modifications through 
demethylation, in contrast, would erase the "epigenetic memory" of the 
H3K9 methyl-mark (Trojer and Reinberg, 2006).
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In sum, it seems that the different mechanisms to release effector 
proteins all have their distinct characteristics that make them particularly 
suited for specific situations. Clipping of histone tails and histone 
replacement exchange a whole set of modifications at once and thus allow 
to completely change the character of a histone in a single step. While this 
may be quite helpful in certain cellular contexts, for example changes of 
expression profile during differentiation (Duncan et al., 2008), it comes 
with a significant energy investment and with the loss of the epigenetic 
information of the histone marks. Enzymatic removal of the histone mark 
is quick, specific and energy-efficient, but it also erases the epigenetic 
information deposited in the histone marks. "Methyl-phos switching", on 
the other hand, is fast, energy-efficient and at the same time preserves the 
epigenetic information stored in the methylation marks. Thus, it seems 
perfectly suited for the task of transiently and reversibly releasing the 
effector protein HP1 during mitosis.
potential contribution of other mechanisms to the mitotic release of 
hp1 in vivo
It is clear at this point that "methyl-phos switching" is an essential step 
in the release of HP1 from chromatin. However, as described in more 
detail in the Discussion section of chapter 3, it is still an open question 
whether "methyl-phos switching" is actually sufficient for HP1 dissociation 
in mitosis.
In in vitro binding experiments with the HP1 chromo domain and 
H3 peptides, H3 phosphorylation is always sufficient for HP1 release. 
Experiments with full-length HP1 isoforms, however, have led to different 
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observations with the individual HP1 isoforms, and even to contradicting 
results (Fischle et al., 2005; Hirota et al., 2005; Terada, 2006). In binding 
experiments in the presence of cellular extracts, retention of HP1 upon 
abolishment of the chromo domain-H3K9me interaction has been observed 
as well (Fass et al., 2002; Fischle et al., 2005).
In vivo experiments so far could only confirm that "methyl-phos 
switching" is necessary for HP1 release in the cell (Fischle et al., 2005; Kloc 
et al., 2008; Sabbattini et al., 2007; Terada, 2006), but have not addressed 
the question whether it is also sufficient. Testing this question in vivo is not 
straightforward. Because there are multiple genes for H3 in mammalian cells 
(Marzluff et al., 2002), it is difficult to do an overexpression experiment with 
an H3 construct with a S10E mutation: if such an overexpression partially 
releases HP1, it is hard to tell if the residual chromatin-bound HP1 is all 
due to HP1 association with simultaneously present wild-type copies of 
H3, or if some of it is still associated with the mutated H3 through chromo 
domain-independent mechanisms. Moreover, observations with chromo 
domain mutants (which do not localize to heterochromatin at all in vivo, 
Platero et al., 1995; Stewart et al., 2005; Thiru et al., 2004) suggest that 
there may be a sequential order of the different interactions that mediate 
stable chromatin association of HP1. It seems initial contact is made by the 
CD and methylated K9. This may increase the local concentration of the 
protein, and then a subsequent "locking" step by additional interactions 
stabilizes HP1 binding to heterochromatic sites (Singh and Georgatos, 
2002). Thus, constitutive disruption of the CD-H3K9me by mutation of 
serine 10 may actually prevent CD-independent mechanisms from being 
established in the first place.
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This difficulty is exemplified by a recent publication reporting that 
phosphorylation in the chromo domain of HP1β by CK2 (casein kinase 
2) is a necessary step in the release of HP1β from chromatin at sites of 
UV-induced DNA damage (Ayoub et al., 2008). Mutation of the site of 
phosphorylation, threonine 51, to glutamate abolished the interaction of 
HP1β with chromatin. However, since the T51E mutant does not bind to 
H3K9me (as shown by in vitro binding experiments), it is not clear whether 
additional mechanisms of binding could be established at all. The system 
may be used, however for an interesting test: if overexpression of casein 
kinase 2 leads to the release of HP1, this would be an indication that 
reversal of the CD-H3K9me3 interaction may indeed be sufficient for HP1 
release in vivo.
An alternative approach that may at least allow to estimate the 
severity of the contribution of other mechanisms besides "methyl-phos 
switching" may be to take advantage of Xenopus egg extracts and their 
options to manipulate experimental parameters in a cellular context that 
approximates the in vivo situation. In this system, the release of HP1 from 
interphase extracts could be tested with an H3S10 kinase other than 
Aurora B (judging from my in vitro data, MSK1 may be a good starting 
point; Figure 3.11). While still phosphorylating H3S10 efficiently, MSK1 
is not very likely to phosphorylate, besides H3 serine 10, exactly the same 
targets as the CPC, and it does not initiate and control diverse regulatory 
events in mitosis. The level of retention of HP1 at chromatin may thus 
permit to estimate the contribution of mechanisms other than "methyl-
phos switching".
Otherwise, directly testing the sufficiency of "methyl-phos switching" 
for the release of HP1 inside the living cell may require an artificial system 
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that allows recruitment of a (non-mitotic) H3S10 kinase to a heterochromatic 
locus bound by HP1. While such a system may be difficult to set up, it 
should allow to give a final answer to the still open question whether other 
mechanisms besides "methyl-phos switching" are required for the release 
of HP1 from chromatin at the onset of mitosis.
Why does hp1 have to be removed from chromatin during mitosis?
In the course of my thesis work, my collaborators and I have studied the 
mechanisms underlying the localization changes as well as the striking 
alterations in posttranslational modifications that HP1 undergoes during 
mitosis. Despite progress made, however, the overarching biological 
question remains – what is the biological function of HP1 release from 
chromatin during mitosis?
A challenging question to address experimentally
Experimentally, it is extremely challenging to address this question 
directly. One obvious way to get insight into this question is to prevent HP1 
dissociation by inhibiting/depleting Aurora B and studying the effects on 
the mitotic cell. As shown by us and others, Aurora B inhibition/depletion 
causes retention of HP1 (Fischle et al., 2005; Hirota et al., 2005; Sabbattini 
et al., 2007; Terada, 2006). At the same time, it leads to a number of 
unusual observations about chromosome structure and behaviour, such 
as reduced cohesin dissociation from chromosome arms, a less pronounced 
primary constriction at centromeres, "fuzzy" appearance of chromosomes 
in hypotonic buffers, and syntelic attachment of the kinetochores of sister 
chromatids to microtubules of the same spindle pole (Giménez-Abián et 
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al., 2004; Hauf et al., 2003; Hirota et al., 2005). Eventually, it results in 
chromosomal defects and polyploidy (Hauf et al., 2003).
However, it is well established that Aurora B is not just a histone H3 
kinase, but also has important functions (besides HP1 phosphorylation) 
at the spindle checkpoint and during cytokinesis with functions in 
metaphase chromosome alignment, sister chromatid resolution, spindle 
checkpoint signaling, bipolar spindle assembly, and cytokinesis (Ditchfield 
et al., 2003; Hauf et al., 2003; Lampson and Kapoor, 2005). Thus, it is 
impossible to differentiate whether the observed defects are indeed caused 
by the failure of HP1 to dissociate from chromatin, lack of mitotic H3S10 
phosphorylation (which may have other functions in addition to HP1 
"methyl-phos switching"), or the inability of Aurora B to phosphorylate 
other important mitotic targets.
One possible approach to see what the effects of HP1 retention are, 
while not abolishing Aurora B activity, would be to replace the endogenous 
H3 with an H3 that cannot be phosphorylated at serine 10, for example by 
a S to A mutation. However, this is quite difficult to do in mammalian cells, 
because mammals have a high copy number of H3 genes (twelve; Marzluff 
et al., 2002). The only established experimental systems that contain an 
HP1-like protein and have a low complexity of histone genes and thus 
may allow such a study are S. pombe or Neurospora. Indeed, in S. pombe 
the phenotype of H3S10 mutation has already been described as having 
mitotic defects (Mellone et al., 2003).
However, this is hard to interpret due to a second  caveat: H3S10A 
does not only prevent phosphorylation, but also causes by itself already a 
significant reduction in the affinity of the HP1 chromo domain for H3K9me 
(by almost a factor of 10; Fischle, 2005; Hirota et al., 2005). This is not 
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surprising, considering the stabilizing contribution of the hydrogen bonds 
that serine 10 undergoes with residues of the HP1 CD (see Figure 3.2B). 
It is therefore questionable whether HP1 would bind to H3S10A at all in 
vivo (presumed that H3S10A is indeed subject to methylation in vivo, an 
assumption that has not been tested yet). These doubts are further fueled 
by the observation that GFP-Swi6 is mislocalized upon H3S10A mutation 
in S. pombe (Mellone et al., 2003), and if indeed differences were observed, 
it would be hard to tell if these were not simply due to effects of H3S10A 
mutation on HP1 recruitment.
A second, alternative approach to get insight into the biological 
function of mitotic HP1 dissociation would be to design an HP1 protein with 
mutations in the chromo domain that make it "immune" to phosphorylation 
of serine 10 (i.e. HP1 mutants that bind to H3K9me3S10ph equally well 
as to H3K9me3). Due to the multiple effects of serine 10 phosphorylation 
on the interaction of the CD with the methylated H3 tail (steric hindrance, 
electrostatic repulsion, and loss of hydrogen bonds; see Figure 3.2B), it 
is clear that this would be extremely difficult to achieve. Several such 
mutations have been tested (Fischle et al., 2005). However, neither chromo 
domain mutants designed to reduce the steric hindrance by the phosphate 
group (E53A, E53G) nor mutants engineered to relieve the electrostatic 
repulsion (E53Q, E53K) showed any increase in binding to H3K9meS10ph 
peptides in vitro. Rather, these mutants showed significant loss of affinity 
for H3K9me3 peptides, as expected owing to the loss of the hydrogen 
bonds with serine 10. Thus, it will be a real challenge to engineer such a 
switching-resistant HP1.
If experimental findings identify in the future other mechanisms 
involved in the mitotic release of HP1, this may open new roads to study 
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this question: While Aurora B kinase has various different functions 
in mitosis, these potential other mechanisms might be easier to inhibit 
specifically without side-effects on many other steps in mitosis.
Hypotheses on the biological function of HP1 release in mitosis
A direct experimental approach to this challenging question may therefore 
require years of research. However, in the following I will speculate 
about possible reasons why HP1 has to be released from chromatin 
during mitosis. Three steps during mitosis come particularly to mind: (1) 
condensin-mediated chromatin condensation, (2) removal of cohesin from 
chromosome arms, and (3) proper resolution/segregation of chromatids.
During prophase of the cell cycle, the chromosomes are highly 
compacted, in preparation of the spatial rearrangements involved in 
chromosome alignment and segregation. The mechanism of this chromatin 
condenstion at the onset of mitosis seems to be distinct from that of HP1-
mediated heterochromatin formation. It is possible that HP1 proteins need 
to be released from chromatin, in order to permit mitotic chromosome 
compaction by other factors (Figure 5.2).
CondensinHP1
5.2
Figure 5.2: hp1 dissociation might be required for full mitotic chromatin 
condensation (possible biological function of mitotic hp1 dissociation from 
chromatin) Figure adapted from Dormann et al., 2006.
left: In a cell that progresses through M phase, HP1 is released at the onset of 
mitosis. This process allows condensin to access chromatin, therefore promoting 
mitotic chromatin condensation. right: If HP1 does not dissociate, condensin 
cannot get full access to chromatin and mitotic chromatin condensation is in-
hibited.
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One of the components involved in mitotic chromosome compaction 
it condensin, a multisubunit complex formed by the association of two 
SMC subunits (Structural Maintenance of Chromosomes, members of a 
large family of ATPases with key function in higher-order chromosome 
organization and dynamics (Yokomori, 2003)) with three non-SMC subunits 
(Kimura and Hirano, 1997). Condensin’s exact mechanism of action is 
not fully understood at this point. However, it is clear that the complex 
binds to DNA and induces positive supercoiling (Bazett-Jones et al., 2002; 
Kimura and Hirano, 1997; Kimura et al., 1999; Stray et al., 2005; Stray and 
Lindsley, 2003), which probably contributes to chromosome compaction. 
It is tempting to speculate that the presence of HP1 (or the chromatin 
condensation mediated by HP1) would prevent access of condensin to DNA 
and thus interfere with mitotic chromosome condensation. In keeping 
with this model, it has been observed in S. pombe that in cells defective 
in CPC function condensin does not localize to mitotic chromosomes and 
chromosome condensation is impaired (Morishita et al., 2001). Similarly, in 
human cells Aurora B depletion results in loss of centromeric localization 
of condensin (Ono et al., 2004). Thus, from a biological point of view 
dissociation of HP1 through binary switching may be essential for mitotic 
chromosome condensation through condensin.
A second hypothesis is that the release of HP1 may be required for 
the removal of cohesin from chromosome arms (Figure 5.3). Biorientation 
of chromosomes on the mitotic spindle requires cohesion between sister 
chromatids (Losada, 2007). This cohesion is accomplished by cohesin, a 
multisubunit complex related to condensin, that forms a ring-like structure 
around the sister chromatids (Gruber et al., 2003). Separation of sister 
chromatids is dependent on the removal of cohesin from chromosomes, 
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which in vertebrates is a two-step process (Losada, 2007). Originally 
localized all over the chromosomes, at prophase the bulk of cohesin is 
removed from chromosome arms. This removal depends on the mitotic 
kinases Plk1 and Aurora B, and on the phosphorylation of one of the 
cohesin subunits (Giménez-Abián et al., 2004; Losada et al., 2002; Sumara 
et al., 2002). Only little cohesin persists on chromosomes, mostly at the 
centromeric regions (Hoque and Ishikawa, 2001; Waizenegger et al., 2000), 
where it is protected from removal through the protein Sgo1/MEI-S332 
and the phosphatase PP2A (Kitajima et al., 2004; Salic et al., 2004; Sgo1 
recruitment depends on centromeric HP1, Yamagishi et al., 2008). This 
remaining cohesin is then removed at the metaphase-anaphase transition 
by cleavage through separase, enabling the separation of sister chromatids 
(Hauf et al., 2001; Waizenegger et al., 2000).
HP1/Cohesin HP1/Cohesin
5.3
Figure 5.3: Dissociation of hp1 may be required for the release of condensin 
from chromosome arms (possible biological function of mitotic hp1 disso-
ciation from chromatin) Figure adapted from Dormann et al., 2006.
left: HP1 release at the onset of mitosis also removes cohesin, which is associ-
ated with HP1, from chromosome arms. This allows for proper segregation of 
chromatids into the two daughter cells. right: If HP1 is not released, cohesin re-
mains associated with the chromosome arms. The chromatids cannot separate, 
which may lead to missegregation of chromosomes.
The exact function of Aurora B in the prophase dissociation of 
cohesin is currently unknown. However, it seems possible that HP1 
is involved in this dissociation. In S. pombe, cohesin binds to the HP1 
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homolog Swi6, an interaction that is necessary for cohesin localization to 
the heterochromatic structures of the pericentric regions and that seems 
to be conserved in mammalian cells (Nonaka et al., 2002). Moreover, HP1 
dissociation from chromatin and the release of cohesin occur with a very 
similar timing during prophase. Thus, it seems quite possible that cohesin 
removal from chromosome arms at prophase could be accomplished by 
Aurora B through the ejection of HP1 by "methyl-phos switching", making 
the biological function of HP1 release to help resolve the arm regions of 
sister chromatids from each other.
A third possibility is that HP1 proteins may have to dissociate from 
mitotic chromosomes to facilitate separation of chromatids (Figure 5.4). 
HP1 is assumed to mediate chromatin condensation by crosslinking K9-
methylated nucleosomes through its ability to dimerize and interact with 
other chromatin components (Figure 1.9A). If such crosslinking occurs 
between different chromatids, it may not be possible to segregate sister 
chromatids to opposing poles of the spindle during anaphase. In this 
scenario, if HP1 is not removed before anaphase, the consequence might 
be segregation defects such as lagging chromosomes, chromosome bridges, 
and aneuploidy. Thus, according to this model, the biological function 
of mitotic HP1 release of HP1 might be to reverse crosslinks between 
individual chromatids to allow for the proper resolution and segregation of 
chromosomes. In keeping with this interpretation, Interestingly, Terada, 
while overexpressing an H3 construct with a S10A mutation in mammalian 
cells, observed lagging chromosomes and chromatin bridges (Terada, 
2006). It is impossible to differentiate whether these effects are due to the 
retention of HP1 or reduced levels of K9 methylation and/or HP1 binding 
to this H3 mutant in the first place (see above). However, the observations 
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would match the phenotype expected for problems with chromosome 
separation due to the failure to remove HP1 crosslinking of chromatids.
Figure 5.4: hp1 release may be necessary for proper resolution/segregation 
of chromatids (possible biological function of mitotic hp1 dissociation from 
chromatin) Figure adapted from Dormann et al., 2006.
left: If HP1 is released at the onset of mitosis, the pulling forces exerted by the 
spindle microtubuli segregate the chromatids into the two daughter cells (as indi-
cated by the green arrow heads). right: If HP1 is not removed, different chroma-
tids (in this case sister chromatids) may remain attached to each other via HP1 
cross-linking. This entangling inhibits proper resolution of chromatids and may 
lead to defective chromosome segregation.
HP1
5.4
hp1 phosphorylation
hp1 isoforms are subject to phoshporylation
Prompted by experimental observations made during the study of HP1 
"methyl-phos switching" in the test tube, in the second part of my thesis I 
have focused on a potential involvement of posttranslational modifications 
of HP1 itself during mitosis. Together with my collaborators, I have mapped 
a set of in vivo phosphorylation sites of all three human HP1 isoforms, shown 
that most of these sites map to the HP1 hinge region (see Figure 4.23), and 
found evidence that HP1α and HP1γ are specifically phosphorylated in 
mitosis (the levels of the observed HP1β phosphorylation were equally high 
in interphase and mitosis, see Chapter 3, Section "Discussion"). One site 
that is part of a highly conserved sequence motif ("KRKS"), HP1αS92ph, I 
characterized in detail and present data that implicates Aurora B as the 
212
responsible kinase in vivo. While testing specific candidates for an effect 
of HP1α hinge phosphorylation on their association with HP1, I made in 
vitro observations that suggest that HP1α hinge phosphorylation may be 
regulating the association of HP1α with RNA.
The sites of phosphorylation presented in my thesis is among the 
first sites identified in mammalian HP1 proteins. While this work was in 
progress, reports on two individual modifications on the two other HP1 
isoforms have been published.
The Urrutia lab describes a role for HP1γ serine 93 phosphorylation 
(or, assuming a different translation start site, serine 83 phosphorylation) 
in interphase (Lomberk et al., 2006). According to their interpretation, 
phosphorylation of this site by PKA leads to exclusively euchromatic 
localization of HP1γ, interaction with the DNA repair factor Ku70 (but in the 
absence of the other complex members that Ku70 usually associates with), 
and impaired silencing activity. Another study reported phosphorylation 
of HP1γS93 (but not HP1α and HP1β) in cells entering senescence, where 
the modification is required for efficient incorporation of HP1γ into SAHF 
(senescence-associated heterochromatin foci), domains of facultative 
heterochromatin that repress proliferation-promoting genes (Zhang et al., 
2007). Ayoub and colleagues have recently implicated phosphorylation of 
HP1β at threonine 51 by casein kinase 2 in the mobilization of HP1β after 
DNA damage (Ayoub et al., 2008; see above).
HP1γS93ph is homologous to HP1αS92ph, the site of Aurora B 
phosphorylation that I characterized in more detail in my thesis. However, 
as opposed to these studies, I do not observe any localization effects upon 
HP1αS92 mutation, HP1α is known to interact with Ku70 already in 
an unphosphorylated state (Song et al., 2001), and I studied the events 
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connected to HP1αS92 phosphorylation specifically in mitosis, which was 
not investigated in these studies (similar to HP1αS92, HP1γS93, is also 
upregulated in mitosis, even though that was not part of the study by 
Lomberk and colleagues; my own observations in western blotting and 
IF experiments with an antibody kindly provided by the Urrutia lab). 
Nevertheless, these papers illustrate the potential of HP1 modifications to 
control HP1 interactions and functions.
no effect of hp1 phosphorylation on localization dynamics in 
mitosis
In my thesis work, I tested the hypothesis that HP1α hinge phosphorylation 
may be involved in the different localization changes observed for HP1α 
during mitosis, but did not observe any effect. Is it possible that the HP1α 
hinge region nevertheless plays, besides regulating RNA association, a role 
in HP1α release in vivo, and that this role was missed due to shortcomings 
of the experimental approaches taken to address those questions?
My experiments designed to test different hypotheses about the 
function of HP1α hinge mutations in vivo were largely based on mutation 
of the identified phosphorylation sites. Serine to glutamate mutations were 
used, for example, for testing a role of HP1 hinge phosphorylation in HP1α's 
reassociation at metaphase; if HP1α hinge phosphorylation regulated this 
reassociation of HP1α with metaphase centromeres, increased/decreased 
binding of mutated constructs was expected. Glutamate is known to be a 
good mimic for the negative charge effect of the phosphoryl-group, but it 
is structurally different (planar instead of tetrahydric). Therefore it may 
not always function as a mimic for phospho-serine, and problems like this 
could of course prevent the observation of effects in experimental tests 
based on such mutations.
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However, mechanisms that may besides "methyl-phos switching" be 
involved in the regulation of HP1 localization changes during mitosis will 
likely depend on additional interaction partners of HP1. The identity of 
these interactors is currently unknown, and they may actually not have 
been identified at all. Thus, there is little alternative for systematic testing 
of such hypotheses but in vivo. While far from perfect, glutamate and 
alanine are probably still the best mimics for constitutively phosphorylated/
not phosphorylatable serine available (aspartate is clearly smaller than 
phospho-serine).
Considering that HP1 chromatin binding can be guided by different 
mechanisms, it is possible that only a small subpopulation of HP1 
associated with a few loci is affected by HP1α  hinge phosphorylation 
(see also below, Section "Speculations on the biological function of the 
HP1-RNA interaction and of HP1α hinge phosphorylation"). In such a 
scenario, effects of the mutations at these sites may have been missed 
in my immunofluorescence analysis. Indeed, this cannot be completely 
excluded, and it may be worth reconsidering some of my experiments in a 
more detailed way (different extraction/fixation procedures, chromosome 
spreads; alternatively even ChIP or examination of different cell types). 
However, considering the detailed analysis that I have carried out already, 
it does not seem worthwhile to continue along this path, unless additional 
evidence for such an involvement of HP1 phosphorylation in HP1 localization 
should emerge.
Furthermore, the analysis presented in this thesis was carried out with 
fixed cells and therefore looks only at single time-points in the release/
reassociation process. The release and reassociation of HP1, however, is 
a dynamic process, and it is possible that HP1 phosphorylation affects 
the dynamics of this process rather than the final outcome. Elegant stud-
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ies have already examined the dynamics of HP1 in living cells  in other 
context (during the activation of a silenced locus; Janicki et al., 2004), 
and it may be worth it to carry out similar experiments to analyze the ef-
fect of HP1 phosphorylation mutations on the dynamics of HP1 in living 
cells.
possible existence of other hp1 binders regulated by hp1 hinge 
phosphorylation
In vitro experiments presented in this thesis implicate HP1 phosphorylation 
in the control of RNA binding to the HP1α hinge. This exciting finding 
opens new doors for potentially interesting follow-up experiments and 
allows for some intriguing hypotheses (see below). However, it should be 
noted that this observation does not exclude that there may be other, 
additional interactions besides RNA binding that may be regulated by the 
same mechanism.
One protein that may be interesting to test in the future for 
phosphorylation-dependent binding to HP1 may be the CPC component 
INCENP, because there is literature suggesting that it binds to the HP1 
hinge region. Even though it has been demonstrated that the interaction 
with HP1α is not required for INCENP localization or localization changes 
during mitosis (Ainsztein et al., 1998) and vice versa (Terada, 2006), it is 
possible that this interaction affects for example the enzymatic activity 
of the CPC on partners associated with HP1 (such as histone H3) by 
positioning the complex in a favourable position. The ability of HP1 to 
fulfill such a function might be modulated by HP1 phosphorylation.
It is also possible that so far unknown HP1 binders are regulated 
through HP1 hinge phosphorylation. My experiments indicate that unbiased 
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pull-down experiments to identify such factors may not be straightforward 
with the isolated hinge domain (see Chapter 4, Section "Reduncancy / 
Requirement for Cooperation"), but with careful optimization this may also 
be a promising approach in the future.
reasons for exclusion of hp1αs92ph signal from chromatin at 
telophase
Originally, my interest in the role of HP1 phosphorylation in the regulation 
of HP1α localization during mitosis was raised by IF experiments with the 
HP1αS92ph antibody, when I made the observation that the signal of an 
HP1S92ph antibody is excluded from chromatin, while with a general HP1α 
antibody staining is observed (Figures 4.7B, 4.9BC, 4.13B). According my 
mutation analysis, HP1α hinge phosphorylation has no effect on HP1α 
localization in mitosis. How can the IF observations then be explained?
One possibility is that the S92ph epitope is masked by a molecular 
interaction that HP1α undergoes when it reassociates with chromatin. 
Alternatively, a chromatin-associated phosphatase could remove the 
phosphorylation as soon as HP1 binds to chromatin. Notably, in a 
fractionation experiment (Figure 4.13A) I observed by western blotting 
that HP1α from a fraction loosely associated with chromatin showed 
significantly higher levels of S92 phosphorylation than HP1α that was 
tightly associated with chromatin. This might point to the latter of the two 
possible explanations, a chromatin-associated phosphatase.
hp1 and rna binding / nature of the bound rna(s)
In chapter 4 of my thesis, I have presented in vitro observations suggesting 
that HP1α hinge phosphorylation may control the association of HP1α 
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with RNA (Figure 4.30). These observations were made with recombinant 
HP1α hinge constructs, that associated with bacterial RNA in the case of 
the wild-type hinge sequence, but did not associate in the case of a hinge 
sequence with S to E mutations at the phosphorylation sites. The effect 
was reproduced in an electrophoretic mobility-shift assay (EMSA) with a 
Drosophila mRNA sequence as probe. The conditions under which these 
observations were made are certainly quite artificial and raise the question 
whether this is indeed a real interaction or rather an in vitro artifact.
A first evaluation of this question may come from a closer look at 
what is known in the literature about the interaction of HP1 with RNA. 
There are reports by several groups that suggest such a connection., and 
findings demonstrating a direct interaction of HP1 with RNA have been 
published in mammals (Muchardt et al., 2002) and in S. pombe (Motamedi 
et al., 2008). In addition, observations that could readily be explained by 
direct RNA binding of HP1 were made in both Drosophila (Piacentini et al., 
2003) and mammals (Maison et al., 2002).
The first real in vivo evidence for a direct interaction of HP1 with 
RNA has been reported only very recently from RNA immunoprecipitation 
experiments with Swi6, the HP1 homolog in fission yeast (Motamedi et al., 
2008). These experiments demonstrated that Swi6 specifically binds to 
noncoding cenRNAs (transcripts generated from the centromeric regions 
of the S. pombe chromosome). While an indirect involvement of RNA in the 
formation of Swi6-dependent heterochromatin is well established (Swi6 is 
essential for an RNAi-dependent silencing loop which requires transcription 
though noncoding heterochromatin to be sustained, see Introduction), 
this is the first occasion that direct RNA binding is demonstrated in S. 
pombe. As a model, Motamedi and colleagues suggest that Swi6 association 
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with cen transcripts may tether nascent heterochromatic transcripts to 
heterochromatin and allow RNAi complexes to assemble on the transcript. 
It should be noted that detection of the transcripts was carried by RT-PCR 
and only two transcripts were tested (cen and actin mRNA, which does 
not associate with Swi6). Thus, no conclusion can be drawn from these 
experiments whether there are other RNAs that may associate with Swi6.
In mammalian cells, there are also observations indicating a direct 
association of HP1 with RNA, even though these experiments have not 
been done in genuine in vivo systems. In 2002, Maison et al. noted in 
work with mouse cells that RNase treatment during immunofluorescence 
experiments destroys the architecture of heterochromatic domains and 
specifically releases HP1α, a finding that could be reproduced in overlay 
assays (Maison et al., 2002). Adding back RNA reversed all observed effect. 
Maison and colleagues showed that there is some specificity with respect 
to the species of RNA: only RNase A, and not RNase H (cleaves dsRNA and 
DNA-RNA duplices) disrupts the heterochromatic structures and releases 
HP1, and restoration of heterochromatic architecture and HP1α foci is 
observed upon adding back total and especially nuclear RNA, while there 
is little effect with tRNA and bacterial mRNA.
Prompted by similar observations in overlay assays, Muchardt and 
colleagues showed that HP1α and HP1γ can bind RNA directly in vitro 
and mapped this binding to the C-terminal part of the HP1α hinge region 
(Muchardt et al., 2002). By competition experiments with different nucleic 
acids in EMSAs, they carried out a preliminary characterization of the 
RNA interaction that allow some conclusions about the specificity of HP1's 
RNA-binding in this experimental system.
219
It is unlikely that HP1 recognizes a complex RNA sequence motive, 
because Muchardt and colleagues were able to carry out their EMSAs with a 
random bacterial mRNA probe. On the other hand, binding is also not simply 
dictated by attractive electrostatic forces either, because the interaction is 
not competed by ssDNA, dsDNA, AU- or GC-rich RNA oligomers or tRNA. 
Ribosomal RNA and especially total nuclear RNA, in contrast, compete 
the interaction with the bacterial probe RNA efficiently. This suggests that 
there is either some promiscuity with regard to the sequence specificity 
of the HP1 hinge region, or the hinge recognizes a rather short sequence 
or small structural RNA motif that is found rather often in a complex 
sequence. It should be noted, though, that these in vitro observations do 
not categorically exclude binding of only one specific RNA by HP1α in vivo. 
The chromatin proteins MOF and MSL-3, for example, show no or little 
binding specificity in their RNA binding in vitro, although they have a very 
specific physiological target, roX RNA (Akhtar et al., 2000).
The RNA-binding region of HP1 was mapped by EMSA and overlay 
assay to residues 86-108 of HP1α (the C-terminal part of the hinge region). 
The region has no clear homology to known RNA-binding modules, despite a 
high density of basic amino acids. However, RNA binding of sequences with 
similar composition has been demonstrated in several ribosomal proteins 
and retroviral virulence factors, such as HIV TAT (Brodersen et al., 2002; 
Weiss and Narayana, 1998). An interacting domain of this size is not capable 
of contacting more than 6 to 10 nucleotides at once (Ruthenburg, 2009), 
which would explain the low sequence specificity of HP1 RNA binding. 
The RNA binding domain includes most of the phosphorylation sites that I 
have identified in the HP1α hinge. Interestingly, Muchardt and colleagues 
demonstrated that simultaneous mutation of only three conserved lysines 
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within the RNA binding region (K104/105/106A) abolishes RNA binding. 
Thus, it seems feasible that introduction of a few negative charges by 
phosphorylation of the RNA interacting domain may have a similar effect.
In addition to the reports in S. pombe and in mammals, a connection 
between HP1 and RNA has been suggested in one other context. In 
Drosophila, HP1a is recruited to the very actively transcribed sites of 
developmental  and heat shock-induced chromosomal puffs (Piacentini et 
al., 2003). The association of HP1a with these puffs is functionally relevant 
(reduced expression of HP1a results in decreased levels of transcripts at 
these sites, overexpression of dHP1a in elevated levels) and RNA-dependent 
(RNase treatment and induction of puffs without transcription). HP1 binds 
specifically to coding regions of the actively transcribed hsp70 gene (rather 
than to promoters). It has not been investigated so far whether there is 
indeed a direct association of HP1 with RNA at these sites, and if so, what 
the nature of this RNA may be. Since these findings in Drosophila implicate 
HP1 with euchromatic RNA (as opposed to heterochromatic RNAs as in 
the reports in S. pombe and mammals), HP1’s RNA binding may be more 
complex and possibly directed towards different kinds of RNA (Kellum, 
2003).
All in all, my experimental observations are in agreement with 
published findings on HP1 interaction with RNA, and it seems quite possible 
that HP1α hinge phosphorylation may indeed regulate the interaction of 
HP1α with RNA in vivo. However, my preliminary observations and the 
very limited data in the literature do not yet allow to draw any definite 
conclusions to this important question.
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next experimental steps
To expand on my preliminary finding that HP1 phosphorylation regulates 
RNA binding in vitro, the first follow-up step will have to be a rigorous 
confirmation of this experimental observation will be required. The EMSA 
could be repeated with new preparations of labeled RNA (hopefully without 
any aggregation), full-length HP1α constructs could be tested, and the 
in vitro interaction could be further characterized, e.g. by the use of 
different salt concentrations that would permit a qualitative evaluation 
of the interaction’s affinity. Competition with different RNA species could 
be carried out to verify if my HP1 hinge constructs reproduce the results 
published for RNA binding of full-length HP1 before (Muchardt et al., 
2002).
As helpful as further examination of the interaction of HP1 with RNA 
in the test tube may be, it will not get beyond the basic limitations of the in 
vitro system. It is hard to exclude that observations made in such a system 
are simply general effects of changes in charge that are amplified by the 
artificial conditions of the test tube, while no such effect exists under in 
vivo conditions. Thus, for meaningful data it will be necessary to study the 
HP1α-RNA interaction in vivo.
A quick way to show that HP1 hinge phosphorylation indeed 
affects RNA binding of HP1α in vivo would be by purification of HP1 from 
tissue culture cells and autoradiographic analysis of copurifying RNAs 
after radioactive labelling. From cell lines expressing tagged wt HP1α or 
HP1α with S to A and S to E mutations, HP1 could be purified e.g by 
immunoprecipitation/pull-down. Coprecipitating RNA could be labelled by 
polynucleotide kinase end-labelling with 32P-ATP (assuming free 5’-OH), 
and then analyzed by gel electrophoresis and autoradiography. Differences 
222
in the RNA binding of the constructs should be visible as variations in the 
banding pattern between the different constructs.
However, it is unclear how interpretable such a pull-down experiment 
would be. Considering that HP1 undergoes dozens of different interactions 
and is part of large heterochromatic complexes (see Chapter 1, Introduction), 
the mixture of copurifying RNAs may simply be too complex to allow any 
meaningful evaluation from an autoradiograph. Some improvement might 
be achieved by the use of crosslinking methods such as CLIP (Cross-
linking and immunoprecipitation, see below) to allow for more rigorous 
purification.
By far the most insight into the interaction of HP1α with RNA, the role 
of RNA in HP1 biology, and the part that HP1α hinge phosphorylation plays 
in this context, will however come from identification of RNAs associated 
with HP1α in vivo. While the exact experimental approach would depend 
on the type and the size of the RNA associating with HP1 (e.g. non-coding 
RNA, mRNA, small RNAs), Various protocols for this different purposes 
have already been developed by others (e.g. Pfeffer et al., 2005; Rinn et 
al., 2007). CLIP (Cross-linking and IP), a method specifically developed for 
the highly specific purification of RNAs binding to protein in intact cells 
(Ule et al., 2003), could be used. By a UV cross-linking step, specifically 
interacting RNA is bound covalently to protein and can be purified by 
harsh purification steps, such as denaturing purification or transfer to 
nitrocellulose, which discards of free RNA (Ule et al., 2005). After removal 
of HP1 protein by proteinase K digest, linker RNA can be ligated to the 
5’ and 3’ ends, and the RNAs amplified by RT-PCR with DNA primers 
complimentary to the RNA linkers. Sequence analysis could be carried out 
either by microarray analysis or by Solexa sequencing.
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Purification and identification of protein-associated RNAs profits 
immensely from a negative control that allows to distinguish specific 
interactions from unspecific ones. Since my in vitro data indicates that 
HP1α hinge phosphorylation abolishes RNA binding to HP1, the hinge 
phosphorylation may offer a highly useful handle for the identification of 
HP1-binding RNAs in vivo (cell lines expressing HP1α constructs with S to 
E mutations in the hinge could be used as negative control and compared 
to either wt or S to A constructs).
The experimental work and technical expertise required to 
successfully identify HP1-associated RNAs through this approach is of 
course significant. Therefore, I have recently entered into a collaboration 
with Dr. Emily Bernstein, a former colleague in the Allis lab (now a faculty 
member at Mount Sinai School of Medicine, New York). Dr. Bernstein is an 
expert in RNA biology, and we are optimistic that our collaboration will soon 
provide experimental validation whether my in vitro observations reflect 
real in vivo behavior of HP1. Successful identification of HP1-associated 
RNAs in mammalian cells will undoubtedly contribute significantly to 
our understanding of this highly interesting chromosomal protein and its 
function in the cell.
hypotheses on the biological function of the hp1-rna interaction 
and of hp1α hinge phosphorylation
The fundamental biological question underlying these future experiments 
is of course, what the role of the RNA interaction may be and why the RNA 
has to be released during mitosis. As pointed out before, a very limited 
amount of data is available on the connection between HP1 and RNA, 
making models speculative by necessity. Even so, I want to propose three 
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hypotheses what the role of RNA may be in HP1 biology and how the 
regulation by HP1 hinge phosphorylation would fit into these scenarios.
1) RNA could play the role of "molecular glue" that stabilizes heterochromatic 
structures.
The currently favored model of HP1-mediated heterochromatin 
formation involves recruitment of HP1 by H3K9me and condensation 
of heterochromatic domains by crosslinking through HP1 dimerization 
of the chromoshadow domain (Jenuwein and Allis, 2001). Due to 
the diverse molecular interactions that HP1 undergoes, it has been 
suggested that HP1-mediated heterochromatin formation may be 
enhanced by additional factors that, through interactions with HP1 
and possibly each other, contribute to the formation of a tightly packed 
dense heterochromatic structure (Craig, 2005; Dillon and Festenstein, 
2002). According to my model, RNA fulfills such a function (Figure 
5.5). By interacting with the hinge regions of multiple HP1 molecules, 
RNA assists HP1 crosslinking in the formation of densely packed 
heterochromatic regions and further stabilizes the heterochromatic 
architecture.
The role of HP1α hinge phosphorylation in this model may be 
a contribution to the disassembly of large heterochromatic complexes 
during mitosis, at the time when HP1 is released by "methyl-
phos switching" (and, possibly, other mechanisms). HP1 hinge 
phosphorylation reverses the RNA-HP1 interaction, helping to break 
down large heterochromatic complexes and to set HP1 molecules free 
for reassociation with chromatin at the end of mitosis. Removal of HP1 
hinge phosphorylation after mitosis (possibly by a chromatin-associated 
phosphatase) would then reestablish RNA binding.
225
This model is in keeping with several observations made by me 
and others. In 2002 the Almouzni lab showed that an RNA component 
is required for the maintenance of  mouse pericentric heterochromatin 
organization (Maison et al., 2002).  Recently, it has been demonstrated 
that in S. Pombe Swi6/HP1 directly associates with centromeric 
transcripts (Motamedi et al., 2008), giving further credence that such a 
model may indeed be possible in vivo.
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Figure 5.5: rna as "molecular glue" to stabilize and compact hp1-depen-
dent heterochromatic structures (hypothetical model for the biological role 
of the hp1α-rna interaction)
According to this model, RNA may have a role in stabilization and compaction 
of heterochromatic domains. Through the interaction of its chromo domain with 
H3K9me (and likely, other interactions), HP1 is recruited to chromatin. Dimeriza-
tion of HP1 molecules through their chromoshadow domain leads to crosslinking 
of nucleosomes and significant compaction of the domain. Filling in the spaces 
of this meshwork, RNA may bind to the hinge regions of several HP1 molecules 
simultaneously. Like a "molecular glue", this further stabilizes and compacts the 
heterochromatic structure.
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In my own experiments, I observed during a fractionation 
procedure that (S92-) phosphorylated HP1α could be easily stripped 
off of chromatin, while unphosphorylated HP1α was part of much 
more stable chromatin structures (Figure 4.13A). That HP1α hinge 
phosphorylation had no effect on HP1 localization would be explained in 
this model by the fact that RNA compacts heterochromatic structures, 
but is not directly involved in HP1 chromatin binding.
To test this model, one could analyze the complexes that HP1 
is part of during mitosis and how they are affected by HP1 hinge 
phosphorylation or mutation of the phosphorylation sites. Alternatively, 
a more detailed analysis of the composition and architecture of 
heterochromatic domains (and, possibly, how these are affected by 
mutations of the HP1α hinge) may be a possible approach.
2) The interaction of HP1 with RNA could mediate the association of HP1 
with euchromatic regions within the genome. Most likely in collaboration 
with other interactions, interaction with mRNA recruits HP1 to these 
sites, where the protein plays a role in the promotion of gene expression 
(Figure 5.6).
This model is in agreement with my experimental findings and 
several observations in the published HP1 literature. The association 
of HP1 with euchromatic sites within the genome has been observed 
in Drosophila and mammalian cells by various experimental methods 
(Cryderman et al., 2005; de Wit et al., 2007; Johansson et al., 2007; 
Piacentini et al., 2003; Vakoc et al., 2005; see Introduction). 
Association of HP1 with such sites seems to be RNA-dependent, as 
suggested by the observation that HP1 association with heat-shock and 
developmentally induced puffs (highly expressed regions in Drosophila 
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polytene chromosomes) is only observed in the presence of RNA 
(Piacentini et al., 2003). High-resolution mapping of HP1a binding sites 
in Drosophila HP1a shows that HP1 localizes specifically to transcribed 
regions of actively expressed genes, and is excluded from the promoter 
(de Wit et al., 2007; Johansson et al., 2007). This raises the possibility 
that HP1 may actually be binding to the transcribed mRNA. However, it 
is clear that there must be contributions of other mechanisms, because 
HP1 associates only with few of the many actively transcribed loci in 
the genome.
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Figure 5.6: rna binding of hp1 recruits hp1 to euchromatic loci (hypotheti-
cal model for the biological role of the hp1α-rna interaction)
RNA binding of HP1 could recruit HP1 to euchromatic loci. Besides abundant as-
sociation with heterochromatic regions, HP1 is also found at a few euchromatic 
sites (top). According to this model, the association of HP1 with these euchro-
matic regions is mediated by HP1 binding to mRNA (in green), most likely in col-
laboration with other interactions (not shown in this cartoon). At the locus, HP1 
promotes gene expression by unknown mechanism (such as a role in mRNA sta-
bilization), and may also recruit other factors (X, Y; shown in purple) to the site.
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The function of HP1 at these sites is currently not understood, 
but the protein seems to positively regulate gene expression (loss of 
HP1 results in reduced, overexpression in increased gene expression at 
such sites, Cryderman et al., 2005; correlation of HP1 binding with gene 
expression, de Wit et al., 2007). On a molecular level, it may be that HP1 
promotes transcription at these sites through a role in transcriptional 
elongation or even in mRNA stabilization (Kellum, 2003).
According to my proposed model, HP1 is recruited to these sites by 
an interaction with RNA. During mitosis, the protein has to be released 
from the sites of active transcription, possibly because transcription 
has to be shut down to allow full condensation of the chromosomes. 
In the model, the dissociation of HP1 from these sites is accomplished 
by phosphorylation of HP1 in the hinge region, which abolishes RNA 
binding.
Upon S to A mutation or S to E mutation of the HP1 phosphorylation 
sites, HP1 is retained or released, respectively. But since there are only 
few of such HP1-binding euchromatic loci, this effect is not readily 
observed in my immunofluorescence assay, because there is a huge 
excess of heterochromatic HP1 that at the same time dissociates from 
chromatin by "methyl-phos switching" and this larger population 
dominates IF observations.
In this model, only the small subpool of HP1 at euchromatic sites 
depends on HP1 phosphorylation for its release in mitosis. However, 
my data indicates that there is a significant amount of phosphorylated 
HP1 present in mitotic cells. This could be explained by the existence of 
additional functions of HP1 phosphorylation Alternatively, it is possible 
that the "collateral" phosphorylation of the other pool of HP1 does not 
hurt the cell and is therefore not selected against.
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First hints whether such a model would be feasible at all could 
come from the identification of the RNA(s) associated with HP1. As a 
more direct test of the model, ChIP experiments at known euchromatic 
binding sites of HP1 could be carried out. By comparing the association 
of HP1 constructs with wt sequence and with mutated phosphorylation 
sites, it should be possible to verify whether HP1 binding to these sites 
is regulated by HP1α hinge phosphorylation.
3) HP1 binding to RNA could be important in regions of constitutive 
heterochromatin for tethering nascent RNA transcripts to 
heterochromatin.
This hypothesis was recently formulated by Motamedi and 
colleagues (Motamedi et al., 2008) and is based on their observation of an 
in vivo interaction of Swi6 (the S. pombe homolog of HP1) with noncoding 
cen transcripts (transcripts originating from baseline transcription of the 
silenced centromeric repeat regions) in fission yeast. The model (Figure 
5.7) suggests that Swi6/HP1 tethers these nascent heterochromatic 
RNA transcripts to chromatin. The stable association of the transcripts 
with the sites of RNA synthesis is required for the subsequent assembly 
of the RNAi complexes RITS (RNA-induced transcriptional gene 
silencing complex) and RDRC/Dcr1 (RNA-dependent RNA polymerase 
complex/Dicer 1) on the RNA (Motamedi et al., 2008), which facilitates 
efficient processing of the transcripts to double-stranded siRNAs, a 
step that is required for H3 lysine 9 methylation and heterochromatic 
silencing (Grewal and Jia, 2007; Volpe et al., 2002). In keeping with the 
hypothesis, in the absence of Swi6, the levels of centromeric siRNAs 
are dramatically reduced (Motamedi et al., 2008), and localization of 
RITS and RDRC to cen transcripts (Motamedi et al., 2008), and Rdp1 
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to cen DNA (Sugiyama et al., 2005) is decreased compared to wild-type 
cells, demonstrating that Swi6 is required for the efficient association 
of RITS, RDRC and Dicer with their target transcripts at centromers.
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5.7Figure 5.7: hp1 tethers nascent heterochromatic rna transcripts to the 
heterochromatic locus (hypothetical model for the biological role of the 
hp1α-rna interaction)
HP1 could bind nascent heterochromatic RNA transcripts and tether them to the 
heterochromatic locus. This enables assembly of RNA processing complexes on 
the RNA that are required for heterochromatin formation/maintenance. Accord-
ing to this model, HP1 associates with heterochromatin through the chromo do-
main – H3K9me interaction. Through the hinge region, HP1 associates with RNA 
transcripts (in dark green) that are generated at low levels, and thus stably teth-
ers them to the site. This permits assembly of machinery required for processing 
of the transcript, such as the RNA-dependent RNA polymerase complex (RDRC, 
in yellow) that generates double-stranded RNA (dsRNA), Dicer (in blue) that cuts 
the dsRNA into siRNAs (short interfering RNAs), or RITS (in purple) that contains 
siRNAs and is required for establishing/maintaining H3K9 methylation at centric 
regions. Figure adapted from Motamedi et al., 2004.
It is possible that the interaction of Swi6 with cen RNA has to 
be released during mitosis, for example because the heterochromatic 
complexes associated with RNA processing would impede the efficient 
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interaction of Swi6 with cohesin (Nonaka et al., 2002). Such an ejection 
of cen RNA from Swi6 binding could conceivably be regulated by Swi6 
phosphorylation.
It should be noted, though, that at the moment it is not yet 
established if Swi6 indeed binds cen RNA through its hinge domain, 
nor has it been investigated in detail to which extent the pathways 
of heterochromatin nucleation/maintenance are conserved in higher 
organisms.
All in all, little is known about the connection between HP1 biology and 
RNA. As outlined above there are some very intriguing possibilities, and 
my finding that RNA binding to HP1 is regulated by HP1 phosphorylation 
may open the door for some exciting further discoveries in the future.
Conclusion
In my Ph.D. project I have explored the ways how phosphorylation 
regulates Heterochromatin Protein 1, an important chromatin effector 
protein. As I have shown, phosphorylation controls HP1 function on two 
different levels: On one level, phosphorylation of histone H3 regulates 
HP1 chromatin release during mitosis through binary switching, and the 
discovery of this mechanism leads the way to a better understanding not 
only of the mechanisms that control HP1 chromatin association, but also 
of many other molecular interactions in chromatin biology and beyond, 
that are regulated by similar mechanisms. On the other level, mitotic 
phosphorylation of HP1 itself in its hinge domain appears to control the 
association of HP1 with RNA. My observations open up new experimental 
directions that may lead to a better understanding of the role and regulation 
of RNA in the biology of Heterochromatin Protein 1.
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The recruitment of effectors by posttranslational modifications of 
histone proteins is one of the key mechanisms to control chromatin structure 
and function. The findings presented in my thesis illustrate, however, that 
there are additional levels of complexity that involve an intricate interplay 
between multiple histone modifications, as well as modulation of effector 
function by posttranslational modification of the effectors themselves. 
Exploring these layers of regulatory complexity will surely be challenging, 
but the therapeutic potential of chromatin, especially for the treatment of 
cancer, indicates that the effort will be well-invested.
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